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Abstract

CNS Neural/Glial Progenitors as Targets of HIV-1 and Opiates: Effects on
Proliferation and Population Dynamics, May Alter Behavior Outcomes.
A dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy at Virginia Commonwealth University.
By Yun Kyung Hahn,
Director: Pamela E. Knapp, Ph.D., Professor, Department of Anatomy and Neurobiology

Human immunodeficiency virus (HIV) infected patients with a history of injection
opiate abuse have higher incidences of acquired immunodeficiency syndrome (AIDS) and
neurological dysfunction. The use of combined anti-retroviral therapy has significantly
reduced the prevalence of mortality and progression to AIDS. Due to extended life
expectancy, these patients are still at a great risk for HIV-associated neurological disorders
and impairment in their later life. Neural progenitor cells (NPCs) play critical roles in brain
growth and repair after injury and insult. Pediatric HIV patients whose glial populations are
still developing are especially at risk for central nervous system (CNS) damage. Our
previous reports suggest that HIV-1 transactivator of transcription (Tat) can directly cause
pathology in neural progenitors and oligodendroglia (OLs) (Hauser et al. 2009). Thus, we
have hypothesized that NPCs and/or glial progenitors may be targets of HIV proteins ±
opiates drugs of abuse.
To determine whether progenitors are targets of HIV-1, a multi-plex assay was
performed to assess chemokine/cytokine expression after treatment with viral proteins Tat
or glycoprotein 120 (gp120) with/without morphine. Murine striatal progenitors released
x

increased amount of the beta-chemokines CCL5/regulated upon activation, normal T cell
expressed and secreted (RANTES), CCL3/macrophage inflammatory protein-1α (MIP-1α),
and CCL4/macrophage inflammatory protein-1β (MIP-1β) after 12 h exposure to HIV-1
Tat, but no to gp120. Secreted factors from Tat-treated progenitors were chemoattractive
towards microglia, an effect blocked by 2D7 anti- C-C chemokine receptor type 5 (CCR5)
antibody pre-treatment. Tat and opiates have interactive effects on astroglial chemokine
secretion, but this interaction did not occur in progenitors.
We also examined effects of Tat and morphine on proliferation and lineage
progression of NPCs in vitro and in vivo. In vitro, Tat and morphine independently reduced
the proliferation and population of Sox2+ and Olig2+ cells in the absence of cell death. The
interactive effects of morphine and either Tat or supernatant from HIV-1SF162 infected
monocytes varied depending on outcome measure and time of exposure, but interactive
effects occurred primarily on proliferation. In rare instances, viable human progenitors
were associated with p24 immunolabeling suggesting that progenitors may be infected, a
concept that is still controversial. To investigate effects of Tat and morphine on NPCs in
vivo, we used a mouse model in which HIV-1 Tat1-86 is conditionally expressed in astroglia.
In vivo results in neonatal striata were similar to those in cell cultures.
We extended the experiments into adult mice with inducing Tat expression for 3
month and the effect of sexes was examined in these animals. Intriguingly, males showed
more Tat-induced impairment in behavioral tests (rotarod, grip strength, light-dark box)
than females. Tat+ males also showed a greater reduction in the proportion of NeuN+ cells
and NeuN immunoreactivity in the striatum, accompanied by greater microglial activation
(3-nitrotyrosine+/Iba-1+). Unbiased stereological estimation in Nissl staining revealed that
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the depletion of NeuN immunoreactivity in these mice was not due to neuron cell death or
loss, because the total neuron number in striatum and total striatal volume were not
affected by long-term Tat induction. Tat exposure appears to selectively reduce levels of
NeuN in living neurons, although the reason is not known. Therefore, both the enhanced
microglial reactivity and depletion of NeuN levels in males may help to explain sexspecific behavioral outcomes. Sox2+ and Olig2+ cells showed equivalent reduction in their
population in both sexes.
Overall, our findings show that CNS progenitors, including both undifferentiated
NPCs and glial progenitors, are vulnerable to individual or combined effects of HIV-1 or
Tat and opiates. Changes in progenitor dynamics may alter the balance of cell populations
in both the developing and adult CNS. We speculate that such changes may contribute to
the behavioral abnormalities that we observed in Tat+ mice and which appear to model
aspects of motor, cognitive and anxiety deficits in HIV-infected patients.

xii

Chapter 1
Introduction to the Neuroscience of HIV

Epidemiology of HIV
Over 1 million individuals in the United States (US) and nearly 33 million people
worldwide are estimated to be infected and living with HIV (UNAIDS 2010). An estimated
number of people newly infected with HIV in 2009 are 43,000 in the US and 2.6 million
worldwide. Injection drug abusers are a major part in this population; 3 million people
having the history of injection drugs are living with HIV. The rate of HIV infection along
with drug injection are raising fast in developing countries and over 80% of all HIV
infections in some countries are estimated to be related to drug use (UNAIDS 2009).
Twenty to thirty percent of new HIV infections in the US occur among injection drug
abusers annually (CDC 2009). Furthermore, they a have high a risk for faster progression
to be acquired immune deficiency syndrome (AIDS), and higher incidence of HIV-related
neurocognitive deficit/impairments compared to non-drug abusers (Bell et al. 2002). The
population of women living with HIV in US are less than 25% of HIV positive people
(CDC 2009), while 51% of people HIV positive population in worldwide are women
(UNAIDS 2009), and HIV infections in women appear to be increased with globalization.
HIV infection does not exclude children as its victims; about 370,000 children under 15
years old are also living with HIV globally (UNAIDS 2009), around 10,000 children in US
were diagnosed as AIDS in US 2009 (CDC 2009). Children are known to be more
vulnerable to HIV complication and neuropathogenesis than adults (Civitello 1991; Drotar
et al. 1997; Drotar et al. 1999; Lobato et al. 1995; Sharer and Cho 1989; UNAIDS 2009;
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Van Rie et al. 2007). Since the introduction of combination antiretroviral therapies (cART)
since 1996, survival rates related to HIV infection have dramatically improved in the US
and other developed countries. Despite these outstanding improvements in mortality and
co-morbidity of HIV, the prevalence of HAND continuously raises and remains as a
significant public health concern.

Virology of HIV-1
HIV-1 has a single RNA genome consisting of seven structural elements (LTR,
TAR, RRE, PE, SLIP, CRS, and INS), and nine genes (gag, pol, env, tat, rev, nef, vif, vpr,
and vpu). Six genes transcript into accessory proteins and nine other genes produce
envelope, core, and polymerase of HIV-1 (Kuiken et al. 2008). The viral proteins from
these genes are essential for infection and new viral replication, and some of them are
known to have significant toxicity to neural cells. In this thesis, we will focus two viral
proteins, Tat and gp120, which are well studied in HIV neuropathogenesis.
Firstly, gp120 is a viral envelop protein and plays a critical role in HIV infection.
The gene env encodes gp160, the precursor of both gp120 and gp41. During HIV
replication, furin, one of the host cell's protease, cleaves gp160 into the external gp120 and
the transmembrane gp41 prior to viral assembly (Kuiken et al. 2008). For the initiation of
HIV infection, gp120 binds the CD4 protein of target cells then the envelope complex
undergoes a structural change, exposing the chemokine binding domains of gp120 and
allowing them to interact with the target chemokine receptors, C-X-C chemokine receptor
type 4 (CXCR4) and/or C-C chemokine receptor type 5 (CCR5), co-receptors for HIV-1.
This allows the N-terminal fusion peptide gp41 to penetrate the cell membrane as a last
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step of infection (Chan et al. 1997; Chan and Kim 1998; Wyatt and Sodroski 1998). gp120
is also known to give the viral tropism to HIV by the preference of gp120 to bind either
CXCR4 or CCR5 to infect specific cells (Chan et al. 1997). For examples, T-tropic strains
of HIV-1 use the α-chemokine receptor, CXCR4, for entry to CD4+ T cells (Coakley et al.
2005; Deng et al. 1996; Feng et al. 1996). M-tropic strains use the β-chemokine receptor,
CCR5, to infect macrophage/microglia (Coakley et al. 2005). Dual-tropic HIV-1 strains are
known to be able to use both CCR5 and CXCR4 as co-receptors for viral entry. As well as,
other chemokine receptors, such as CCR2, CCR3 and C-X3-C chemokine receptor 1
(CX3CR1)/fractalkine receptor, have been shown to serve as co-receptor for viral entry
(Choe et al. 1996; Garin et al. 2003; Parczewski et al. 2009; Puissant et al. 2003).
Another HIV-1 protein, Tat, refers to trans-activator of transcription. This protein is
one of regulatory proteins, which is synthesized at the early and late stage of viral
replication. Tat can be released by HIV-infected cells into the extracellular environment,
and can be taken up by the surrounding cells (Westendorp et al. 1995). This protein is
known to have multiple forms; 86 or 110 amino acid forms are formed from two exons.
The first exon contributes to the 1-72 amino acid variant, and the second exon forms the
remaining 14 to 32 amino acids (Jeang et al. 1999; Kuiken et al. 2008; Li et al. 2010; Nath
et al. 1996). HIV-1 Tat is one of the transactivating proteins regulating in HIV expressions.
It is essential for retroviral replication by binding to long terminal repeat (LTR) of HIV to
lead massive transcription level of the HIV dsRNA. HIV-1 Tat also is required for efficient
HIV genomic transcription. The presence of Tat can induce more than hundred-fold levels
of HIV transcription compared to activation of the absence of Tat (Cann et al. 1985). There
are five functional domains in Tat protein including N-terminal, cysteine-rich, core, basic,
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and C-terminal domains. Before identifying the function of Tat in HIV replication, HIV-1
Tat was firstly recognized as having a unique protein transduction domain (Frankel and
Pabo 1988; Green and Loewenstein 1988). This domain in HIV-1 Tat contains specific
amino acid sequence, GRKKR, which act as a nuclear localization signal. Tat could enter
cells by crossing the cell membrane due to its rich lysine and arginine content of this
domain (Morris et al. 2001; Schwarze et al. 2000). In summary, viral envelop protein
gp120 and regulatory protein HIV-1 Tat can contribute to AIDS pathogenesis in multiple
ways. These include facilitating infection, activating HIV transcription, increasing
replication of HIV and dysregulating the host’s cytokine expression and immune responses.
These proteins can affect the cells that are not infected in secondary manner, by their
directly binding to target cells which can induce abnormal multiple signal transductions
and morphological changing. Understanding the mechanism of these viral proteins in
neurobiology may allow us to have opportunities to control or manage HIV associated
neurological defects HIV.

Invasion of HIV into CNS
The central nerve system (CNS) is susceptible to infection by HIV. It has been
elusive and controversial when and how HIV invades into brain. Although it is unclear
wheather HIV infection remains in the CNS, or is cleared and re-enters in later stage of
infection, HIV appears to infiltrate into the CNS with different amount of infection and in
different regions of the brain (An et al. 1999; Davis et al. 1992; Gonzalez-Scarano and
Martin-Garcia 2005; Shapshak et al. 1999; Smit et al. 2004). The HIV infiltrations in
multiple brain regions supports researchers in HIV-neuropathogenesis studies to establish
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the various mechanisms that how the virus can infiltrate into CNS. Even there are a lot of
mechanisms for HIV infiltration in CNS; we will briefly discuss some of mechanisms
which are widely accepted. One of mechanisms, once HIV infect monocyte, macrophage or
CD4+ lymphocytes in peripheral system, these infected cells brought the virus into brain by
accrossing the blood brain barrier (BBB), because the HIV infected cells can express
adhesion molecules on their surface to help the infected cells to attach to brain endothelial
cells and lead transendothelial migration into the CNS (Dhawan et al. 1997; Hickey et al.
1991; Hult et al. 2008). Second, HIV infected cells released cytokine/chemokines (de Jong
et al. 1996; Nottet et al. 1996; Persidsky et al. 1997), Tat (Hofman et al. 1994; Lafrenie et
al. 1996a; Lafrenie et al. 1996b) and gp120 (Annunziata et al. 1998), which can up-regulate
adhesion molecules on brain endothelial cells and also alter the permeability of BBB,
which allow HIV infiltrate easily into the CNS. Third, as HIV can do transcytosis itself
(Hocini and Bomsel 1999), HIV in circulating blood stream firstly infect brain endothelial
cells lining besides BBB and then HIV can be released by viral budding from the
endothelial cells to infect astrocytes in BBB. Therefore, the process of transcytosis allows
HIV passage into the CNS (Banks et al. 2001; Bomsel 1997; Owens et al. 1991). Once the
virus enter the CNS by utilizing all these mechanisms, HIV can affect all cell types in CNS
to induce neuropathogenesis both in direct and indirect manner. Many of the cell types in
CNS, including astrocytes, microglia, neurons, oligodendrocytes, endothelial cells and
NPCs, are considered to be either direct or indirect targets of HIV. The former two are
considered to be target of HIV infection in CNS (Gonzalez-Scarano and Martin-Garcia
2005). These cells will be discussed in sections that follow.
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Interaction of HIV-1 and opiate in neuropathogenesis
Injection drug abuse and HIV-1 are tightly interacted in epidemics mentioned
above. HIV-1 is widely spread through injection drug use, because of their risk drugseeking behaviors, needle sharing and sex-trading for drug purchase. Indeed, injection drug
users are at higher risk both for HIV-1 infection and for developing neuropathological
complications (Hauser et al. 2006; Hauser et al. 2007; Nath et al. 2000; Nath et al. 2002).
Opiates, including heroin, oxycodone, morphine and fentanyl, are known to intrinsically
exacerbate the pathogenesis and neurological complications of HIV-1 through direct
actions in the CNS (Hauser et al. 2006; Hauser et al. 2007). Opiates majorly act through μopioid receptors (MORs), and κ-/δ- opioid receptors play roles in their signaling cascades.
All these receptors are G-protein coupled receptors and are known to activate inhibitory G
proteins (Al-Hasani and Bruchas 2011). The neurotoxicity of opiates has been well
documented in opiate addition studies, and furthermore recent studies suggested that opiate
abuse might lead Alzheimer-like changes in brains. These studies have shown that opiate
alone can increase the depositions of hyper-phosphorylated tau and beta amyloid in brains
of drug abusers; even these patients do not have history of HIV infection (Anthony et al.
2010; Ramage et al. 2005). The interaction of opiate and HIV-1 in the CNS mediated by
either indirectly or directly manners in astrocytes (1.), microglia (2.), neurons (3.),
oligodendrocytes (4.) and neural progenitor cells (5.) will be demonstrated in followed
sections.
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1. Astrocytes
Firstly, astrocytes can be infected by HIV-1 with low productive manner, and the
infected astrocytes can shed HIV-1 protein Tat and gp120 into extracellular spaces.
Additionally these HIV proteins can direct affect neighboring astrocytes and other cells. In
a way of bystander effects on neurons, infected or affected astrocytes may fail to provide
metabolic support to neurons, show reduced ability to buffer toxic substances from
surrounding environment, release neurotoxic molecules, increase inflammation response
and spread cell death signals through their gap junction to affect other cells (Eugenin and
Berman 2007; Eugenin et al. 2011). As subsets of astrocytes express several types of opioid
receptors, including mu-opioid receptor, these cells can be affected by and respond directly
to opiate drugs (Hauser et al. 1996; Stiene-Martin et al. 2001). In in vitro studies, the
combination of HIV-1 Tat and morphine causes an exacerbated loss in intracellular Ca2+
homeostasis in astrocytes and increased various cytokines released by affected astrocytes
(El-Hage et al. 2008b; El-Hage et al. 2005; El-Hage et al. 2006b) and increased in astrocyte
death (Khurdayan et al. 2004). Activated astrogliosis by Tat induction was also detected in
transgenic mice and this activation might contribute stress to neurons with co-exposure to
opiates (Bruce-Keller et al. 2008; Fitting et al. 2010b; Fitting et al. 2010c). Astroglia can be
also influenced by glycoprotein 120 (gp120), this HIV viral protein can increase the levels
of intracellular calcium (Codazzi et al. 1995; Codazzi et al. 1996; Holden et al. 1999) and
modify gene expression (Galey et al. 2003; Wang et al. 2004) to enhance
chemokine/cytokine secretion (Buriani et al. 1999; Fitting et al. 2010b; Kong et al. 1996;
Ronaldson and Bendayan 2006; Yeung et al. 1995). However, gp120 relatively induces less
chemokine/cytokine secretion than Tat with regional heterogeneity and diversity in
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chemokine/cytokine production (Fitting et al. 2010b). In the interaction of opiates and
gp120,

morphine-induced

CCL5/RANTES

secretion

from

astrocytes

might

be

neuroprotective against the HIV protein gp120 (Avdoshina et al. 2010), it still
controversial. Interaction of opiates and other viral proteins in responses of astrocytes have
been less well investigated, thus opioid-induced changes in astrocytes function associated
with HIV viral proteins may have critical implications for the neuropathogenesis of HIV.

2. Microglia
Microglia are the brain-resident immune cells to be productively infected by HIV-1.
These cells are considered as a major reservoir of viral replication in brain, and can
massively produce toxic viral proteins, such as Tat, gp120, and Vpr during viral
replication. Moreover, various toxic cellular products are released by infected microglia
include cytokines such as tumor necrosis factor alpha (TNF-α), interleukins, platelet
activating factor, as well as mediators of inflammation arachidonic acid, L-cysteine,
glutamate, quinolinic acid, and nitric oxide (Bruce-Keller et al. 2008; Gupta et al. 2010;
Persidsky and Gendelman 2003). As these cellular toxins can activate adjacent uninfected
microglia and astrocytes, their activation may initiate cascades through the whole brain
which may occur chronically in HIV infected patients (Hult et al. 2008). Abnormal
microglia activation is prominently detected in various neuropathological diseases
including brains from the end stage of HANDs (Kaul et al. 2001; Persidsky and Gendelman
2003; Tyor et al. 1995). Microglia also express most opioid receptors and each receptor can
be a target of opiates and may have different responses corresponding to HIV-1. For
example, opiate drugs increase HIV-1 replication in microglia through the activation of µ-
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opioid receptors (MOR), and can also induce apoptosis in microglia (Singhal et al. 2002).
Furthermore,

co-exposure

to

morphine

synergistically

increased

Tat-induced

chemokine/cytokine production and microglial activation through CCL5/RANTES- driven
amplification of CCL2/MCP-1 (El-Hage et al. 2008b; El-Hage et al. 2006a; El-Hage et al.
2006b), and that may partly explain relatively high incidences of microglial activation,
neuropathology and cognitive disturbance among HIV patients who abuse opiates
(Anthony and Bell 2008; Arango et al. 2004; Bell et al. 2006; Bouwman et al. 1998;
Dougherty et al. 2002) et al. 2008). Otherwise, the activation of κ-opioid receptor (KOPr)
activation is known to reduce viral replication in microglia (Chao et al. 1996). These facts
implicate that the interaction of HIV-1 and opiates underlay complicate mechanism in HIV
neuropathogenesis.

3. Neurons
It is generally accepted that neurons are defiantly direct and major target of viral
proteins, such as such as gp120 (Dreyer et al. 1990), Tat (Haughey et al. 1999; Sabatier et
al. 1991), and Vpr (Piller et al. 1998). These viral proteins are considered as major
contributing factors to developing neuropathogenesis. Even neurons that are not infected
with HIV are also considered as targets of indirect or bystander inflammations and
toxicants released by infected microglia and astrocytes, mentioned above. Infected
astrocytes and microglia may produce inconsistent amounts of individual viral proteins
(Brack-Werner 1999), each HIV-1 protein released from infected cells is directly toxic to
neurons (Mattson et al. 2005). Various studies in the neurotoxicity of HIV-1 viral proteins
suggests that opiate exposure exacerbates the toxic effects of HIV-1 Tat and gp120 in
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neurons, and this interaction of HIV-1 and opiates can induce cell death in neurons, as well
as in glial cells (Gurwell et al. 2001; Hu et al. 2005; Khurdayan et al. 2004). Interestingly,
opiate exposure seems to reduce the threshold for neurotoxicity (Zou et al. 2011), but
opiates make neurons be more susceptible to toxic insults (Hauser et al. 2005; Nath et al.
2002). Moreover, the interactions also results in the destabilization of Ca2+ in astrocytes
and induce them to release proinflammatory cytokine/chemokines like monocyte
chemoattractant protein-1 (MCP-1), monocyte chemoattractant protein-5 (MCP-5), and
regulated upon activation, normal T-cell expressed, and secreted (RANTES) (El-Hage et al.
2005), which can significantly affect the functional integrity of neuronal synapse and
morphology of neurons (Fitting et al. 2010c). How interactions between opiate drug abuse
and HIV-1 toxicity affect the relationships between microglia, astrocytes and neurons is
necessary to understand the mechanisms of HIV-1 pathogenesis in the CNS.

4. Oligodendrocytes
The oligodendrocytes are the myelin producing cell in CNS, responsible for proper
conduction of axonal signals. Even they have significant contributions for proper function
of CNS and the specific vulnerability to many neuropathologic disease, these cells have
been underestimated and have a short history in HIV neuropathogenesis compare to
neurons. Generally autopsy studies in HIV infected brains detected demyelination,
oligodendrocyte cell death and white matter abnormality although the exact mechanism is
unknown (Petratos and Gonzales 2000; Richardson-Burns et al. 2002). At least, HIV-1
protein Tat seems to have more direct toxicity to oligodendrocytes than gp120 has by
changes of cell morphology (Fitting et al. 2008; Hauser et al. 2009). Oligodendrocytes
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express most of opioid receptors including MOR, κ-opioid receptor (KOR), and δ-opioid
receptor (DOR), which play important roles in proliferation, differentiation and maturation
of oligodendrocytes (Hahn et al. 2010a; Hayashi et al. 2004; Persson et al. 2003). However,
the condition of opiate drugs act by mimicking the endogenous opioid system can enhance
toxicity of HIV-1 to oligodendrocytes. Previous in vitro and in vivo data from our
laboratory strongly indicated that Tat and morphine significantly induce stress in
oligodendrocytes without cell death in vitro, but the combined exposure of Tat and
morphine synergistically increase oligodendrocyte stress and cell death in vivo (Hauser et
al. 2009) with their morphological changes. Oligodendrocytes might be more sensitive to
co-exposure of HIV-1 than neurons are. For examples, Tat induction through 7 to 10 days
significantly increase the proportion of caspase-3 activity, as an indication of stress rather
than cell death, in NeuN+ cells. While the Tat induction in the same period increase
TUNEL staining in O4+ and APC+ cells, which indicates cell death (reviewed by BruceKeller et al. 2008; Hauser et al. 2009). Therefore, opiate drugs in HIV neuropathogenesis is
also likely to be complicatedly involved in the development and survivals of
oligodendrocytes.

5. Neural Progenitor cells (NPCs)
The definition of neural progenitor cells (NPCs) in this thesis is the early
(primitive) stage of cells having the capacity of proliferation and the multi-potential ability
to generate various neural lineages of mature brain cells including neurons, astrocytes, and
oligodendrocytes. The NPCs are abundant in different distinct regions of the brain during
embryonic and postnatal development, while the adult brain contains these NPCs in limited
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neurogenic regions including the subgranular zone (SGZ) in the dentate gyrus, the
subventricular zone (SVZ) in the lateral walls of the lateral ventricles, and the olfactory
bulb (Ming and Song 2005). In the normal adult brain, NPCs is known to be involved in
learning and memory and neural turnover in the hippocampal dentate gyrus and olfactory
bulb. However, accumulating evidence suggest that NPCs exist in numerous regions of the
brain including the neocortex, spinal cord, tegmentum, substantia nigra, amygdala, and
brain stem, as well as in the hippocampal dentate gyrus and olfactory bulb (Ming and Song
2005). The functional significance of the NPCs in these regions is incompletely
understood; however, they may play critical roles in damage repair following any injury or
insult as well as in learning and memory formation (Brazel et al. 2003; Gage 2000; Gage et
al. 1998; Gould 2007; Kempermann and Gage 2000; Ming and Song 2011; Nait-Oumesmar
et al. 2008; Romanko et al. 2004).
The procedure of NPCs turning into matured neural cells mainly requires the
multiple steps including proliferation, migration, differentiation, survival, and integration
of the newly formed matured neural cells into the pre-existed environmental cells in the
brain (reviewed Trapp et al. 1997). These multiple steps of NPCs are known to be affected
by various endogenous factors (Yoneyama et al. 2011). Although neurological deficits due
to brain injury/insults or neuropathogenesis are mainly caused by loss of synaptic integrity,
malfunction or loss/death of neurons, the disruption of endogenous neuro/gliogenesis from
NPCs might contribute to neurological deficits by hindering the recovery from brain
injury/insults. Notably, cumulative reports indicate that the properties of NPCs in HIV
neuropathogenesis can be affected by cytokine/chemokines, neurotransmitters, and reactive
oxygen/nitrogen species (ROS), which are released by HIV-1 affected neurons as well as
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by activated macrophages, microglia, and astrocytes (Whitney et al. 2009; Yoneyama et al.
2011), mentioned above.
Although the critical roles of these cells is in maintaining and repairing of
mammalian CNS system, the underlying mechanism of NPCs in HIV neuropathogensis is
still elusive. The RNA/DNA of HIV-1 was detected in regions of neurogenesis in human
adult and pediatric brain, and in vitro studies suggested the prolonged HIV-1 infection of
NPCs, it is still controversial whether NPCs can be infected by HIV or not (reviewed Das
and Basu 2011; Mishra et al. 2010; Rothenaigner et al. 2007; Schwartz et al. 2007).
Moreover, the limited availability and purity in human primary NPCs make numerous
difficulties in studies of HIV neurobiology. Since NPCs express opioid receptors, MOR,
KOR and DOR (Buch et al. 2007; Hahn et al. 2010b; Hauser et al. 2009; Knapp et al.
2009), these receptors play important roles in proliferation, differentiation and survival of
NPCs through endogenous opioids and also make these cells become targets of opiates and
their antagonists. Besides, various cytokine/chemokine receptors, including CXCR4 and
CCR5, are also expressed on surface of NPCs (Kao and Price 2004; Li et al. 2011; Li and
Ransohoff 2008; Tran and Miller 2005), which allow NPCs can be direct and indirect
targets of HIV-1. As the indirect way HIV-1 affects NPCs, there have been some reports
that cytokine/chemokines released by HIV-1 infected macrophage/microglia affect
proliferation and differentiation of NPCs (Peng et al. 2011; Peng et al. 2008) and
reductions of NPCs in hippocampus paralleled increased HIV-1-infected microglial
activation in mice model of HIV encephalopathy (HIVE) (Poluektova et al. 2005). A few
studies indicated that the direct effect of HIV-1 Tat and gp120 can attenuate the
proliferation and differentiation of NPCs and exposure to these proteins might lead cell
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death in NPCs (Mishra et al. 2010; Okamoto et al. 2007; Tran et al. 2005). Moreover,
NPCs may be preferentially vulnerable to HIV-1 infection or chronic opiate exposure
because Tat or morphine alone or in combination caused significant increases in NPC cell
death in vitro and in vivo (Buch et al. 2007; Khurdayan et al. 2004). However, most of
studies in NPCs with HIV-1 or their viral proteins were only concentrated on reduction in
proliferation of NPCs or decreased differentiation into neurons rather than any other cells
in brain. Questions still remain, such as what specific stage of NPCs are affected by HIV-1,
how HIV-1 affects the properties of NPCs and what population can be generated after the
HIV-1 affect NPCs etc. The detail of studies in NPCs under the condition of HIV and
opiates are required in HIV neuropathogenesis.
NPCs are relatively less investigated in HIV neuropathogenesis compared to other
major neural cells in brain, even these cells might have a significant potential to contribute
the recovery or marinating of normal CNS functions during HIV-1 invasion in CNS.
Furthermore, NPCs are likely to have different responses from HIV-1 or its viral effects on
mature glia as well as neurons. This may critically contribute the facts that pediatric
patients frequently present with early and with more pathological forms of neuroAIDS
(Drotar et al. 1997; Lobato et al. 1995; Van Rie et al. 2007), since these patients have
abundant NPCs which are still developing in their CNS. Thus, opiate-induced changes in
functions of NPCs may have critical implications for the pathogenesis of HIV.
Taken altogether, the studies in this article will show that NPCs in striatum can be
major target of HIV-1 Tat proteins with opiates exposures by altering their
chemokines/cytokines secretions, proliferation and population in specific stage of
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progenitors and these potential consequences may result in changing behavior of animal
model with sex-specific manner.
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Chapter 2
β-Chemokine Production by Neural and Glial Progenitor Cells is Enhanced
by HIV-1 Tat: Effects on Microglial Migration.

(This chapter was published as a paper in the Journal of Neurochemistry in April of 2010,
114(1):97-109)

Introduction

Human immunodeficiency virus (HIV) infection within the central nervous system
(CNS) causes a variety of neuropathological changes. Neurons are not generally thought to
be infected by HIV, although latent neuron infection has been reported (Torres-Munoz et
al. 2001; Trillo-Pazos et al. 2003).

Neuropathology is instead mediated by direct

neurotoxic actions of released viral proteins, or secondarily, through toxic effects
orchestrated by glial cells (Brack-Werner 1999; Gendelman et al. 1994; Hauser et al. 2007;
Kaul et al. 2001; Kramer-Hammerle et al. 2005b; Persidsky and Gendelman 2003). HIVinfected macrophages/microglia reaching the brain create a reservoir of viral infection, and
lay the groundwork for inflammation leading to neuropathology and cognitive changes.
Although there is little evidence that macroglial cells in vivo are productively infected by
HIV (Brack-Werner 1999; Gorry et al. 2003; Kramer-Hammerle et al. 2005b), activation of
astroglia by viral proteins, or by substances released from reactive microglia, can amplify
brain inflammation and neurotoxic sequelae, and also promote infiltration of infected
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monocytes from the periphery. Thus, HIV neuropathology results from collective effects
of viral proteins and inflammatory mediators on several cell types.
Astroglia from humans and rodents secrete chemokine/cytokines in response to
HIV-1 transactivator of transcription (Tat) protein (Conant et al. 1998; El-Hage et al. 2005;
Kutsch et al. 2000; McManus et al. 2000; Nath et al. 1999; Rappaport et al. 1999). We
have shown that Tat-induced [Ca2+]i responses mediate (CC motif chemokine ligand)
2/monocyte chemoattractant protein-1 (MCP-1), CCL5/regulated upon activation, normal T
cell expressed and secreted (RANTES) and interleukin-6 (IL-6) release, resulting in
downstream signaling through necrosis factor kappa B-dependent pathways (El-Hage et al.
2008b; El-Hage et al. 2005). Concurrent exposure to morphine exacerbates Tat-induced
chemokine/cytokine production and microglial activation through CCL5/RANTES-driven
amplification of CCL2/MCP-1 (Bruce-Keller et al. 2008; El-Hage et al. 2008a; El-Hage et
al. 2006a; El-Hage et al. 2006b), an observation that may partly explain relatively high
incidences of microglial activation, neuropathology and cognitive disturbance among HIV
patients who abuse opiates (Anthony and Bell 2008; Arango et al. 2004; Bell et al. 2006;
Bouwman et al. 1998; Dougherty et al. 2002). Astroglia are also sensitive to glycoprotein
120 (gp120), which can elevate [Ca2+]i (Codazzi et al. 1996; Holden et al. 1999), and alter
gene expression (Galey et al. 2003; Wang et al. 2004) leading to chemokine/cytokine
secretion (Buriani et al. 1999; Kong et al. 1996; Ronaldson and Bendayan 2006; Yeung et
al. 1995), with some evidence for exacerbation by opiates (Mahajan et al. 2005). In our
hands, Tat generally elicits a much higher chemokine and cytokine response than gp120,
and we observe regional heterogeneity in secretion by astroglia (Fitting et al. 2010c).
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Responses of astroglia to other HIV-1 proteins have been less well studied (KramerHammerle et al. 2005a; Lehmann et al. 2006).
We were intrigued by the possibility that less differentiated CNS cells, in addition
to microglia and astroglia, might contribute to inflammation. This would parallel situations
in other tissues. Unstimulated bone marrow or cord-derived mesenchymal stem cells
secrete a spectrum of chemokine/cytokines and growth factors, including multiple
fibroblast growth factors (FGFs), interleukins, insulin like growth factor 1 (IGF-1),
leukemia inhibitory factor (LIF), CCL2/MCP-1, CCL3/macrophage inflammatory protein1α (MIP-1α), and CCL4/macrophage inflammatory protein-1β (MIP-1β), stromal cell
derived factor-1 (SDF-1), and vascular endothelial growth factor (VEGF) (Chen et al.
2008; Croitoru-Lamoury et al. 2007; Liu and Hwang 2005; Rafei et al. 2008; Schinkothe et
al. 2008; Wagner et al. 2007). As mesenchymal stem cells differentiate, the balance of
factors released varies with cell fate (Kilroy et al. 2007; Molloy et al. 2009). Neural
progenitor cells (NPCs), which derive from undifferentiated neuroepithelial cells, are a
self-renewing and multipotential source of neurons and macroglial cells. Common markers
for NPCs include the intermediate filament nestin and the transcription factor Sox2 (sex
determining region of Y (SRY)-related HMG-box gene 2).

As NPCs continue to

differentiate, they become largely restricted to either neuronal or glial fates. Differentiating
glial-restricted progenitors (GPCs) express markers typical of oligodendrocytes (e.g. Olig1,
Olig2, Sox10, myelin proteins) or astroglia (e.g. GFAP, EAAT2). Nestin+ and Sox2+ cells
continue to be found in the mature CNS, although in more restricted germinal zones
(Komitova & Eriksson 2004, Ellis et al. 2004). There is evidence that neurally-restricted
progenitors may have a secretory role. For example, human NPCs expressing nestin and
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A2B5 release IP-10/CXCL10 and MCP-1/CCL2 after exposure to TNF-α (Sheng et al.
2005). NPCs also secrete neurotrophins and other growth regulators (Benoit et al. 2001;
Llado et al. 2004; Shingo et al. 2001; Taupin et al. 2000), and transplantation of stem cells
and/or NPCs increases their own survival (autocrine effects), as well as promoting neuron
survival after injury (paracrine effects) (Chang et al. 2003; Llado et al. 2004).
Effects of HIV proteins on NPCs or GPCs are relatively unexplored, and are likely
different from effects on mature glia.

They may be critically important to pediatric

patients, who frequently present with early and with more pathological forms of
neuroAIDS (Drotar et al. 1997; Lobato et al. 1995; Van Rie et al. 2007). The majority of
these patients are infected at birth, when glial populations are still developing. The present
study was designed to determine whether NPC/GPCs from striatum have the capacity to
produce chemokines/cytokines, and if so, whether exposure to HIV proteins can modify
production, with potential functional consequences.

Materials and Methods

All experimental protocols conformed to local Institutional Animal Care and Use
Committee (IACUC) and national (PHS) guidelines on the care and ethical use of animals.
Experiments were designed to minimize the total number of animals used and their
discomfort.
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Progenitor Cell Cultures
The striatum is a region that is particularly vulnerable to both HIV-induced and
opiate-induced degenerative changes, and is a region of great interest for the synergistic
effects of these two insults. Progenitor cell cultures were prepared from the striatum of
embryonic day 15 (E15) mice using modifications of a previously published technique
(Khurdayan et al. 2004). In brief, embryos were aseptically removed from the uterus of
timed pregnant ICR dams (Charles River, Boston, MA) following cervical dislocation. The
striata from 10-12 embryos were dissected from the rest of the cortex, finely minced, and
incubated with DNase (0.015 mg/ml, Sigma-Aldrich Co., St. Louis, MO) in Dulbecco's
Modified Eagle's Medium without additives (15 min, 37˚C). Tissue was triturated through
a 5 ml pipette, centrifuged, and resuspended in 5 ml of defined, progenitor maintenance
medium containing 1:1 DMEM/F12 (Invitrogen Corp., Carlsbad, CA) and 10%
Knockout™ SR (Invitrogen), a commercial serum replacement product that does not
contain serum or growth factors.

Additional additives included insulin (25 µg/ml),

transferrin (100 µg/ml), progesterone (20 nM), putresceine (60 µM), Na-HCO3 (6 mM),
and sodium selenite (30 nM) (all from Sigma-Aldrich Co.). Resuspended cells were
filtered through a 70 µm nylon Cell strainer (BD Falcon, Bedford, MA), counted,
centrifuged as above, and resuspended in the appropriate volume of the same medium to
obtain desired plating densities. Cells were plated on either poly-L-lysine coated 24 well
plates for Multi-plex assay (105 total cells per well) or poly-L-lysine coated 15mm glass
coverslips for immunostaining (5x104 cells in 150 µl), and medium was changed after 2
days. Cells were growth at 37˚C, in a humidified atmosphere with 5% CO2 throughout. At
5 days the medium was refreshed again and cells were treated with Tat1-86 (100 nM;
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ImmunoDiagnostics,

Woburn,

MA),

and/or

gp120

(MN

strain;

500

pM;

ImmunoDiagnostics), and/or morphine sulphate (500 nM; NIDA Drug Supply System,
Rockville, MD), and/or naloxone (1.5 μM; Sigma-Aldrich, St. Louis, MO). Morphine, the
major bioactive product of heroin in the brain, is a potent µ-opioid receptor agonist, and
naloxone is a broad spectrum opioid receptor antagonist. These are concentrations of HIV
proteins and opiates that have elicited functional effects, including increases in
chemokine/cytokine secretion, in astroglia, oligodendrocytes, and neural progenitors in our
earlier studies (Buch et al. 2007; El-Hage et al. 2005; Hauser et al. 2009; Khurdayan et al.
2004). In studies with naloxone, the inhibitor was applied 30 min prior to other treatments,
which were applied simultaneously in pre-warmed medium.

Primary microglial cultures
Primary cultures enriched in microglia were prepared from mixed murine glial cultures
using modifications of rat culture protocols (Kong et al. 1997; Levesque et al. 2010).
Briefly, meninges and blood vessels were removed from whole brains of 1 day postnatal
pups. Tissues were gently triturated in microglia-enrichment media and seeded (four brains
or > 5 × 107 cells) in poly-L-lysine-coated 150 cm3 flasks. Microglia-enrichment medium
consists of 1 : 1 DMEM/F12 containing 10% heat-inactivated fetal bovine serum, 2 mM Lglutamine, 1 mM sodium pyruvate, 100 µM non-essential amino acids, 50 U/mL penicillin,
and 50 µg/mL streptomycin (Invitrogen). Cell suspensions were filtered through nylon
mesh with 70 µm pores before plating onto 150 cm3 flasks. Cultures were maintained at
37˚C in a humidified, 5% CO2 atmosphere. Medium was replenished every third day after
the initial seeding. 10~12 days after seeding, when the glia had formed a confluent
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monolayer, microglia were mechanically dislodged and the detached cells were panned on
uncoated tissue culture dishes for 1–2 h to remove more adherent cells such as astrocytes
and progenitors. Microglia were pelleted at 100 g for 5 min, then resuspended in fresh
medium. We confirmed that the primary microglia were > 95% pure by immunostaining
with the specific marker, Iba-1 (not shown).

Immunohistochemistry and Quantification
Progenitor cell cultures were immunostained at 5 days post-plating, using cellspecific and lineage-specific markers including the O4 antibody which detects sulfatide
(Sommer and Schachner 1982), and antibodies to glial fibrillary acidic protein (GFAP;
1:2,000, Chemicon/Millipore, Billerica, MA), CD11b (1:100, Millipore, Billerica MA),
Olig2 (1:100, Immuno-Biological Laboratories, Minneapolis, MN), Sox2 (1:100, R&D
Systems; Millipore) and nestin (1:5,000, Aves Labs, Inc., Tigard, OR).

In some

experiments, and based upon the Bio-plex data, cells were double-immunostained with
CCL5/RANTES (1:100, Santa Cruz Biotechnology Inc., Santa Cruz, CA), CXCR4 (clone
12G5, 1:50, Abcam Inc., Cambridge, MA), and CCR5 (clone 45523, 25

g/ml, R&D

Systems; clone 2D7, 1:100, BD Pharmingen TM, San Jose, CA) to examine whether
precursors and other cells within the cultures could express particular chemokines and their
receptors. In all cases, cells were fixed with 4% paraformaldehyde, and for intracellular
markers, cells were permeabilized with 0.1% Triton X-100 in PBS containing 5% normal
goat serum for 30 min. Double-staining was performed sequentially, with staining for
chemokines and receptors followed by immunostaining for precursor markers. Antibodies
were applied overnight at 4˚C, followed by visualization with appropriate fluorescent-
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conjugated

second

antibodies

(Molecular

Probes/Invitrogen,

Carlsbad,

CA).

Immunostained coverslips were finally incubated with Hoechst 33342 dye (8 min) to
identify nuclei (Molecular Probes/Invitrogen), then mounted in ProLong Gold antifade
reagent (Molecular Probes/Invitrogen) and dried for 8h in the dark.

To assess the

proportion of different cell types in the cultures, 350-500 Hoechst+ cells were selected
randomly per coverslip and assessed for nestin, Olig2, Sox2, O4, GFAP, or CD11b
immunostaining (N=3-5 different experiments) under oil immersion at 63× using a Zeiss
AxioObserver system with an integrated MRM camera system (Carl Zeiss, Inc.,
Thornwood, NY). At least 100 random Olig2+ cells were assessed for RANTES in similar
cultures. Similar staining methods were applied to 10 µm tissue sections from adult mouse
striatum.

Immunoblotting
CXCR4 and CCR5 expression was examined in 5-day cultures. Cells were
harvested by scraping into ice-cold RIPA buffer (50 mM Tris, pH 7.4; 150 mM NaCl; 1%
Nonidet; 0.5% deoxycholic acid; 0.1% SDS; protease inhibitor cocktail, Roche,
Indianapolis, IN, USA). Cell lysates were pelleted and stored at −80°C until use. Protein
was assayed using the BCA protein assay (Pierce, Rockford, IL, USA). Duplicate samples
of 20μg total protein were loaded per well onto 4-20% Tris–HCl Ready Gels (Bio-Rad
Laboratories, Hercules, CA) using Precision Plus Protein Dual Color Standards (Bio-Rad;
MW range: 10–250 kDa) to monitor protein transfer and molecular weight. Proteins were
transferred to Hybond-P PVDF membranes (Amersham Biosciences, Piscataway NJ),
probed with a monoclonal antibodies to either CXCR4 (ab2074, 1:1,000, Abcam) or CCR5
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(clone 45523, 1:1,000, R&D Systems), and visualized using a chemiluminescent substrate
(Super Signal West Femto substrate, Pierce). Protein bands were detected on a Kodak
Image Station 440CF and analyzed using 1D software.

Multi-plex Assay
After 12 hrs of treatment, 450 µl of media were harvested from each well and
stored at -80˚C. 50 µl of media from each treatment group was analyzed for
chemokine/cytokine content using the Bio-Plex 200 System (Bio-Rad) and standard mouse
23-plex assay kits or custom 12-plex assay kits, according to the manufacturer’s
instruction. Concentrations were determined using Bio-Plex Manager Software (Version
5.0), based upon individual standard curves calculated for each chemokine/cytokine.

Microglial Chemotaxis Assay and CCR5 Antibody Neutralization
An 8.0-µm transwell system (Costar, Corning, NY, USA) was used to measure
changes in the motility of BV-2 microglia-derived cells or primary microglia in response to
Tat- or gp120-treated glial precursor cells in 24-well plates. BV-2 cells were cultured in T75 flasks in medium consisting of DMEM (Invitrogen, Carlsbad, CA, USA) supplemented
with glucose (27 mM), Na2HCO3 (6 mM), 10% defined fetal bovine serum (Hyclone
Laboratories, Inc., Logan,UT, USA) and antibiotics. Cells were harvested at 90%
confluency using a non-enzymatic cell dissociation solution (Sigma-Aldrich Co.), washed
and resuspended in DMEM supplemented with glucose (27 mM), Na2HCO3 (6 mM), and
1% fetal bovine serum, and then plated onto transwell inserts (105 BV-2 cells per insert).
Primary microglia were grown in microglia-enrichment medium and mechanically
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harvested as described earlier. They were washed, resuspended and plated onto inserts
similarly to BV-2 cells. Prior to the addition of transwell inserts containing microglia or
BV-2 cells, 106 progenitors were cultured in each well of a poly-L lysine coated 24 well
plate for 5 days, then treated with Tat or gp120 ± opiates for 12 h. A transwell insert
containing BV-2 cells or microglia was then placed into each well. The transwell inserts
were incubated for an additional 3 h and then removed for analysis. Cells remaining on the
upper surface of the insert were carefully aspirated, leaving those which had migrated to
the surface underneath in place. The insert was then transferred to a clean well containing
225 µL of non-enzymatic cell dissociation solution (Sigma-Aldrich Co.) and incubated for
30 min, at 37˚C, during which time each insert was gently tilted several times to
completely detach cells. The inserts were discarded and 75 µL of 4 × Lysis
Buffer/CyQuant® GR dye solution (Millipore) wereapplied to each well and incubated per
manufacturer’s instructions. 200 µL of dye/buffer/lysate solution were transferred to a 96well plate, and the fluorescence intensity of each sample was measured using a PHERAstar
FS plate reader (BMG LABTECH Inc. Cary, NC, USA) with a 485 nM excitation filter and
520 nM emission filter. In experiments to assess the role of CCR5 in migration, the BV-2
cells or microglia were incubated with anti-CCR5 (clone 2D7, without sodium azide; BD
PharmingenTM) or control IgG (mouse, IgG2a, BD Pharmingen) at a dose of 2 µg per 106
cells for 1 h at 4˚C, prior to the placement of the inserts.

Viability Assay
Neural/glial precursor cells were cultured on poly-L-lysine precoated 48 well plates
and treated at 5 days after plating with morphine, Tat, gp120, and naloxone either alone or
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in combination as in experiments described above. After 12 h, medium containing
treatments was replaced with sterile, tissue culture–grade D-phosphate- buffered saline
containing the LIVE/DEAD® reagents (Invitrogen; calcein AM, 2 µM and EthD-1, 4 µM)
and 5 µg/mL Hoechst 33342. The working solution was added directly to cells and
incubated for 15 min, at 37˚C. The fluorescence intensity of each color was measured using
a PHERAstar FS plate reader (BMG LABTECH) in n = 8 different cultures using
appropriate excitation and emission filters (calcein AM: 495/515 nm; EthD-1: 495/635 nM;
Hoechst: 350/510 nM).

Statistical Analysis
Statistical analyses were done by analysis of variance (ANOVA) followed by
Bonferroni’s post-hoc testing using StatSoft software (Statistica, Tulsa, OK).
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Results

Progenitor cells from E15 striatum secrete chemokines: Effects of viral proteins and
opiates
After 5 days growth in chemically defined medium, the progenitor cell cultures
consisted overwhelmingly of a mixture of immature cell types (Fig. 2.1 A), containing both
NPCs and GPCs at various states of differentiation.

The majority of the cells were

immunostained for nestin (82%) and/or Sox2 (44%), markers of relatively undifferentiated
CNS progenitors (Ellis et al. 2004; Komitova and Eriksson 2004; Lendahl et al. 1990;
Tanaka et al. 2004). Of the nestin-positive cells, 47% also showed Sox2 immunreactivity.
Approximately 20% of the cells had entered the oligodendrocyte lineage, as indicated by
expression of Olig2 (Ligon et al. 2006; Woodruff et al. 2001). Another ~40% expressed
DCX, a microtubule-associated protein found almost exclusively in neuronal precursors.
Somewhat surprisingly, very few of the cells expressed the astrocyte marker GFAP (< 3%).
Many DCX+, Olig2+ and GFAP+ cells also were nestin+ or Sox2+, suggesting relatively
recent entry into a specific lineage. Less than 0.8% of cells stained with the CD11b
microglial marker. As reported previously, over 70% of the Olig2+ cells in these cultures
expressed the µ-opioid receptor (MOR) (Hauser et al. 2009). Most cells that were Olig2- or
DCX- were also MOR+, indicating that MOR was also expressed in uncommitted
precursors (Fig. 2.1 B and C). Thus, multiple types of progenitors are potential targets of
MOR agonists and antagonists such as morphine and naloxone.
Progenitors were treated for 12 hr with HIV-1 proteins and/or opiates, after which
their conditioned medium was harvested and screened for expression of an array of
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chemokines and cytokines significant in the pathobiology of inflammatory disease and/or
displaying cross-sensitization to opiates. The 12 hr time-point was chosen because it gave a
consistently detectable accumulation of secreted products. Based on our earlier studies
with other types of glia (El-Hage et al. 2005), longer time-points can result in higher
accumulation, but they also increase the likelihood that autocrine and paracrine effects of
the chemokines/cytokines will influence cell secretions. Of the 23 factors initially tested,
only 10 were expressed and/or secreted at detectable levels by untreated striatal progenitor.
The concentrations of the individual chemokines/cytokines detected after 12 hrs (pg/ml)
are given in Table 1. Exposure of progenitors to viral proteins and/or opiates did not
change the factors that were secreted, but did affect the accumulated amounts of several.
The secretion of β-chemokines CCL3/MIP-1α, CCL4/MIP-1β and CCL5/RANTES were
all significantly increased by Tat exposure, but not by gp120 exposure (Fig. 2.2). Unlike
prior observations in astrocytes, concurrent exposure to Tat and morphine did not have an
interactive effect on chemokine/cytokine release, even though the majority of cells in the
cultures expressed MOR. Neither was there an interactive effect of Tat and gp120.
CCL2/MCP-1 showed a trend towards a Tat response, but the effect was not significant
using ANOVA analysis. It is likely that cells at multiple stages of differentiation
contributed to both baseline and Tat induced secretion, as CCL5/RANTES was detected by
immunostaining in a subset of both Sox2+ and Olig2+ cells in vitro (Fig. 2.3 A–C).
CCL5/RANTES staining was also evident in Sox2+ cells in vivo (Fig. 2.3 D), but it was
quite difficult to detect in Olig2+ cells in vivo (not shown), suggesting down-regulation in
oligodendroglial precursors in the brain. We also examined expression of the β-chemokine
receptors CXCR4 and CCR5, known to be co-receptors for gp120 binding and HIV entry
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into cells. Immunohistochemistry showed that both CCR5 and CXCR4 were present on
Olig2+ and Sox2+ progenitors, as well as on neighboring Olig2- and Sox2- cells. Both
receptors were also readily detected on western blots from progenitor cultures (Fig. 2.4 E;
20-µg load), as well as astroglia and striatal homogenates. Major bands were found at ~40
kD, which is the reported molecular weight of both CCR5 and CXCR4.

Progenitor cells induce a chemotactic response in microglial cells
A transwell apparatus was used to test whether secreted factors from progenitors
could influence the movement of BV-2 and primary microglial cells. All tests were
conducted over a 3-h period. Some cells moved randomly across the membrane during the
test period (Fig. 2.5 A–C, medium only). Addition of Tat or gp120 to the medium in the
absence of NPC/GPCs did not change the migration of either BV-2 cells or primary
microglia (Fig. 2.5 A–C, medium + Tat, medium + gp120). When NPC/GPCs were plated
in a 24 well plate and transwell inserts were added after 5 days, secretions from NPC/GPCs
did not alter BV-2 or primary microglial migration (Fig. 2.5 A–C, NPC/GPC). However,
when the progenitors were pre-treated for 12 h with HIV-1 Tat the result was quite
different (Fig. 2.5 A–C, NPC/GPC + Tat). In that case, there was a significant increase in
migration of both BV-2 cells and primary microglia across the transwell membrane
towards the Tat-treated progenitors. NPC/GPCs treated with gp120 did not elicit a similar
enhancement of migration in either type of microglial cell.
As microglia can be attracted by signals from dying cells, we examined cell death
using a fluorescent LIVE/DEAD assay kit (Invitrogen). Approximately 10% of the total
Hoechst-labeled nuclei belonged to dead cells, but there were no significant differences
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among treatments that might account for the additional BV-2 cell migration induced by
HIV-1 Tat (n = 8; Fig. 2.6). This suggests that the microglial chemotaxis observed in our
experiments is most likely to result from enhanced chemotactic signals released from
progenitors stimulated by viral proteins. CCR5 is the common receptor for the bchemokines that were up-regulated by Tat in progenitor cultures. To further confirm that
chemokines up-regulated by Tat were contributing to the enhanced migration of microglial
cells, we conducted experiments to neutralize CCR5. Both BV-2 cells and primary
microglia were incubated for 1 h with the 2D7 antibody (sodium azide-free), which has
been shown by others to be suitable for receptor blockade studies (De Clercq 2009;
Jayasuriya et al. 2004; Lee et al. 1999). Figure 2.5 (B) and (C) shows, respectively, that
treatment of both BV-2 and primary microglia with the 2D7 monoclonal CCR5 antibody
prior to their addition to the transwell insert completely abolished the enhanced migration
elicited by NPC/GPCs.

Discussion

HIV-associated neuropathology in the CNS is generally thought to result from the
combined effects of direct viral protein toxicity, and inflammatory/toxic conditions
propagated by surrounding glial cells.

Because of our interests in the effects of co-

morbidity between opiate drugs of abuse and HIV exposure in the CNS, we chose to
examine the striatum, an area which is both rich in opiate receptors and extremely
vulnerable to HIV-induced neuropathology.

Our data show that progenitors from

embryonic striatum secrete a variety of chemokines/cytokines in culture, and that exposure
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to HIV-1 Tat1-86 selectively increases secretion of a subset of these. The concept that
NPC/GPCs in the normal brain may secrete factors to regulate either their own function or
fate, or that of surrounding cells, has been previously established (Benoit et al. 2001;
Chang et al. 2003; Shingo et al. 2001; Taupin et al. 2000). Further, it is known that
progenitors or stem cells from other regions have this ability. Mesenchymal stem cells, for
instance, secrete multiple chemokine/cytokines and growth factors, including multiple
FGFs, IGF-1, IL-1β, IL-6, CCL2/MCP-1, CCL3/MIP-1α, CCL4/MIP-1β, SDF-1, VEGF,
and others (Chen et al. 2008; Croitoru-Lamoury et al. 2007; Liu and Hwang 2005; Rafei et
al. 2008; Schinkothe et al. 2008; Wagner et al. 2007). Importantly, this is the first study to
show that secretions from a neural progenitor population have a chemotactic effect on
microglial cells, and that these secretions and their effects can be enhanced by exposure to
HIV-1 Tat.
A previous study on E15 striatal progenitors grown as proliferating neurospheres
(Benoit et al. 2001) examined some of the cytokines that we initially screened.

In

agreement, we both found a complete lack of IL-3, IL-4 and IL-1α secretion. However, our
cells also secreted detectable levels of granulocyte macrophage colony-stimulating factor,
IL-6, IL-9 and TNF-α, as well as five other chemokines/cytokines that were not assayed in
the previous study. Our cells were grown in monolayers, and assayed at an earlier in vitro
age using a different methodology, so these differences are perhaps not surprising. There
are likely to be additional chemokine/cytokines secreted by striatal progenitors, as our
initial screening process used the manufacturer’s standard kit which assays for a group of
23 selected analytes.
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The progenitor cultures from E15 striatum contain a mixture of cells at different
stages of differentiation (Fig. 2.1). Immunocytochemistry showed that most expressed
either nestin, Sox2, or both. While 20% expressed Olig2, a transcription factor that
indicates commitment to an oligodendroglial fate, there was a complete absence of O4
staining, suggesting that the Olig2+ cells were still quite immature. Likewise, the 3% of
cells that were GFAP+ seemed quite immature based on morphology and variable coexpression of nestin or Olig2. As expected in a striatal progenitor culture, many of the cells
were young neural precursors expressing DCX (~40%), but the absence of NeuN reactivity
suggested their relative immaturity. Individual chemokines/cytokines appear to be secreted
by cells across several stages of development, and there is also variability of expression
within specific populations. For example, although most CCL5/RANTES+ cells do not
immunostain for Olig2, a subset are Olig2+ (Fig. 2.3); and among Olig2+ cells, only about
50% are CCL5/RANTES+ (data not shown).
Regardless of the stage at which progenitors release these factors, our results show
that the production of CCL5/RANTES, CCL3/MIP-1α and CCL4/MIP-1β, is significantly
increased following exposure to HIV-1 Tat for 12 hr (Fig. 2.2). In contrast, exposure to
gp120 did not affect levels of any of the chemokines/cytokines. It is unlikely that the very
small populations of microglia (< 0.8%) or immature astroglia (3%) are responsible for
either baseline or Tat-induced chemokine/cytokine secretion, especially as MIP-1α and
MIP-1β were not been detected in our other studies. The earlier studies also showed that
co-exposure to morphine enhanced Tat-induced CCL5/RANTES production by astroglia
(El-Hage et al. 2008b; El-Hage et al. 2005). The lack of morphineinduced synergy in the
present results also suggests that astroglia are not the primary source.
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In striatal astroglia there is a synergistic effect of morphine on Tat-induced
secretion of CCL2/MCP-1, CCL5/RANTES and IL-6. The lack of morphine-induced
synergy in progenitor cultures is not because of a lack of appropriate receptors as most
progenitors express MOR (Fig. 2.1) (Buch et al. 2007; Hauser et al. 2009). However, the
signaling pathways leading to synergistic secretory responses may not be functional in
immature cells. gp120 did not increase NPC/GPC secretion of the panel of analytes that we
examined. This is similar to our observations in mature astroglia fromseveral brain regions
(Fitting et al. 2010c), although gp120 from different HIV strains is variably reported to
induce TNF-α, IL-1α, IL-1β, and IL-6 in other astroglial preparations (Buriani et al. 1999;
Kong et al. 1996; Ronaldson and Bendayan 2006; Yeung et al. 1995). CD4 is the major
receptor for gp120 binding and virus entry, and binding is facilitated by expression of CD4
co-receptors such as CCR5 and CXCR4. The strain of gp120 that we used (MN)
preferentially uses the CCR5 co-receptor. Progenitors expressed abundant CCR5 (Fig. 2.6),
but do not express CD4 and therefore may have limited ability to respond to gp120.
Binding of chemokine ligand versus gp120 to a chemokine receptor may have
fundamentally different consequences. For example, in a previous study, gp120 IIIb
required ‘priming’ by exposure to soluble CD4 in order to elicit a simple CXCR4-mediated
Ca2+ response from similar murine progenitors (Tran et al. 2005).
As Tat exposure can clearly enhance chemokine secretion from progenitors, might
this have functional consequences? A transwell assay showed that progenitors exposed to
HIV-1 Tat for 12 h were able to enhance the directed movement of both BV-2 cells and
primary microglia (Fig. 2.5). gp120 did not enhance chemokine production, so it was not
surprising that progenitors treated with gp120 did not elicit the same migratory response
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(Fig. 2.5). Importantly, blockade of the CCR5 receptor on microglial cells eliminated the
enhanced migration (Fig. 2.5 B and C), showing that secretions of the CCR5 ligands
RANTES, MIP-1α and MIP-1β, from progenitors have the potential to direct microglial
movement. We believe that our data suggest chemotaxis, not just enhanced, random
motility, as there is only a modest exchange of medium over the short assay period through
the small membrane plating area. The BV-2 cells are plated into a well containing their
original culture medium and are moving towards the continually renewed source of
chemokines.
What are the potential consequences of chemokine/cytokine secretion by
NPCs/GPCs, and the upregulation of β-chemokine production by HIV-1 Tat? These are
best discussed considering the two very different contexts of interest – the normal brain and
the HIV-infected brain. Ten of the chemokines/cytokines we examined were secreted at
detectable levels by untreated progenitors, and several of these are chemoattractants for
inflammatory cells. Under normal conditions, attracting monocytes/microglia may not be
harmful. They serve diverse roles essential for normal brain function, independent of the
innate immune response, which include providing trophic support, regulating neurogenesis
and neuron development, and clearing toxic debris (Aarum et al. 2003; Block et al. 2007;
Polazzi and Contestabile 2002; Simard et al. 2006; Walton et al. 2006; Whitney et al. 2009;
Ziv et al. 2006). During HIV-infection there are different considerations. CCL5/RANTES,
CCL3/MIP-1α and CCL4/MIP-1β are all known to act as endogenous suppressors of HIV
infection and cell damage due to their ability to block gp120 binding with its CCR5 coreceptor (Catani et al. 2000; Cocchi et al. 1995), and both CCR5 and its ligands are the
subject of ongoing investigation as therapeutic targets to reduce viral entry (reviewed in
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DeVico and Gallo 2004; Vangelista et al. 2008). Thus, enhanced β-chemokine secretion
might afford a degree of protection. However, all three β-chemokines are also implicated in
HIV-neuropathology. Depending upon the severity of inflammation they may contribute to
an environment that is detrimental to neurons. RANTES is a well known chemoattractant
for T-cells, granulocytes, and monocytes, and is thought to recruit HIV-infected monocytes
to the brain, either alone or through triggering MCP-1 production (Conant et al. 1998; ElHage et al. 2005; Kelder et al. 1998; Luo et al. 2003; Schall et al. 1990). CCL3/MIP-1α
and CCL4/MIP-1β are routinely produced by activated macrophages and attract monocytes
as well as lymphocyte subpopulations including granulocytes and neutrophils (Menten et
al. 2002).

β-chemokines also stimulate synthesis and release of pro-inflammatory

cytokines, are upregulated and expressed by astroglia and microglia in the HIV infected
brain (Kelder et al. 1998; Letendre et al. 1999; Schmidtmayerova et al. 1996), and correlate
positively with HIV dementia (Letendre et al. 1999). Thus, dysregulated β-chemokine
expression by progenitors and glia might potentiate local inflammation, and might enhance
local trafficking of HIV-infected cells into the brain. Supporting this concept, multiple
indicators of inflammation were reduced after intrastriatal injection of HIV-1 Tat into
RANTES/CCL5 deficient mice compared to control (El-Hage et al. 2008a).
The concept that chemokine/cytokine effects may differ in normal versus
inflammatory situations is well-illustrated by considering CCL2/MCP-1. While
CCL2/MCP-1 can be protective towards isolated neurons (Eugenin et al. 2003; Madrigal et
al. 2009; Yao et al. 2009), in the context of HIV-1 infection, the negative effects of
attracting infected monocytes and driving inflammation are likely to outweigh direct,
neuroprotective effects observed in isolation. The complexity of these issues is clearly
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highlighted by disparate results in two studies using mice deficient in CCR2, showing
either protection (Eugenin et al. 2003; Madrigal et al. 2009; Yao et al. 2009) in the context
of HIV-1 infection, the negative effects of attracting infected monocytes and driving
inflammation are likely to outweigh direct, neuroprotective effects observed in isolation.
The complexity of these issues is clearly highlighted by disparate results in two studies
using mice deficient in CCR2, showing either protection (El-Hage et al. 2006a) or
exacerbation (Yao et al. 2009) after intrastriatal Tat injection, depending on timing, region
examined, and outcome measure.
Importantly, we found robust expression of CCL5/RANTES associated with some
Sox2+ cells in the striatum (Fig. 2.3 D), suggesting that secretion of chemokines by NPCs
does occur in vivo, and in the adult CNS. Progenitors are a relatively small population in
the mature brain and will have less influence on overall inflammatory tone than microglia
and astroglia. However, we speculate that they may have an important influence on the
local milieu, and particularly in situations where progenitor populations are increased, such
as regions of active CNS repair, or during development. In the context of HIV, progenitors
may particularly contribute to the neuropathology that occurs in young pediatric patients,
where glial populations are still developing. HIV-1 associated progressive encephalopathy
occurs in a relatively high percentage of pediatric HIV patients, where it develops
aggressively and is frequently the earliest clinical manifestation of disease (Drotar et al.
1997; Ensoli et al. 1997; Schwartz and Major 2006; Van Rie et al. 2007). Chemokine
production by progenitors might normally be an adaptive process, to encourage the
immune surveillance and approval of cells before they make additional contributions to
neural or glial populations. Enhanced secretion of chemokines in the context of HIV might
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circumvent this adaptive strategy, by attracting HIV-infected microglia/monocytes to
NPC/GPCs, which can be infected by HIV (Lawrence et al. 2004; Rothenaigner et al.
2007), and which appear to pass the virus to their neuronal and glial progeny (Lawrence et
al. 2004).

In summary, we have shown that HIV-1 Tat increases production b-chemokines by
striatal progenitors, resulting in the CCR5-mediated movement of microglial cells. As Tat
mRNA and/or protein have been detected in CNS tissue samples from both patients with
HIV-1 encephalitis and rhesus macaques infected with a chimeric HIV-SIV (SHIV) virus
(Hudson et al. 2000), these findings have significant disease relevance. The effects of
enhanced chemokine release will be contextual, because of complex interplay between
multiple secretory and responder cell types in vivo, as well as temporal issues during
normal and disease processes. Emerging evidence suggests that human neural progenitors
may be cellular reservoirs of HIV infection (Lawrence et al. 2004; Rothenaigner et al.
2007; Schwartz and Major 2006), although the extent of NPC/GPC infection in the brain
remains unclear. The potential contribution of this infected population to the chemokine
milieu must also be considered.

Acknowledgements
We acknowledge generous NIH support from R01 DA024461 and P01 DA19398.

37

Table 2. 1: Chemokines/cytokines secreted by progenitor cells from E15 striatum
(pg/ml)
IL-1β
C
M
T
G
N
MT
MG
MTN
MTG
MTGN
MN

C
M
T
G
N
MT
MG
MTN
MTG
MTGN
MN

<0.85

#

1.10±0.25
5.54±1.52
1.35±0.32
<0.85

#

5.76±2.31

GM-CSF
<1.17
<1.17

TNF-α

#

<0.3

#

<0.3

2.43±0.83

#

0.68±0.28

1.64±0.47
<1.17

#

0.44±0.09

#

1.27±0.21

IL-6
1.78±1.06
<0.72

#

5.10±2.88
<0.72
<0.72

#
#

<20.4

#

23.21±2.57
28.85±3.15
27.54±6.53
<20.4

#

1.64±0.47

1.14±0.36

1.96±0.79

0.34±0.04

7.46±4.47

2.46±1.29

0.76±0.23

6.72±4.74

23.21±2.57

6.99±2.77

3.22±0.96

1.20±0.81

3.09±1.06

26.03±3.15

9.87±4.02

1.81±0.64

0.51±0.14

1.78±1.61

<0.85

<0.85

#

#

<1.17

#

<0.3

#

4.81±3.00

IL-9

<0.72

<0.72

#

#

26.03±3.15
<20.4

<20.4
<20.4

#

#
#

KC

RANTES

MIP-1α

MIP-1β

MCP-1

6.70±2.42

5.74±0.56

57.86±15.59

135.5±36.09

68.77±26.9

6.21±2.52

5.09±0.35

26.94±0.02

98.07±22.08

57.03±24.12

25.40±10.81

336±26.8

312.5±25.11

957±102.5

183.6±78.2

7.63±2.29

6.34±1.03

119.5±62.8

273±185.1

94.26±38.65

6.11±2.39

3.59±0.81

26.95±0.0

75.17±16.64

58.83±23.72

20.61±9.52

292±59.7

307.1±62.06

714.5±127.8

170.15±76.58

5.74±2.03

5.06±1.09

48.63±21.69

94.12±17.35

47.85±16.08

32.62±15.89

397±105

376.8±104.6

1009.1±194

237.2±131.6

24.12±9.13

271.7±32.33

321.9±61.6

945±165.9

167.9±75.83

24.81±9.51

336.3±28.31

376.0±46.9

1063±116.3

124.8±75.26

5.85±2.58

4.08±0.58

26.94±0.0

66.93±18.06

55.79±21.8

a

Sample concentration was determined to be below the accuracy limit of the assay

software, based on the standard curve generated for the individual chemokine/cytokine. In
those cases, we have indicated the lower limit value in pg/mL. For all samples, n = 6.
The following proteins were not routinely detected in control or treated cells:
IL-1α, IL-2, IL-3, IL-4, IL-5, IL-10, IL-12(p40), IL-12(p70), IL-13, IL-17, G-CSF,
Eotaxin, IFNγ.
C, control; M, morphine; Tat, transactivator of transcription; G, gp120; N, naloxone.
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Figure 2.1
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Figure 2.1 Characterization of progenitor cultures from E15 striatum. Cultures were
immunostained after 5 days for typical markers of neural and glial precursors, and for
MOR. (a) Most cells stained for nestin (> 80%) and/or Sox2 (> 40%), indicating that they
were relatively immature precursors. Approximately 40% were DCX+ and 20% were
Olig2+, indicating entry into the path leading towards a neuronal or oligodendrocyte fate,
respectively, while less than 3% of cells were GFAP+. Many cells that expressed DCX,
Olig2 or GFAP also expressed nestin or Sox2, suggesting very recent entry into a specific
lineage. CD11b+ microglia were < 0.8% of the population. None of the cells stained for O4,
a marker of more mature OLs. (B–E) Triple labeling shows that most precursors in these
cultures, regardless of differentiation state, express MOR (red, B and D). The Hoechst+
nucleus of a cell that is MOR) is indicated by (*) in panel (d). Two Olig2+ cells the express
MOR are indicated by arrowheads in each panel. Scale bar = 10 µM.
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Figure 2.2

Figure 2.2 Exposure to HIV-1 Tat1-86 increases progenitor secretion of a select group of
chemokines. Cells were treated at 5 days after plating with morphine (M), Tat (T), gp120
(G), and naloxone (N) either alone or in combinations as indicated. Of 23 factors tested, 10
were secreted by unstimulated cells (see Table 1). Only RANTES, MIP-1α, and MIP-1β
showed a significant change in concentration after 12-h treatment. Cells responded to Tat,
but not to gp120. There was no synergistic response of concurrent exposure to either
morphine or gp120. MCP-1 showed a similar trend towards a Tat response, but the effect
was not significant. *p < 0.05; **p < 0.01; ***p < 0.001 vs. untreated control cells (C),
ANOVA and post-hoc Bonferroni’s test. n = 6 independent cultures.
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Figure 2.3
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Figure 2.3 Localization of CCL5/RANTES in NPC/GPCs in vitro and in vivo. Cultured
cells were immunostained (A–C) at 5 days in vitro. In vivo staining (D and E) was done in
adult striatum. (A and B) NPC/GPCs were immunostained with an antibody to Olig2 (A) to
identify oligodendroglial precursors, and an antibody to CCL5/RANTES (B) to determine
which cells are producing this chemokine. Of the five Olig2+ cells in this field, two show
CCL5/RANTES expression in their cytoplasm (arrows indicate double-labeled cells).
Three other cells that are Olig2+ (asterisks) do not express detectable levels of
CCL5/RANTES. For (C–E), Z stacked images (AxioVision software, version 4, Carl Zeiss,
Inc.) were taken through the entire depth of the cell layer (C) or section (D and E), then
optimized for deconvolution microscopy (AutoQuant X Version 2, Media Cybernetics,
Bethesda, MD, USA) in order to better demonstrate sub-cellular details of Sox2 and
CCL5/RANTES co-localization. (C) Cells in the same NPC/GPC cultured stained for Sox2
(green) and CCL5/RANTES (red). The Sox2+ cells are a mixture of CCL5+ (asterisks) and
CCL5) (arrows). Note also that many CCL5+ cells are Sox2) (arrowheads). Hoechst
staining (blue) identifies the nuclei of all cells in the field. (D and E) Co-localization of
Sox2 (green) and CCL5/RANTES (red) in the adult mouse striatum in situ. Hoechst
staining (blue) identifies nuclei of all cells in the field. As CCL5 is a secreted, soluble
chemokine, it is difficult to associate specific cell boundaries with CCL5 immunostaining.
However, it can be appreciated from panel (D) that Sox2+ cells (asterisks) in the striatum
are frequently associated with significant CCL5 immunostaining. The region shown in (E)
has a high density of Sox2- cells, as indicated by the Hoechst staining, and little CCL5
signal.
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Figure 2.4

Figure 2.4 NPC/GPCs express both CCR5 and CXCR4 in vitro. Olig2+ (green)
oligodendroglial precursors show both CCR5 (A) and CXCR4 (C) immunoreactivity. The
signal for CXCR4 was generally light in these cells, and is indicated by arrows in (C).
Undifferentiated Sox2+ NPC/GPCs (green) also are immuno-positive for CCR5 (B) and
CXCR4 (D). Asterisks in (A–D) indicate double-labeled cells. Hoechst33342 nuclear
staining (blue) shows that some cells positive for CCR5 or CXCR4 do not express Olig2 or
Sox2. (E) A major band at approximately 40 kDa was noted on immunoblots of NPC/GPCs
harvested at 5 DIV using antibodies to both CCR5 and CXCR4. Actin detection is included
as a loading control. These bands are also detected in homogenates of cultured astroglia
(AS) and whole striatum, preparations that are known to express both receptors.
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Figure 2.5
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Figure 2.5 Chemotaxis of BV-2 cells and primary microglia in response to NPC/GPCs in
transwell cultures. (A) NPC/GPCs grown on a 24-well plate were treated with Tat or gp120
for 12 h prior to the addition of transwell inserts containing BV-2 cells. Transwell inserts
were removed after 3 h, and cells crossing the insert membrane were labeled with
CyQuant® GR dye and quantified on a PHERAstar FS plate reader with appropriate filters.
Migration of BV-2 cells was not affected when either Tat or gp120 alone was added to the
medium. Untreated NPC/GPCs also had no effect on BV-2 migration. However, the
number of BV-2 cells moving across the transwell membrane was significantly enhanced
when NPC/GPCs were pre-treated with Tat for 12 h (***p < 0.001 vs. all other groups; n =
6 independent cultures). Pre-treatment of NPC/GPCs with gp120 did not affect BV-2
migration. The inset image shows Hoechst staining of BV-2 cells, and illustrates the effect
of NPC/GPC treated with Tat to enhance migration. (B) Antibody neutralization of CCR5
on BV-2 cells significantly attenuated Tat-enhanced migration. BV-2 cells on transwell
inserts were preincubated with either 2D7 anti-CCR5 monoclonal antibody or control
IgG2a for 1 h at 4˚C, then placed into wells containing treated or untreated NPC/GPCs.
Incubation with 2D7 antibody, but not control IgG2a, reduced BV-2 cell migration in the
NPC/GPC + Tat treatment group back to basal levels. This suggests that the enhanced
microglial migration caused by secretions from Tat-treated NPC/GPC is entirely mediated
by CCR5-signaling. Antibody neutralization did not reduce migration in other treatment
groups to below basal levels. (**p < 0.01 vs. all other groups; n = 6 independent cultures).
(C) Studies in (A) and (B) were repeated on primary murine microglia with similar results.
Migration of primary microglia was significantly enhanced by the presence of NPC/GPCs
pre-treated with Tat, although there was no effect of gp120 pre-treatment. Incubation with
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2D7 antibody reduced migration in the NPC/GPC + Tat treatment group back to basal
levels, but did not affect migration in other treatment groups. (***p < 0.001 vs. all other
group; n = 4 independent cultures).
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Figure 2.6

Figure 2.6 A fluorescent viability assay reveals that 12-h exposure to HIV-1 Tat1-86 or
gp120 alone or in combination with opiates did not increase the rate of NPC/GPC cell
death in vitro. Cells were treated at 5 days after plating with morphine (M), Tat (T), gp120
(G), naloxone (N) either alone or in the combinations indicated. There was no significant
increase in cell death in any treatment group. n = 8 independent cultures
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Chapter 3
HIV-1 Alters Neural and Glial Progenitor Cell Dynamics in the CNS:
Coordinated Response to Opiates During Maturation

(This chapter was submitted as a paper to Glia and is accepted pending revision.

Introduction

Morbidity and mortality due to human immunodeficiency virus (HIV-1) infection has
significantly decreased since the introduction of combined anti-retroviral therapy (cART).
cART treatment has also changed the landscape of central nervous system (CNS) disorders.
Fewer patients exhibit HIV associated dementia (HAD), but there is increased prevalence
of asymptomatic and mild-to-moderate HIV-associated neurocognitive disorders (HAND)
among patients with absence of peripheral viremia (Cysique et al. 2004; Gonzalez-Scarano
and Martin-Garcia 2005; Gonzalez et al. 2002; Sacktor 2002; Simioni et al. 2010). Factors
contributing to CNS pathology and dysfunction include an increased life expectancy of
HIV-1 patients receiving cART, and potential toxic effects of long-term anti-retroviral
exposure (Apostolova et al. 2011; Clifford 2002). In addition, many HIV therapeutics do
not readily penetrate the blood brain barrier, leaving a reservoir of HIV in the CNS.
Microglia are the principal source of active HIV infection in the brain; astroglia can also
be infected but tend not to produce new virus (Gonzalez-Scarano and Martin-Garcia 2005;
Jordan et al. 1991; Kaul 2008). Several studies suggest that CNS neural progenitor cells
(NPCs), the undifferentiated precursors of both neurons and glia, are also susceptible to
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HIV-1 infection (Lawrence et al. 2004; Rothenaigner et al. 2007; Schwartz et al. 2007), but
the extent that this contributes to the spectrum of CNS disorders remains unclear. Even if
NPCs are not readily infected, they may be affected either by HIV-1 proteins directly
(Buch et al. 2007; Hahn et al. 2010b; Krathwohl and Kaiser 2004b; Lee et al. 2011; Mishra
et al. 2010; Okamoto et al. 2007; Peng et al. 2008), or secondarily by changes in the
extracellular milieu. NPCs are widely distributed in germinative zones within the
developing CNS. Neurons in most brain regions are formed prenatally, but production of
astroglia and oligodendroglia continues into the postnatal period in both rodents and
humans (Chan et al. 2002; Geha et al. 2010; Lee et al. 2000; Skoff 1990; Skoff and Knapp
1991; Suh et al. 2007). NPCs also are present in the adult CNS. While neurogenesis occurs
in specific regions, including the subgranular zone in the dentate gyrus of the hippocampus
and the subventricular zone of the lateral ventricles (Doetsch et al. 1997; Eriksson et al.
1998; Kaplan and Hinds 1977; Kornack and Rakic 1999), glial progenitors are found
throughout the adult CNS. There is a slow turnover of glial cells throughout life (Goldman
and Sim 2005; Imamoto and Leblond 1978; Kornack and Rakic 1999; Kornack and Rakic
2001; Liu et al. 2004; Messier et al. 1958; Sturrock 1979), and more active gliogenesis
occurs during situations of injury/disease (Burns et al. 2009; Rola et al. 2006; Romanko et
al. 2004). Glial progenitors constitute 1-to-4% of the cells in normal adult brains (PicardRiera et al. 2004; Reyners et al. 1986).
To test the hypothesis that HIV-1 infection can affect the dynamics of cell production
during development, we used stage-specific markers to follow changes in the proliferation
rate and populations of NPCs (nestin+ and Sox2+ [SRY (sex determining region Y)-related
HMG (high mobility group)-box gene2]) and their glial progeny both in culture and in the
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intact brain during the perinatal period. Opioid receptors are present and functional on
NPCs and glial progenitors in adult and neonatal rodent and human CNS (Buch et al. 2007;
Hauser et al. 2009; Persson et al. 2003; Reznikov et al. 1999; Rius et al. 1991; Tripathi et
al. 2008). Since co-exposure to opiate drugs of abuse enhances HIV-related deficits in the
CNS in patients and experimental models (Anthony and Bell 2008; Bell et al. 2006; Burdo
et al. 2006; Byrd et al. 2011; Hauser et al. 2007; Kopnisky et al. 2007), we also examined
interactive opiate effects. HIV-1 Tat was used to model HIV exposure both in vitro and in
vivo. We also assessed progenitor responses in a more clinically relevant model by
exposing human NPCs (hNPCs) to supernatant from HIV-infected monocytes ± opiates.
Results showed that HIV-1 Tat or morphine alone reduced NPC and glial progenitor
proliferation and/or altered the population dynamics of murine progenitors both in vitro and
in vivo. In certain subsets of progenitors, co-exposure to morphine accelerated the timing
and extent of Tat effects. Similarly, the proliferation of hNPCs was reduced by exposure to
Tat or R5 HIV-1SF162, and there was an interactive opiate-virus effect. Findings support the
concept that HIV ± opiates can affect the expansion of specific CNS progenitor
populations. We speculate that this might alter the balance of glia and neurons in the CNS
of pediatric HIV patients. Since NPCs and glial progenitors in adult share certain
characteristics with those found in neonatal brains, our findings might also relate to adult
HIV patients. At either age, an altered progenitor pool is predicted to adversely affect CNS
function.
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Materials and Methods

Experimental protocols conformed to Virginia Commonwealth University
Institutional Animal Care and Use Committee and national (PHS) guidelines on the care
and ethical use of animals. Experiments were designed to minimize the total number of
animals used and their discomfort.

Murine neural progenitor cell cultures
Murine NPCs were cultured from striata of embryonic day 15 (E15) mice (ICR
strain; Charles River, Boston, MA) using modifications of a published technique
(Khurdayan et al. 2004). In brief, embryos were harvested aseptically, and striata from 10
to 12 embryos were dissected from the cortex. Striata were dissected out, finely minced and
incubated with DNase (0.015 mg/mL, Sigma-Aldrich Co., St. Louis, MO) in Dulbecco’s
Modified Eagle’s Medium (DMEM) (15 min, 37ºC). Tissue was triturated, centrifuged (5
min at 1000 rpm), and resuspended in 5 mL of defined, NPC maintenance medium
consisting of 1:1 DMEM/F12 (Invitrogen Corp., Carlsbad, CA), 10% Knockout® SR
(Invitrogen; a serum replacement product), insulin (25 µg/mL), transferrin (100 µg/mL),
progesterone (20 nM), putresceine (60 µM), Na-HCO3 (6 mM), and sodium selenite (30
nM) (all from Sigma-Aldrich). Cells were filtered through a 70-µm nylon cell strainer (BD
Falcon, Bedford, MA), counted, centrifuged as above, and resuspended in an appropriate
volume of the same medium to obtain desired plating densities. A total of 5 ×104 cells were
plated on poly-L-lysine coated coverslips, and medium was refreshed every 2-3 d until
treatment started. Cells were grown at 37ºC in a humidified atmosphere of 5% CO2. After 5
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d, the medium was replaced and cells were treated with Tat1-86 (100 nM;
ImmunoDiagnostics, Woburn, MA), ± morphine sulphate (500 nM; NIDA Drug Supply
System, Rockville, MD), ± naloxone (1.5 µM; Sigma-Aldrich) for 12 h, 24 h, or 48 h.
Morphine, the major bioactive product of heroin in the brain, is a potent µ-opioid receptor
(MOR) agonist; naloxone is a broad spectrum opioid receptor antagonist. These
concentrations of Tat1-86 and morphine have been established to elicit functional effects in
astroglia, oligodendrocytes (OLs), and neural progenitors in our earlier studies (Buch et al.
2007; El-Hage et al. 2005; Hauser et al. 2009; Khurdayan et al. 2004). Naloxone was
applied 30 min prior to other treatments, which were added simultaneously in pre-warmed
medium. Lastly, 5-bromo-2′-deoxyuridine (BrdU, Sigma-Aldrich) was added to the
medium at 12 h prior to harvest (10 µM) to detect proliferating cells in S phase.

Opiate delivery to prenatal and postnatal Tat transgenic mice in vivo
For in vivo studies in perinatal mice, we utilized Tat transgenic mice engineered to
express the HIV-1 Tat1-86 protein under control of a glial fibrillary acidic protein (GFAP)
promoter in a doxycycline-inducible manner. As previously described (Bruce-Keller et al.
2008; Fitting et al. 2010b; Hauser et al. 2009), mice expressing the tat gene under control
of a tet responsive element (TRE) in the pTREX vector (Clonetech, Mountain View, CA)
were crossed with mice expressing the reverse tetracycline transactivator (RTTA) driven
by a human GFAP promoter. Inducible Tat+ transgenic mice express both GFAP-RTTA
and TRE-Tat genes; Tat- mice express only the GFAP-RTTA gene. To induce Tat
production during the pre- and early postnatal period, pregnant dams were given chow
containing doxycycline (Harlan, Indianapolis, IN; 6 mg/g) from gestational day 15-16 until
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postnatal day 7. Doxycycline, a water-soluble tetracycline derivative that crosses the
placenta and is secreted in breast milk, is reported to reliably induce transgene expression
in embryos and postnatally via the tet-on system during perinatal development (Fedorov et
al. 2001; Perl et al. 2002a; Perl et al. 2002b; Shin et al. 1999). All dams received the same
chow, to control for effects of doxycycline unrelated to activation of the transgene in Tatpups. Standard PCR procedures were performed on genomic DNA isolated from ear clip
samples to confirm the genotype of individual mice. Morphine was delivered by
subcutaneous (s.c.) injection (NIDA Drug Supply System) at a dose of 2 mg/kg in a 20 µl
volume of saline, based on the average daily litter weight. Male, P4 to P7 Tat+ mice
received a morphine injection twice daily at 10:00 am and 6:00 pm. For sham pups, 20 µl
of saline was injected s.c. twice daily. According to a previous report, 2 mg/kg of morphine
s.c., based on the average daily litter weight, gave circulating morphine levels that
approximate the range measured in human preterm infants who are given an intermittent or
continuous intravenous morphine infusion (Vien et al. 2009). For BrdU labeling in vivo, 50
µl of 10 mg/ml BrdU (32.5 mM) was injected s.c. in sterile saline twice at 2 h intervals
immediately prior to perfusion. Fewer than 5% of the neonatal mice in our studies died,
and there was no relationship between morphine-induced toxicity and either genotype or
doxycycline administration. For immunohistochemistry studies, pups were deeply
anaesthetized with isoflurane (Baxter, Deerfield, IL) prior to perfusion with 4%
paraformaldehyde (pH 7.4). After perfusion, brains were removed and post-fixed in fresh
fixative overnight. Brains were hemisected, rinsed several times and overnight in 15 ml
changes of phosphate-buffered saline, cryopreserved through graded sucrose solutions (10
and 25 %), embedded in Tissue Tek OCT compound (Sacura Finetek, Torrance, CA), and
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stored at –80˚C. 10 µm frozen sections containing the striatum were thaw-mounted on
SuperFrost Plus slides (VWR Scientific, West Chester, PA) and processed for
immunostaining.

Immunohistochemistry and quantification
For in vitro studies, NPCs on coverslips were immunolabeled after 12, 24, and 48 h
treatment, using antibodies to cell-specific and lineage-specific markers including nestin
(1:5000, Aves Labs, Inc., Tigard, OR), Olig2 (oligodendrocyte transcription factor 2;
1:100, Immuno-Biological Laboratories, Minneapolis, MN), and Sox2 (1:200, Millipore,
Temecula, CA). Cells were fixed with 4% paraformaldehyde; for intracellular markers,
cells were permeabilized with 0.1% Triton X-100 in phosphate-buffered saline containing
1% bovine serum albumin (Sigma-Aldrich) for 30 min. Antibodies were applied overnight
at 4ºC, followed by visualization with appropriate fluorescent-conjugated second
antibodies (Invitrogen). Double-staining was performed with anti-BrdU (1:200, Abcam,
Cambridge, MA) and anti-Sox2 or anti-Olig2 to detect proliferating progenitors. Coverslips
were treated with 1 N HCL in PBS to expose incorporated BrdU followed by
immunostaining for precursor markers. BrdU antibody was applied overnight at 4ºC,
followed by appropriate fluorescent-conjugated second antibodies. Immunolabeled
coverslips were finally incubated with Hoechst 33342 dye (0.5 µg/ml, 8 min) to identify
nuclei (Molecular Probes/Invitrogen), then mounted in ProLong Gold anti-fade reagent
(Molecular Probes/Invitrogen) and dried in the dark. To assess the proportion of different
progenitors in the cultures, 300–350 Hoechst+ cells were selected randomly per coverslip
and assessed for nestin, Sox2, and Olig2 (n = 6) under oil immersion at 63× using a Zeiss
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AxioObserver system with integrated MRm camera system (Carl Zeiss, Inc., Thornwood,
NY). Proliferation was assessed in the overall NPC population by scoring 300-350
Hoechst+ cells for expression of BrdU. Proliferation was also assessed in each progenitor
population by scoring BrdU expression in 200 nestin+, Sox2+, and Olig2+ cells on each
coverslip. Similar immunodetection methods were applied to 10 μm tissue sections from
neonatal brains. The proportion of different cell types in vivo was estimated by averaging
the percentage of Sox2+ or Olig2+ cells among 250–350 randomly selected Hoechst+ cells
per striatum (left side) in two sections, in a total of n = 6 mice. Proliferation was assessed
in the same mice by scoring BrdU expression in 200 cells positive for each progenitor
marker in two striatal sections per mouse. Double-immunolabeling was performed to assess
whether hNPCs expressed the mu opioid receptor (MOR) and C-C chemokine receptor
type 5 (CCR5) in vitro. MOR (1:250, Antibodies Incorporated, Davis, CA) and CCR5
(1:200, BD Pharmingen, Mountain View, CA) antibodies were applied to fixed hNPCs and
incubated overnight at 4°C, then visualized as described above, prior to labeling with NPC
markers and Hoechst 33342. p24 was detected on hNPCs after exposure to HIV-1SF162,
with an antibody commonly used to study infective processes (1:50, Dako, Carpinteria,
CA) (Eugenin et al. 2011; Hahn et al. 2008; Lawrence et al. 2004). Images were taken
under oil immersion at 63× using a Zeiss AxioObserver and integrated MRm camera
system.

Viability assay
Mouse NPCs were cultured on poly-L-lysine coated 48 well plates and treated at 5
d after plating with Tat, morphine and naloxone either alone or in combination as in
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experiments described above. After 12, 24, and 48 h, medium containing treatments was
replaced with sterile, tissue culture–grade D-phosphate-buffered saline containing the final
concentration of 4 µM ethidium homodimer-1 (EthD-1) and 5 µg/mL Hoechst 33342. The
working solution was added directly to cells and incubated for 15 min, at 37˚C. The
intensity of EthD-1 and Hoechst signals was measured using a PHERAstar FS plate reader
(BMG LABTECH, Ortenberg, Germany) in n = 8-10 different cultures using appropriate
excitation and emission filters (EthD-1: 495/635 nM; Hoechst: 350/510 nM).

RNA Extraction and Reverse transcription PCR
Non-quantitative RT-PCR was performed to confirm expression of Tat mRNA in
the striatum of 7 day postnatal pups treated with doxycycline administered through
placenta and lactation as described. Pups were deeply anaesthetized with isoflurane prior to
perfusion. The striata were rapidly dissected from brains, and stored at -80°C. Total RNA
was isolated using TRIzol reagent (Invitrogen). Each RNA sample was cleaned using
GenEluteTM Mammalian Total RNA kit (Sigma-Aldrich), after RNase-free DNase I
treatment to eliminate genomic DNA. cDNA was synthesized from 2 μg of total RNA
using the High-Capacity cDNA Archive Kit (Applied Biosystems, Warrington, UK) per
manufacturer’s instructions. PCR procedures were performed to detect Tat mRNA
expression using primers previously described with 18S mRNA as a control (Bruce-Keller
et al. 2008; Hauser et al. 2009) Tat1 5′-ATGGAGCCAGTAGATCCTAG-3′, Tat2, 5′TCATTGCTTTGATAGAGAAACTTG-3′,
rTta2,

rTta1

5′-AATCGAAGGTTTAACCCG-3′,

5′-TTGATCTTCCAATACGCAACC-3′,

18S1

5’-

CACTTGTCCCTCTAAGAAGTTG-3’, 18S2 5’-GACAGGATTGACAGATTGATAG-3’)
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(Chauhan et al. 2003). Final PCR products were separated by electrophoresis using a 1.5%
agarose gel, stained with ethidium bromide, and visualized using a Kodak 440CF Image
Station (Rochester, NY).

Viral stock preparation
HIV-1SF162 viral stock was obtained from Dr. Jay Levy through the AIDS Research
and Reference Reagent Program, Division of AIDS, NIAID, HIV (Cheng-Mayer and Levy
1988). The R5 strain was propagated in a U937 monocyte cell line (ATCC, Chicago, IL).
U937 cells were activated with IL-2 (10 U/ml) and phytohaemagglutinin (1 mg/ml) for 2 d
in RPMI with 10% fetal calf serum. The peak of infection was monitored by p24 ELISA,
and the culture supernatant was collected and passed through a 0.2 µm filter and stored at 80˚C. For FACS analysis, 250 μl of media containing 500 pg virus measured by p24
ELISA was added to hNPCs grown to 75-80% confluence in each well of 6-well plates,
with a final volume of 1.5 ml per well. The viral exposure time was 12 h.

Human neural progenitor cell line culture and CCR5 blocking assay
These studies used the human neural progenitor ReNcell VM cell line, derived from 14wk gestation human ventral mesencephalon (Millipore). This cell line contains over 95%
Sox2+ and nestin+ cells, and has the potential to produce dopaminergic neurons (Donato et
al. 2007). For all experiments, cells frozen at passage 3 were thawed and expanded on
laminin-coated T75 cm2 tissue culture flasks (Corning) in ReNcell NSC Maintenance
Medium (Millipore) supplemented with epidermal growth factor (EGF) (20 ng/ml;
Millipore) and basic fibroblast growth factor-2 (FGF-2) (20 ng/ml; Millipore). Three to
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four days after plating (i.e., prior to reaching 80% confluence), cells were passaged by
detachment with accutase (Millipore), centrifuged at 300 × g for 5 min and the cell pellet
resuspended in fresh maintenance media containing EGF and FGF-2. For FACS analysis
experiments, cells were replated in laminin-coated 6-well plates at a density of 30,000 cells
per well. Three to four days after plating, cells were treated for 12 h with Tat or HIVSF162 ±
morphine ± naloxone. For the CCR5 blocking experiment, a non-signaling

monoclonal

antibody (2D7 antibody) to CCR5 (2 µg/ml; BD Pharmingen) (Lee et al. 1999) or mouse
IgG (2 µg/ml; BD Pharmingen) were applied 1 h prior to treatment. The hNPCs were
treated with BrdU solution (10 µM) 2 h prior to harvesting. For p24 immunolabeling, 5,000
cells per well were replated on laminin-coated coverslips in 24-well plates and treated with
HIV-1SF162 prior to reaching 80% confluence as described above. All experiments utilized
cells from passage 4 to minimize changes in cell characteristics over multiple passages that
might influence the results.

FACS analysis of hNPC proliferation and p24 expression
The APC BrdU Flow Kit (BD Pharmingen) was used to determine the proportion of
hNPCs in S-phase of the cell cycle. Cells were incubated with BrdU (10 μM) for the final 2
h of a 12 h exposure to Tat or to supernatant from HIV-1SF162 infected monocytes ±
morphine. The cells were detached using enzyme-free cell dissociation buffer (SigmaAldrich) and fixed with BD Cytofix/Cytoperm buffer (containing 4% paraformaldehyde).
After permeabilization, cells were treated with DNase to expose BrdU incorporated in
DNA. An APC-conjugated anti-BrdU antibody and 7-amino-actinomycin D (7-AAD) were
used to determine cell cycle phases (Go/G1, S, G2+M) in all hNPC groups. Fluorescent

59

signals for APC (Ex: 650 nm; Em: 615 nm) and 7-AAD/DNA complexes (Ex: 546; Em:
647) were detected on a FACSCanto (BD Biosciences, San Jose, CA) and analyzed using
the DIVA FACS data program (BD Biosciences). Single and intact hNPCs were first gated
by cell area and width. APC-BrdU fluorescence intensity was assessed after gating on
approximately 3 x 105, 7-AAD+ cells. Go/G1 phase cells (APC-BrdU- and 7-AAD+) were
defined using appropriate negative (non-specific IgG followed by APC-conjugated
secondary antibody only); and positive (7-AAD only; APC-anti-BrdU antibody only)
controls. S-phase cells were defined as being APC-BrdU+ and 7-AAD+.
After 12 h exposure to supernatant from HIV-1SF162 infected monocytes, p24
expression on hNPCs was determined by FACS analysis. Cells were fixed and
immunolabeled with p24 antibody and Alexa Fluor 488-conjugated second antibody,
followed by incubation in 7-AAD. Single and intact hNPCs were gated as above. The
intensity of p24 immunolabeling was assessed on approximately 3 x 104 intact, 7-AAD+
cells. A single laser (488 nm) and two color fluorescence emission (585/42 band pass;
530/30 band pass) approach was used to account for autofluorescence. Controls included
p24 labeling in untreated cells and non-specific IgG followed by second antibody in HIVtreated cells.

Statistical analysis
Significance was assessed by analysis of variance (ANOVA) followed by Duncan’s
post-hoc testing if indicated, using StatSoft software (Statistica, Tulsa, OK).
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Results

Effect of HIV-1 Tat and morphine on murine neural progenitors in vitro
To determine whether Tat1-86 and morphine affect the maturation of NPCs either
independently or interactively, NPCs from embryonic mouse striata were treated with 100
nM Tat1-86 ± morphine (500 pM) over a period of 48 h, with BrdU added for the final 12 h.
Double-label immunostaining was performed following 12 h, 24 h and 48 h treatments for
BrdU and three lineage specific markers, nestin, Sox2, and Olig2. Nestin and Sox2 are
markers of uncommitted NPCs (Blumcke et al. 2001; Episkopou 2005; Gu et al. 2002;
Nunes et al. 2003; Qu and Shi 2009), while Olig2 is a transcription factor expressed in
more differentiated cells that develop largely into oligodendrocytes (OLs) and motor
neurons (Masahira et al. 2006; Takebayashi et al. 2002). Treatment with Tat ± morphine
for 12 h did not alter either the proportion of nestin+ (nestin+/Hoechst+) or Olig2+
(Olig2+/Hoechst+) cells, or the percentage of nestin+ or Olig2+ cells expressing BrdU (Fig.
3.1 A and D, C and F). There were, however, significant effects on the subset of NPCs
expressing Sox2. While neither morphine or Tat alone had any effect, both the percent of
proliferating Sox2+/BrdU+ cells, and the total Sox2+ cell population were reduced when
cells were exposed concurrently to Tat + morphine (Fig. 3.1 B and E). Since only Sox2+
cells were affected after 12 h, we hypothesized that the sensitivity of NPCs to Tat ±
morphine might depend on their stage of differentiation, and that changes in the Sox2 cells
might affect their progeny. We extended the experiments to 24 h and 48 h using markers
for Olig2 (Fig. 3.2). At both 24 h and 48 h, the total Olig2+ population was reduced by Tat
alone with no added effect of morphine (Fig. 3.2 C, D). The proliferating (Olig2+ / BrdU+)
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population at 24 h was unaffected by either Tat or morphine alone, but Tat and morphine
interacted to reduce BrdU uptake (Fig. 3.2 A). By 48 h, Tat alone, but not morphine alone,
had reduced the proliferating, Olig2+ population. Tat and morphine interacted at this time
point to further decrease BrdU uptake (Fig. 3.2 B). Thus, interactive effects of Tat and
morphine were only observed on the proliferative behavior of Olig2+ cells, while Tat by
itself affected cell populations. Naloxone partially reversed the interactive effects of
morphine in proliferating cells, as the groups receiving Tat, morphine, and naloxone were
not different from control, but also not different from the group co-exposed to Tat and
morphine. It also appeared to reduce the overall numbers of Olig2+ cells when given
concurrently with Tat and morphine. We conducted the additional experiments described
below to understand these findings.

Effect of naloxone on murine progenitors in vitro
Although naloxone partly or fully reversed the effects of morphine in most
instances, naloxone exposure also decreased the percentage of cells expressing Olig2 when
combined with morphine and Tat treatment (“a” in Fig. 3.2 D and E). We thus treated
murine NPCs with naloxone alone for 12-48 h and compared the proportion of Olig2+ cells
in untreated control and naloxone treated groups. There was no significant reduction in the
Olig2+ population (Fig. 3.2 E), suggesting that naloxone by itself is not toxic to Olig2+ cells
or their immediate progenitors. Instead, it might interfere with endogenous opioid signals
under the specific condition of Tat and morphine treatment. Autocrine opiate signaling
pathways are known to play pivotal roles in OL survival (Buch et al. 2007; Hauser et al.
2009; Khurdayan et al. 2004; Knapp et al. 2001), and overall glial cell fate (Gorodinsky et
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al. 1995; Kim et al. 2006; Persson et al. 2003). Naloxone might interfere with multiple
opioid pathways that modulate proliferation and development of OL lineage specific
progenitors under these experimental conditions.

Effect of HIV-1 Tat and morphine on murine neural progenitors: proliferation vs.
viability
To determine whether cell death might contribute to the observed reductions in
proliferating or total NPCs, we examined the viability of total NPCs at up to 48 h of
exposure to Tat ± morphine using an ethidium-based viability assay. There was no
significant cell death in response to any treatment at any time period measured by EthD-1
fluorescence intensity (Fig. 3.3).

Effects of HIV-1 Tat and morphine on neural progenitors in striatum
To assess the effect of HIV-1 Tat and morphine on NPCs in vivo, we utilized an
inducible, tetracycline (tet) “on” system with doxycycline induction. Detection of Tat
mRNA and protein in the brains of these mice, including the striatum, was previously
reported by our group, (Bruce-Keller et al. 2008; Duncan et al. 2008; Fitting et al. 2010b;
Hauser et al. 2009) and also shown here (Fig. 3.4 A-C). Pregnant dams received chow
containing doxycycline from gestational day 15-16 through postnatal day 7 to activate the
HIV-1 Tat transgene in fetal and neonatal mice. Reverse transcription PCR was performed
to detect Tat mRNA expression in cortex and striatum of neonatal mice at P7 (Fig. 3.4 B).
Evaluation of PCR band intensities confirmed that doxycycline delivered to dams induced
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Tat mRNA expression in the cortex and striatum of Tat+, but not Tat- neonatal mice (Fig.
3.4 C).
All mice used in experiments were male. Some mice received morphine s.c. at
postnatal days 4–to-7 to assess whether co-exposure to HIV-1 Tat and morphine caused
effects on NPCs in vivo similar to those seen in culture. There were several significant
effects on proliferating cell populations. Morphine exposure and Tat induction
independently reduced BrdU uptake in both Sox2+ and Olig2+ cells in the striatum, and in
the overall population of striatal NPCs (Fig. 3.4 D). An interactive effect of morphine and
induced Tat was seen in the Sox2+/BrdU+ population and in the overall population of
BrdU+ cells (Fig. 3.4 D). We examined whether this might lead to changes in the overall
populations of Sox2+ and Olig2+ cells. Morphine and Tat by themselves each reduced the
percentage of the population that was Sox2+ or Olig2+ (Fig. 3.4 E); there was no interactive
effect between them. Additionally, Tat alone, but not morphine alone, reduced the
percentage of the population that was Olig2+; again there was no Tat and morphine
interaction.

Effects of HIV-1 Tat, HIVSF162, and morphine on proliferation of a human NPC line
To validate our in vitro and in vivo results in a more clinically relevant system, we
exposed human NPCs to HIV-1 Tat1-86, or to supernatant from U-937 monocytes infected
with R5-tropic HIV-1SF162, with or without concurrent morphine. Before conducting
experiments, we briefly characterized the hNPC cell line by co-localizing MOR, nestin,
and/or Sox2 antigenicity. In accordance with previous reports (Breier et al. 2008), more
than 95% of hNPCs expressed nestin and Sox2. Approximately 95% of hNPC also showed

64

MOR immunoreactivity, suggesting their potential as targets of opiate signaling (Fig. 3.5 A
and B). Olig2 immunofluorescence was not detected in hNPCs (not shown). Since we used
an R5-tropic HIV strain that preferentially uses C-C chemokine receptor type 5 (CCR5) as
a co-receptor for viral entry, we co-localized CCR5 immunoreactivity in Sox2immunopositive NPCs to verify expression (Fig. 3.5 C).
FACS analysis was performed after 12 h exposure to Tat ± morphine to assess the
percentage of hNPCs in S-phase of the cell cycle, as an index of proliferation. We also
tested the effect of HIV-1SF162 supernatant from infected cells that had been treated ±
morphine. Due to their short cell cycle (Breier et al. 2008), hNPCs were treated with BrdU
2 h prior to harvest. FACS analysis showed a significant reduction in S-phase hNPCs in all
treatment groups (Fig. 3.5 D). Approximately 47% of control hNPCs incorporated BrdU.
Both Tat and morphine independently caused a significant reduction in the proportion of Sphase cells as compared to control, with no synergistic or additive effect of morphine (Fig.
3.5 D, E). Interestingly, hNPCs exposed to HIV-1SF162 supernatant by itself also showed
significantly reduced proliferation, and there was an additional reduction in their
proliferation rate with combined morphine (Fig. 3.5 D, F). HIV-1SF162 utilizes CCR5 as a
co-receptor for entry, and although the changes in NPC function are not likely due to
infection, some effects might be due to viral proteins such as gp120 binding to CCR5 on
hNPCs. To examine this question, the specific, non-signaling, CCR5 blocking antibody
2D7 (Lee et al. 1999; Wu et al. 1997) was applied 1 h before exposure to viral supernatant.
Compared to treatment with control mouse IgG, 2D7 immunoblockade partially reversed
the anti-proliferative effect of HIV-1SF162 supernatant (Fig. 3.5 G).
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p24 expression in hNPCs by FACS analysis and immunolabeling
hNPC infection by HIV has been sporadically reported by other investigators
(Lawrence et al. 2004; Mishra et al. 2010; Schwartz et al. 2007). We assessed hNPCs in the
present study for the presence of p24 antigen with an antibody commonly used by other
laboratories to study infective processes (Eugenin et al. 2011; Hahn et al. 2008; Lawrence
et al. 2004). hNPCs were exposed for 12 h to HIV-1SF162 infective supernatant, then fixed
and either detached from the plate, stained with 7-AAD, immunolabeled with p24
antibody, and subjected to FACS analysis (Fig. 3.6 A-C), or immunolabeled for fluorescent
microscopic analysis of p24 within individual cells (Fig. 3.6 D, E). Immunoreactivity was
most often observed in cells that were clearly pyknotic (arrowheads, Fig. 3.6 D, D’). This
may represent non-specific binding of antibody to cell debris, or infection and subsequent
death of hNPCs; our methods cannot distinguish between these two possibilities.
Occasional hNPCs with a normal cellular and nuclear morphology, indicating viability at
the time of fixation, were also p24+ (Fig. 3.6 E, E’). For FACS studies, hNPCs were fixed
and immunolabeled with the same p24 antibody and Alexa Fluor 488–conjugated second
antibody, followed by 7-AAD. Approximately 1 x 104 intact, 7-AAD+ cells were analyzed
by a single laser (488 nm), two color fluorescence (585/42 band pass; 530/30 band pass)
methodology that permits assessment of autofluorescence. Neither control (Fig. 3.6 B, C)
nor experimental (Fig. 3.6 A) groups showed any evidence of autofluorescence. A p24+
signal was detected in 0.34% of the overall population (Fig. 3.6 A). Controls included p24
labeling in untreated cells (Fig. 3.6 B) and non-specific IgG followed by second antibody
in HIV-treated cells (Fig. 3.6 C); p24 was detected in 0.1% and 0.001% of the control
populations, respectively.
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Discussion

NPCs are present throughout ontogeny, including in the adult brain, although the size
of the NPC population is substantially reduced with age, as is their distribution and
recruitment. We used both murine and human embryonic cultures, as well as an in vivo
perinatal model, to determine the ability of HIV-1 Tat, or viral supernatant, to dysregulate
the proliferation of NPCs, and to affect resulting cell populations in developing systems.
Exposure to Tat or supernatant from HIV-1SF162-infected cells both reduced progenitor
proliferation, although exposure time and developmental stage were critical variables.
Morphine interacted with both Tat and infective supernatant to cause further dysregulation.
Results suggest that HIV exposure, and co-exposure to opiates, elicit fundamental changes
in NPC function that likely contribute to neurologic impairment in both pediatric and adult
patients. Morphine by itself caused changes in the behavior of NPCs in mice exposed
during the perinatal period that may be relevant to children exposed to morphine or heroin
before birth.

HIV-1 Tat and opiates alter proliferation/population dynamics of murine NPCs in
vitro
Previous studies have shown effects of HIV-1 Tat on the expansion, viability, and/or
defined populations of fetal human or murine NPCs or glially-restricted progenitors in
culture, without determining if cells at a particular stage of maturation might be selectively
affected (Buch et al. 2007; Khurdayan et al. 2004; Mishra et al. 2010). We were especially
interested to test whether opiate exposure might enhance Tat effects, since opiates are a co-
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morbid factor that can amplify CNS dysfunction, both in experimental models of HIV
(Bokhari et al. 2011; Bruce-Keller et al. 2008; Fitting et al. 2010b; Hauser et al. 2006; Hu
et al. 2005; Kumar et al. 2006; Zou et al. 2011) and in patients (Anthony et al. 2005; Bell et
al. 2002; Byrd et al. 2011). Studies both in vitro and in vivo examined the striatum, an area
that is rich in opiate receptors and extremely vulnerable to HIV-1-induced neuropathology
(Berger and Nath 1997; Mirsattari et al. 1998; Nath et al. 2000; Nath et al. 2002). Murine
NPCs derived from E14 striatum were characterized previously as a mixture of progenitors
and very immature cells (nestin+, Sox2+, DCX+, Olig2+) (Hahn et al. 2010b). Most cells
were actively proliferating and expressed MOR (Fig. 3.5) (Hauser et al. 2009).
We distinguished between cells expressing nestin or Sox2, markers of relatively
undifferentiated NPCs, and Olig2, a marker typical of developing OLs (Masahira et al.
2006; Takebayashi et al. 2002). Tat and/or morphine had effects at specific stages of
differentiation. As early as 12 h after co-exposure to morphine and Tat, the proliferation
rate of Sox2+ cells was reduced (Fig. 3.1 B) and the total Sox2+ population was diminished
(Fig. 3.1 E). With increasing time, Olig2+ proliferation was also affected, first by Tat and
morphine co-exposure, and then by Tat alone, with combined Tat and morphine leading to
an additive effect (Fig. 3.2 A, B). Since Tat by itself did not affect proliferation until 48 h,
and did not affect viability (Fig. 3.3), it was surprising that Tat by itself reduced the
percentage of total cells that expressed Olig2 at both 24 and 48 h (Fig. 3.2 C, D). A
potential explanation that was not explored is that Tat may influence NPC lineage
decisions, perhaps stalling cells at the Sox2+ stage, or increasing the production of GFAP+
or NG2+ cells. In keeping with this idea, an increase in the production of GFAP+ cells was
noted in human progenitors exposed to HIV-1 (Peng et al. 2008).
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Treatment with naloxone partially reversed morphine–Tat interaction in most in vitro
studies. However, in the Olig2 population studies, treatment with naloxone decreased the
percentage of Hoechst+ cells that expressed Olig2 (indicated by “a” in Fig. 3.1 and 2). This
effect only occurred for Olig2+ cells, and not for nestin+ or Sox2+ cells. These results were
reminiscent of in vivo studies with another non-selective opioid receptor antagonist,
naltrexone, which was shown to modulate NPC proliferation in adult rodent hippocampus
(Holmes and Galea 2002; Ra et al. 2002) and developing rat brain (Schmahl et al. 1989).
However, we found that naloxone did not directly affect the Olig2+ population (Fig. 3.2 E).
We have previously suggested that naloxone or naltrexone may interfere with endogenous
opiate signaling pathways that modify the survival and development of OL lineage cells
(Hauser et al. 2009; Knapp et al. 2001; Knapp et al. 1998). The present study suggests a
more complex phenomenon, since naloxone reversal was only partial, and particularly
impaired in the presence of combined Tat and morphine. CCR5, an HIV co-receptor, has
well documented interactions with MOR, leading to bi-directional, heterologous crossdesensitization (Chen et al. 2004; Chen et al. 2007; Suzuki et al. 2002; Szabo et al. 2002;
Szabo et al. 2003). Tat is known to elevate the β-chemokine ligands that activate CCR5
(RANTES, MIP-1α, and MIP-1β) in multiple cell types including NPCs (Hahn et al.
2010b), which may interfere with naloxone activity through the above mechanisms.

HIV-1 Tat and opiates alter proliferation/population dynamics of murine NPCs in
vivo
We used inducible HIV-1 Tat1-86 transgenic mice to model Tat and opiate exposure in
vivo. While all animal models of a human-specific disease have limitations, these mice
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have been extensively characterized and shown to exhibit neurologic abnormalities
associated with chronic HIV-1 exposure, including activation of microglia and astroglia
(Bruce-Keller et al. 2008), dendritic damage and reduced spine density in striatal neurons,
abnormal oligodendroglial phenotypes (Fitting et al. 2010b; Hauser et al. 2009), circadian
rhythm abnormalities (Duncan et al. 2008), and behavioral changes (Fitting et al,
submitted). Since our culture experiments used E14 tissue grown for 7 d in vitro, we
performed in vivo studies at a similar time. Results may therefore have particular relevance
to pediatric HIV patients, but may also pertain to the smaller population of progenitors in
adult brain parenchyma.
We focused on Sox2+ and Olig2+ cells, which are relatively abundant in striata as
compared to nestin+ cells. In vivo results paralleled the tendency towards a decline in
proliferation and progenitor populations seen in cultured cells, but there were notable
differences. Of great interest, in mice exposed only to morphine (Tat- + Morph in Fig. 3.4
D, E), BrdU incorporation was significantly reduced in both Sox2+ and Olig2+ cells, as well
as in the overall Hoechst+ cell population. The Sox2+ population was also decreased in this
group, although surprisingly the Olig2+ population was stable. Morphine alone did not
affect these parameters in cultures. Previous studies of morphine and proliferation have
been directed towards understanding the dynamics of neuron production, and it is clear that
morphine reduces neuron generation in neonatal (Kornblum et al. 1987; Seatriz and
Hammer 1993) and adult rodent brain (Arguello et al. 2008; Eisch et al. 2000; Kornblum et
al. 1987). Similar to our results, Kornblum et al. (1987) found that morphine reduced
proliferation in vivo, but had no effect on tissue dispersed in culture. They postulated an
indirect mechanism for morphine-induced changes in progenitor dynamics; our data would
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support that concept. Our studies modeled morphine exposure acutely to avoid issues of
tolerance and dependence that occur during chronic opiate exposure.
Similar to morphine, the effect of Tat alone was to decrease BrdU uptake into Sox2+,
Olig2+, and total cells (Fig. 3.4 D), but in all cases Tat induction caused significantly
greater reduction than morphine exposure (Fig. 3.4 D). The greater effect of Tat on BrdU
uptake in vivo may reflect the longer Tat exposure time (12 d), as BrdU uptake in cultured
Olig2+ cells was reduced after 48 h but not earlier. Both Sox2+ and Olig2+ populations
were reduced by Tat alone (Fig. 3.4 E), probably due in part to decreased proliferation. As
was true in cultures, the only interactive effect between morphine and Tat was on BrdU
uptake. This was observed in Sox2+ and total cells, but not in Olig2+ cells, even though coexposure reduced BrdU uptake into Olig2+ cells in culture. Given the differences in timing
and dosing of morphine, these somewhat different responses in culture versus in vivo are
not surprising.
We consider it likely that the observed effects of Tat, HIV and/or morphine on
progenitors will modify the balance of glia and neurons in the CNS, but a different
approach, including stereology, is required to determine exactly how mature populations
are affected. Glial populations may be preferential targets, since production of both
astroglia and oligodendroglia continues well into the postnatal period in both rodents and
humans (Altman 1966; Chan et al. 2002; Price 1994; Skoff and Knapp 1991; Skoff et al.
1976; Sturrock 1979; Webster and Astrom 2009). The present studies predict that OLs may
be quite vulnerable to HIV-1 Tat, and this has been observed in the striatum of mature, Tattransgenic mice, especially when the mice are co-exposed to morphine (Hauser et al. 2009).
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Tat, HIV-1SF162, and morphine alter proliferation of hNPCs
Since HIV is a human specific disease, the results of our murine models were reevaluated in a human NPC line generated from 14-wk gestation human ventral
mesencephalon. Over 95% of cells are immunopositive for nestin and/or Sox2, and many
also expressed MOR and CCR5 (Fig. 3.5 A-C). Tat, HIV-1SF162-infective supernatant, and
morphine all individually reduced proliferation after 12 h, with viral supernatant and
morphine displaying additive effects (Fig. 3.5). Supernatant and Tat both decreased
proliferation to the same extent. In general, these results are in accord with a previous
report that 25-100 ng/ml Tat decreased human fetal progenitor proliferation (Mishra et al.
2010). Isolated Tat effects were greater in that study, perhaps reflecting different cell
derivations and culture conditions. Gp120 also was reported to reduce human (Okamoto et
al. 2007) and mouse progenitor proliferation (Lee et al. 2011). A decrease in young
neurons produced in the presence of Tat (Mishra et al. 2010) may also reflect an effect on
cell fate, as hypothesized for certain of our findings. Cell heterogeneity may be an
important consideration in our results, since all nestin+ or Sox2+ cells do not necessarily
express equivalent amounts of functional MOR, and may not uniformly express molecular
targets for Tat, such as α v β 5-integrin (Vogel et al. 1993), mannose (Liu et al. 2004) or
NMDA receptors (Li et al. 2008), or the low-density lipoprotein receptor-related protein
(Liu et al. 2000). The gradually increasing effects of Tat ± morphine during the exposure
period may involve a change in receptivity of the cells with development. Interestingly,
studies by another group, also using an R5 virus, showed an increase in progenitor
production (Peng et al. 2011; Peng et al. 2008). While timing or culture variability might
underlie the different outcomes, another critical difference may be the method for assessing
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proliferation. BrdU uptake into individual cells after a 2 h pulse gives an immediate picture
of DNA synthesis in individual cells. Studies by Peng et al. (2011 and 2008) assayed [3H]thymidine uptake into the population after 16 h, which reflects a combination of DNA
synthesis, division, survival, and further differentiation over time. Those studies
demonstrated that exposure to infected supernatant causes re-direction of progenitors
towards an astroglial fate, a possibility also suggested by our findings and by others
(Mishra et al. 2010). Although concurrent morphine exposure did not alter Tat effects on
hNPCs, there was an additive effect of morphine and HIV-1SF162 supernatant (Fig. 3.5).
Effects of supernatant by itself or with morphine may be due to multiple factors or
interactions,

since

supernatant

contains

virions,

multiple

viral

proteins,

and

cytokines/chemokines from infected cells.
HIV-1 has been reported to infect hNPCs (Lawrence et al. 2004; Rothenaigner et al.
2007; Schwartz et al. 2007). We performed FACS analysis and immunohistochemistry
after 12 h exposure to infective supernatant to examine whether hNPCs in our system were
infected. FACS analyses showed that < 0.04% of intact hNPCs were immuno-positive for
p24 (Fig. 3.6 A), and we very occasionally detected cells with a viable morphology that
appeared to be p24+ by immunocytochemistry (Fig. 3.6 E, E’). Although our experience
does support to the concept that hNPCs can be infected by HIV-1, it was not a common
event under our experimental conditions. Most progenitors in the brain appear to respond
as bystanders to events triggered by infected cells.
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Relationship to HIV Pathology in Humans
Prior to the advent of anti-retroviral therapy, the prevalence, rate of onset, and severity
of HIV-1-associated CNS disease in children was quite high as compared to adult patients
(Mintz 1994; Schwartz et al. 2007; Schwartz and Major 2006). This is not surprising, since
much of CNS development occurs after birth, and the immature brains of children or
adolescents exposed to HIV are highly vulnerable to pathologic agents. Over-expression of
excitatory amino acid receptors during periods of active synapse formation may in
particular contribute to excitotoxic injury (Epstein and Gelbard 1999). CNS disease in
pediatric HIV patients manifested as either a static or progressive encephalopathy, with
classic symptoms that included delay or loss of major motor and mental milestones, as well
as atrophy of cortical/subcortical regions and other abnormalities on CT scans (Drotar et al.
1997; Epstein et al. 1988; Epstein et al. 1985; Schwartz and Major 2006; Tahan et al. 2006;
Ultmann et al. 1985; Van Rie et al. 2007). In developed countries, the rate of HIV-1
vertical transmission has been reduced to 1-2%, from 40% in 1995 (Buchholz et al. 2010;
Van Dyke 2011). Treatment with CNS-penetrating drugs has, by most accounts, reduced
the incidence of pediatric and adolescent HIV-associated encephalopathy by ≥ 50%,
especially in cases of perinatal acquisition (Patel et al. 2009). It is currently estimated that
10% of HIV+ children on cART therapy will show signs of CNS disease (Chiriboga et al.
2005). The situation in resource-limited settings is quite different. According to a 2008
estimate, 1,600 children per day become infected with HIV-1 worldwide, 90% of them in
sub-Saharan Africa (UNAIDS 2009; UNAIDS 2010). In such regions, mother-to-child
transmission of HIV via breastfeeding is common, even in infants not infected at birth, and
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HIV-1 infection is still a major source of infant mortality (Becquet et al. 2009; Meyers et al.
2007).
In the context of pediatric HIV, reduced progenitor production and development are
likely to have serious consequences. Reduced production of Sox2+ progenitors is expected
to impact the populations of neurons and glia that derive from Sox2+ cells. Indeed, we find
that immature, Olig2+ OLs are reduced in vivo, and others have reported lower neuron
production, possibly through altered cyclin D1 and MAPK signaling (Mishra et al. 2010;
Okamoto et al. 2007). Although the hypothesis that Tat exposure can alter lineage
decisions in uncommitted progenitors remains to be fully tested, a proportional increase in
astroglia

might

enhance

interactions

between

astroglia

and

HIV-1

infected

macrophages/microglia that are deleterious for developing neurons and neural circuitry
(Blumberg et al. 1994). Our finding of significant Tat-morphine and HIV-morphine
interactive effects is clinically relevant, given the high rate of opiate abuse in HIV patients,
and the fact that morphine may initially be used to treat neonatal abstinence syndrome in
children of opioid-maintained or non-maintained mothers (Bandstra et al. 2010; Colombini
et al. 2008; Ebner et al. 2007; Jansson et al. 2009).
Our results may also be relevant for the adult CNS. If the Tat effects, and morphine-Tat
interactions that we observed also occur on adult progenitors, the predicted outcome would
be fewer overall NPCs, a tendency towards increased astroglia at the expense of
oligodendroglial production, and abnormal neural function. Importantly, neural precursors
were reduced in human hippocampal slice cultures by HIV coat proteins and patient CSF
(Krathwohl and Kaiser 2004b) and in gp120 transgenic mice (Lee et al. 2011; Mishra et al.
2010; Okamoto et al. 2007). Neural precursors were also reportedly reduced in HIV
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patients with neurological deficits as compared to HIV-1 infected individuals without
neurological deficits and non-infected controls (Krathwohl and Kaiser 2004b).

Summary

Consistent findings that Tat and HIV reduce NPC production in a variety of model
systems that assess maturation are compelling. By disrupting the proliferation of NPCs and
their subsequent differentiation into mature glia and neurons, HIV infection may increase
the severity of neurological deficits and impairment in pediatric and adolescent patients.
Interactions between Tat/HIV and morphine may exacerbate neurologic problems in young
HIV patients receiving opiates prescribed for neonatal abstinence syndrome, pain, or other
valid reasons, as well as HIV-1+ adolescents experimenting with abused opiates. Evidence
that some neurologic abnormalities in the pediatric HIV population may be reversible
(McCoig et al. 2002) is encouraging from a therapeutic standpoint, and points to the need
for full understanding of how HIV and opiates individually and interactively affect CNS
progenitors. This is especially true in resource-limited environments, where the spectres of
perinatal HIV infection and high rates of pediatric disability/mortality have not been
diminished.
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Figure 3.1

Figure 3.1 Co-exposure to HIV Tat and morphine for 12 h alters the Sox2+ population and
proliferation of Sox2+ cells in vitro. Neither the nestin+ (A, D) nor the Olig2+ (C, F)
populations were affected by any combination of Tat, morphine, or naloxone treatment at
12 h. However, both the percentage of the population that was Sox2+, and the proliferation
of cells at this stage of differentiation were decreased in response to Tat and morphine coexposure (B, E). (* p<0.05, ** p<0.01, a <0.05 vs. control; with Duncan post-hoc test, n =
4-6, Morph = Morphine (500 nM), Tat (100 nM), Nal = naloxone (1.5 µM)).
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Figure 3.2
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Figure 3.2 Effects of HIV-1 Tat ± opiates on the population and proliferation of Olig2+
cells, at 24 – 48 h in vitro. Interactive effects of morphine and Tat to reduce Olig2+ cell
proliferation were observed at both 24 h and 48 h (A and B); Tat by itself also reduced
Olig2+ proliferation, but only at the 48 h time point (B). Tat by itself reduced the percent of
Olig2+ cells in the overall population, after both 24 h (C) and 48 h (D) of exposure; there
were no additional effects of morphine co-exposure. Morphine by itself did not affect
populations of Olig2+ cells, or their proliferation indices. Naloxone partially reversed the
effect of morphine in both A and B; the percentage of Olig2+/BrdU+ cells in the
Morph+Tat+Nal groups was not different from the control, or from the Morph+Tat
treatment group at the same exposure time. However, naloxone did not reverse the
interactions between morphine and Tat in C and D (indicated as “a”). This suggested that
naloxone might directly affect the Olig2+ population, but this was not the case at 12 - 48 h
exposure (E). Morph, Morphine (500 nM); Tat, HIV-1 Tat1-86 (100 nM); Nal, naloxone
(1.5 µM); * p < 0.05, ** p < 0.01, *** p < 0.001,
Duncan’s post-hoc test, n = 4-6.
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a

p < 0.05 vs. control; ANOVA with

Figure 3.3

Figure 3.3 Neither Tat nor morphine has a significant effect on NPC death. There is no
difference in the ethidium homodimer-1 (EthD-1) fluorescence intensity, measured in
arbitrary fluorescence units, between any treatment group at 12-48 h of treatment time,
indicating no increase in cell death. The dotted line indicates the signal in empty wells.
Morph, Morphine (500 nM); Tat, HIV-1 Tat1-86 (100 nM); Nal, naloxone (1.5 µM).
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Figure 3.4
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Figure 3.4 Pre- and neonatal Tat and/or morphine exposure reduces proliferation in the
neonatal striatum. HIV Tat1-86 was induced via doxycycline delivered sequentially through
placenta and lactation (A and B); Tat mRNA transcription was detected by RT-PCR in both
cortices and striata of 7 d pups (C). All dams received the same chow so that both Tat+ and
Tat- pups were exposed to doxycycline. 12 d Tat induction and 4 d of s.c. morphine
injections significantly reduced overall proliferation (BrdU+), and also reduced
proliferation in Sox2+ (undifferentiated progenitors) and Olig2+ cells. Additive effects of
Tat and morphine were observed in Sox2+/BrdU+ cells and in the overall BrdU+ population
(D). Changes in progenitor proliferation appear to affect the overall populations of Sox2+
and Olig2+ cells in the neonatal striatum (E). (* p < 0.05; ** p < 0.01; § p < 0.05, Tat- vs.
all other groups, Duncan’s post-hoc test, n = 6-8). DOX, doxycycline.
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Figure 3.5

84

Figure 3.5 Effect of Tat or HIV-1SF162 supernatant ± morphine on proliferation of human
ReNcell VM NPCs. Double-immunolabeling confirmed that 95% of hNPC were nestin+
and Sox2+ positive, and that 95% also showed immunoreactivity for MOR and CCR5 (AC). The colors representing neural precursor makers are separated in the lower panels (A’:
nestin (green), nuclei (blue); A’’: MOR (red), nuclei (blue); B’: Sox2 (green); B’’: MOR
(red), nuclei (blue); C’: Sox2 (green); C’’: CCR5 (red), nuclei (blue)). The presence of
CCR5 on hNPCs suggested that effectors such as gp120 and

-chemokines, released in

response to Tat or contained in the viral supernatant, might affect the behavior of hNPCs
(C). FACS analyses (D) were performed after 12 h treatment with the Tat, virus, or
morphine combinations indicated by the histograms in E-G, with BrdU added during the
last 2 h to label S-phase cells. Exposure to supernatant from HIV-1SF162-infected monocytes
(E), Tat (F), and morphine (E and F) all decreased the proportion of hNPCs in S-phase
compared to control (§ p < 0.05, compared to all other groups). BrdU incorporation was
additively reduced in cells treated with a combination of HIV-1SF162 supernatant and
morphine (E). There was no interactive effect of Tat and morphine (F). A CCR5 blocking
antibody (2D7) reduced, but did not abolish, the effect of HIV-1SF162 supernatant (G),
suggesting that BrdU uptake was sensitive to multiple factors in the supernatant, some of
which interact with CCR5. (§ p < 0.05, compared to all other groups; ** p < 0.01, one-way
ANOVA, Duncan’s post-hoc test, n = 4-7; Morph, Morphine (500 nM); Tat, HIV-1 Tat1-86
(100 nM); Nal, naloxone (1.5 µM); SF162, supernatant from U937 monocytes infected
with HIV-1SF162 (supernatant diluted to 500 pg p24 per well); CCR5 Ab, antibody 2D7 (2
μg/ml); mIgG = monoclonal mouse IgG (2 μg/ml).
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Figure 3.6
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Figure 3.6 Detection of p24 on hNPCs by FACS and fluorescent microscopy.

p24

immunolabeling intensity was assessed on approximately 1 x 104, 7-AAD+ cells using a
single laser (488 nm) and two color fluorescence emission (585/42 band pass; 530/30 band
pass) FACS approach (A-C). A very small percentage (0.33%) of hNPCs exposed to
supernatant from HIVSF162-infected monocytes were p24+ (A). Labeling indices in control
groups, which included untreated hNPCs immunolabeled for p24 (B) and HIV-treated
hNPCs exposed to control IgG and fluorescently-labeled second antibody (C), were 0.1%
and 0.001%, respectively, suggesting that a portion of the p24 labeling was specifically
related to antigen expression. Autofluorescence (585 > 530 signal) was not detected in any
of the samples. FACS diagrams shown are representative of n=3 separate experiments.
When individual cells were examined, p24 signal was not detected in untreated hNPCs (D,
phase contrast; D’, fluorescence). p24 immunoreactivity was associated with two groups of
cells in cultures exposed to HIV-1SF162 supernatant (E, phase contrast; E’, fluorescence).
The first group was clearly pyknotic (arrowhead in E and E’). This staining may be nonspecific, or may represent infected hNPCs that have subsequently died; our methods cannot
distinguish between these possibilities. Other p24+ cells, observed very infrequently, had a
viable phenotype (arrow in E and E’).
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Figure 3.7
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Figure 3.7 Overview of the proposed effects of HIV-1SF162 and/or morphine on NPCs in
the striatum during the perinatal period. Both the intermediate filament nestin and the
transcription factor Sox2 identify undifferentiated and self-renewing NPCs in the
developing CNS, although nestin and Sox2 expression do not entirely overlap. Sox2
expression is maintained in immature cells destined to become neuroglia (glial-restricted
precursors; GRPs) but is lost in immature cells destined to become neurons (neuralrestricted precursors; NRPs) (Ellis et al. 2004). GRPs further differentiate into astroglia and
oligodendroglia; the transcription factor Olig2 is expressed in precursors destined to
become oligodendroglia. Our studies show that HIV-1 Tat, HIV-1SF162, and morphine all
affect the proliferation of certain subtypes of progenitors (red lettering). Morphine and Tat
reduce the proliferation of Sox2+ progenitors and immature Olig2+ oligodendrocytes in the
mouse brain and in vitro, and have an additive effect that reduces proliferation even further.
Proliferation of human Sox2+/nestin+ NPCs is similarly reduced by Tat, morphine, and
infective HIV-1SF162 supernatant, and an additive effect between HIV-1SF162, and morphine
reduces proliferation further. Reduced NPC and GRP proliferation is associated with
changes in cell populations (blue lettering). We specifically measured a reduction in Sox2+
cells with morphine or Tat exposure, and in Olig2+ cells with Tat exposure. Taken as a
whole, the findings support a model where the proliferation of both NPCs and GRPs is
significantly reduced by morphine or HIV, with interactions that compromise progenitor
production even further. While the HIV-1 Tat protein clearly reduces proliferation by itself,
effects of HIV supernatant may also reflect other viral proteins such as gp120 (Lee et al.
2011) or numerous secreted factors present in the medium. Reduced proliferation predicts
an overall reduction in populations of progenitors, which was observed. Continued effects
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on proliferation indices are likely to disturb the overall balance of glia and neurons in the
brain, a prediction that remains to be tested. (Note that arrows and cartoons done in grey
represent hypothesized outcomes for which we have no direct experimental evidence.)
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Chapter 4
Sex Influences the Effects of Long-term HIV-1 Tat Exposure in the Striatum:
Do Changes in Inflammation and Cell population Affect Behavior?

Introduction

Epidemiology of neurocognitive disorders in HIV
The introduction of combination antiretroviral therapy (cART) has resulted in
dramatic declines in the prevalence of HIV associated dementia (HAD) and mortality of
HIV infected individuals, while simultaneously, the overall proportion of HIV-associated
neurocognitive disorders (HAND) have increased in these patients (McArthur et al. 2010).
For instance, the prevalence of neurolocognitive disorders is more frequent in developing
countries (Nakasujja et al. 2005; Wong et al. 2007) and there is a great possibility that these
neurocognitive disorders and impairments become the most common types of dementia
among young-age people globally (Wright et al. 2008). Some clinical reports suggest that
HAND can be diagnosed in HIV infected individuals; even though they have a history of
prolonged aviremia with high adherence to cART (Cole et al. 2007). Regardless of cART
usage, neurological insults and injury by HIV-1 might continue to occur in some patients
(Robertson et al. 2007). HAND can be diagnosed with broad spectrum symptoms ranging
from asymptomatic neurocognitive impairment (ANI), to minor neurocognitive disorders
(MND), to HIV associated dementia (HAD), because HAND is a progressive disease with
different intensity of CNS involvement and symptoms in its development. Approximately,
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40-60% of HIV/AIDS patients can be categorized in one of these diagnoses (Ellis et al.
2007; McArthur et al. 2010).
ANI is the mildest form of HAND and 30% of HIV infected individuals under
cART belong to this group. These individuals with ANI are more likely to develop the
more severe forms of HAND (Ellis et al. 2007). ANI is characterized by a number of
criteria, including measurable neurocognitive impairment without recognition by the
patients and without impact on day-to-day function. Next, MND is a more severe form of
neurolcognitive impairment than ANI, and was often identified in 20 to 30% of HIV
infected adults in pre-cART era (Janssen et al. 1989; McArthur et al. 2010; Sacktor et al.
2002). These individuals usually self-report having impaired cognitive or behavioral
deficits. Such impairments can include a reduction in attention/concentration, mental
slowing, abnormal memory along with other cognitive functions, slowed or uncoordinated
movements, apathy, personality change, depression, irritability and mood swing (McArthur
et al. 2010). These abnormalities typically can cause mild impairment in work, or
negatively affect activities of daily living. MND is known to be associated with shortened
survival, reduced adherence with antiretrovirals, as well as worse employability, and
increased prevalence of HIV encephalitis in patients from pre-cART period (Cherner et al.
2002; Hinkin et al. 2002; Mayeux et al. 1993; Sacktor et al. 1996). Finally, the prevalence
of HAD is rare in cART-treated individuals, approximately 2 to 8% of frequency is still
estimated (McArthur et al. 2010).
According to previous clinical studies, the prevalence of neurocognitive disorders
in HIV infected patients is high in both those complaining of cognitive impairments (84%
of complaining HIV+ patients) and those without complaints (64% of asymptomatic HIV+
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patients) despite suppression of viremia with cART (Simioni et al. 2010). The high
prevalence of neurocognitive disorders and impairments in aviremic, cART-treated
individuals suggested that many anti-retroviral medicines may fail to reverse neurological
damage, even though cART lengthens the survival (McArthur et al. 2010). Therefore,
HAND has become a significant economical and psychological burden to persons living
with HIV infection and places excessive damage on the health care system. What was once
a uniformly fatal illness is now a chronic disease requiring long-term medical management
(Tozzi et al. 2005).

Basal ganglia is especially vulnerable to damage from HIV
The complications of HAND, mentioned above, are tightly associated with
neuropathological changes within subcortical regions of the brain, especially the basal
ganglia, which also retains the major brunt of the infection in the brain (Berger and Nath
1997). These subcortical changes result in cognitive and motor dysfunction such as mental
slowing, memory loss, difficulties in complex tasks, as well as motor disorders (Simioni et
al. 2010; Tozzi et al. 2005). Affected individuals can also present with behavioral
abnormalities, such as apathy, a decrease in spontaneity, and mood swings. In addition, the
incidence of depression and anxiety are more prevalent in HIV infected individuals with
HAND (Simioni et al. 2010). The reasons for regional vulnerability of the basal ganglia for
the associated neuropathological features of HAND are still elusive. HIV-1 virus was
found in the basal ganglia in early infection (Ances and Ellis 2007; Berger and Nath 1997;
Kumar et al. 2007). Before the introduction of cART, multinucleated giant cells, microglial
nodules, HIV-infected microglial cells, and infiltrating macrophages were often detected in
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the basal ganglia compared to other regions within the brain (Navia et al. 1986). These
pathological abnormalities were most common within the putamen and caudate in the basal
ganglia (Koutsilieri et al. 2001; Navia et al. 1986). Paralleling with abnormatlities in these
regions, the atrophy of subcortical brain is often detected in HIV infected individuals in
pre-cART era. Even in post-cART era, this pattern of atrophy was also consistent with
motor dysfunction found in HIV patients with HAND (Becker et al. 2011; Kuper et al.
2011). Neuroimaging studies in pre- and during cART era have indicated that dopamine
transporters and metabolites were abnormal in HAD patients compared with asymptomatic
individuals (Berger et al. 1994; Chang et al. 2008; Kramer and Sanger 1990; Wang et al.
2004). Furthermore, the basal ganglia are where HIV proteins Tat and gp120 were
prominently detected in patients with HIV encephalitis. The proteins can be detected in
glial cells, extracellular matrices, perivascular compartments, and in close proximity to
neurons (Hofman et al. 1994; Kruman et al. 1998). These proteins thus have the
opportunity to interact with neuronal cell bodies, dendrites, and synaptic terminals (Nath et
al. 2000).

Glia associated neuropathogenesis in HIV
The progression of HAND may be associated with chronic inflammation due to
low-level viral replication in the CNS because many cART medicines have poor
permeability through BBB. Despite suppression of viremia due to cART systemically, the
abnormal immune activation of microglia/macrophages triggered by HIV is persistently
remained in the CNS (Woods et al. 2009). Productive HIV infection seen within the basal
ganglia thought to be due to microglia and macrophages (Everall et al. 1995; Jordan et al.

94

1991; Speth et al. 2005). Studies with in situ polymerase chain reaction and laser capture
dissection microscopy have confirmed that productive infection occurs within perivascular
macrophages and microglia in brain parenchyma (Williams et al. 2001). Non-productive
HIV infection has also been detected in astrocytes (Takahashi et al. 1996; Thompson et al.
2004), and this infection is CD4 independent, because CD4 is not normally expressed on
astrocytes (Di Rienzo et al. 1998; Ma et al. 1994). There have been some reports that low
numbers of HIV-infected astrocytes might contribute to the disruption of the blood-brainbarrier in HIV infected CNS (Eugenin and Berman 2007; Eugenin et al. 2011). The toxicity
of HIV, especially the apoptotic cell signaling molecules, might be amplified by gap
junctions in astrocytes, even under the condition of minimal HIV infection in these cells
can result in significant damage in CNS, because the disruption of the BBB allows massive
numbers of macrophages to infiltrate into CNS (Eugenin and Berman 2007; Eugenin et al.
2011). In addition, robust upregulation of chemokines and cytokines in the basal ganglia
also suggests that neuronal dysfunction and injury in progressive HAND may be due to
abnormal cytokine production by these astrocytes and microglia (Suzuki et al. 2011;
Turchan-Cholewo et al. 2009a; Turchan-Cholewo et al. 2009b).
Replication of HIV in infected microglia/macrophages results in the release of HIV
proteins such as gp120 and Tat. In addition the release of viral proteins accompanied by the
secession of cellular gene products, including proinflammatory cytokines such as tumor
necrosis factor-α (TNF-α), as well as eicosanoids, nitric oxide (NO), platelet-activating
factor (PAF), quinolinic acid, and extracellular matrix-degrading proteases (Adamson et al.
1999; Griffin 1997; Heyes et al. 2001; Patton et al. 1998; Smith et al. 2001; Vos et al.
2000; Wesselingh et al. 1997; Yong et al. 1998). gp120 and Tat shed from infected
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microglia can bind to and impair the function of neurons and astrocytes, causing them to
secrete inflammatory cytokines/chemokines, which can activate adjacent microglia and
astrocytes in the early asymptomatic stage of HIV infection. In addition, much evidence
points to the role of activated microglia as a chronic source of multiple neurotoxic factors,
including TNF-α, interleukin-1β (IL-1β), NO, and reactive oxygen species (ROS), driving
progressive neuron damage with opiate exposure (Bruce-Keller et al. 2008; El-Hage et al.
2008b; Turchan-Cholewo et al. 2009a). Furthermore, microglia are known to be
chronically activated by a single or chronic exposure to disease proteins, oxidative stress,
and cytokines/chemokines, this characteristic of microglia could contribute to HIV
neuropathogenesis (reviewed in Lull and Block 2010). Finally, pro-inflammatory factors
can generate more reactive astrocytes and chronically activated microglia, which may
induce functional damage to adjacent neurons. Taken together, the HIV infected or
activated macrophages, microglia, and astroglia up-regulate release of pro-inflammatory
cytokines/chemokines, which probably leads damage neurons and circuitry systems and
lead HIV related neurological disorder and impairments.

HIV associated neurocognitive disorders in sex differences
The incidence of HIV is higher in men than women (75% men vs. 25% women) in
all ethnic groups in the United States and Europe (CDC 2009; UNAIDS 2009). For this
reason, it is not surprising that studies of neurocognitive deficits and impairments in HIV
are mainly based on studies focusing on men. According to recent reports, 51% of people
HIV positive population in worldwide are estimated to be women (UNAIDS 2010). The
availability of antiretroviral treatment in women is higher than or equal to that of men in
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worldwide (UNAIDS 2010). However, the proportion of HIV-infected individuals
receiving antiretroviral therapy was still low in low- and middle-income countries. Only
36% of HIV positive people received antiretroviral therapy in low- and middle-income
countries (UNAIDS 2010), compared to 70% of the HIV positive population receiving
antiretroviral therapy in the United States (CDC 2009).
There have been some reports that women might be more vulnerable to the
development of HIV-associated neurocognitive deficits or impairment than men. However,
these studies in some cases have been inconclusive and differ greatly depending on
outcome measures. For instance, early studies by the AIDS in Europe Study Group found
that the risk of HIV-associated neurocognitive complications (termed as AIDS dementia
complex (ADC) at that time) in Europe during pre-cART era were two-times higher in
women than men (Chiesi et al. 1996). On the other hand, there also have been reports that
the risk of neurocognitive complications among men and women was similar to rates found
among men in the United States, Europe and Australia, where availability of cART are well
established (Robertson et al. 2004; Wojna et al. 2006), as well as in more resource-limited
counties such as Puerto Rico and India (Bouwman et al. 1998; Gupta et al. 2007).
However, there have been some concerns that there are numerous immeasurable factors
that may make sex studies difficult to assess accurately. For example, globally HIV
infected women live under relatively impoverished conditions. This accompanied by low
literacy levels, high injection drug abuse rate, poor mental health, cultural barriers to health
care services, several relevant genetic risk factors and low social status compared men with
HIV, which may significantly influence the diagnosis of neurocognitive disorders in HIV
positive women (Basso and Bornstein 2000; Farinpour et al. 2003; Maki and Martin-
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Thormeyer 2009). Therefore, additional and controlled studies may be required to address
the possibility of sex differences in susceptibility to HIV associated neurocognitive deficits
and impairments.

Material and Methods

Animals, husbandry and general procedures
GFAP-driven, doxycycline-inducible HIV-1 IIIB Tat1-86 transgenic mice were
generated as described in Chapter 3 above. Genotyping was confirmed by PCR and the
method is mentioned in Chapter 3 material and methods. In this study, independent sets of
6-8 mice were utilized in each group and included female Tat-, female Tat+, male Tat-, and
male Tat+. Mice were treated with doxycycline in specifically formulated chows (Harlan
Laboratories, Inc. Indianapolis, IN) with daily dosages of 6 mg/kg for a period of 3 months.
These animals were allowed to reach to chows ad libitum. The doxycycline treatment was
started at 3 months of age and preceded until mice were 6 months old. For control groups
in grip strength test, open field test and light/dark box test, one cohort of mice received
normal chows until they reached to 6 month old.

Accelerating rotarod assay
An accelerating rotarod test, which is sensitive to measures of balance,
coordination, and motor control, was used to evaluate motor performance in groups of Tat
transgenic mice mentioned above. Rotarod testing began after one week of doxycycline
treatment (around 13 weeks old), and was performed once a week (from the first week to
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the fourth week). After four rounds of testing within the first month of doxycycline
treatment, this behavioral test was paused for one month without removal of doxycycline.
This behavioral test was resumed and applied weekly to mice in the third month of
doxycycline treatment (from the ninth week to the twelfth week). Independent, agematched mice were utilized in other behavior tests. The Rotamex-5 treadmill (Columbus
Instruments, Columbus, OH) consists of a 3.0-cm diameter cylindrical treadmill connected
to a computer-controlled stepper motor-driven drum, which can be programmed to operate
in a defined acceleration mode (Rotamex-5, Columbus Instruments). 4 different groups,
female Tat-, female Tat+, male Tat- and male Tat+ mice with doxycycline treatment, were
housed 2–4 to a cage and were tested weekly at 13–16 weeks and 21-24 weeks of age. On
the test day, mice were moved to the testing room and allowed to habituate for 60 min
before testing. All mice in this experiment were naïve to the rotarod apparatus until the first
test day at week 13. Each mouse was placed on the rubber covered rods to evaluate rotarod
performance. On a given trial, four mice were placed on the cylinder, one mouse in each
compartment. The accelerating rotarod was set to accelerate gradually from 1 to 40 rpm, 1
rpm increase per 15 s, for each trial. The starting speed was 1 rpm, and the total time of
each trial was 400 s. Acceleration continued until either 40 rpm was reached or the last
animal was unable to perform the running response and had fallen to the padded surface.
When the animal fell off the rotating drum, individual sensors at the bottom of each
separate compartment automatically record the amount of time (in seconds) spent on the
treadmill. The time spent on the treadmill was recorded for each successive trial, and a
score of one trial per week was analyzed (reviewed Liu et al. 2010).
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Forelimb grip strength test
The apparatus is comprised of a push-pull strain digital force gauge, Chatillon®
DFE II grip strength meter (AMETEK’s Test & Calibration Instruments (TCI), Largo,
Florida USA). Mice were housed 2–4 to a cage and were tested at 6 months of age. On the
test day, mice were moved to the testing room and allowed to habituate for 60 min before
testing. Each mouse was weighed before forelimb grip strength test. A forelimb grip
pedestal was used as the grip bar. The mouse was held near the base of its tail and lowered
toward the bar until it gripped the bar with both forepaws. The mouse was then gently and
steadily pulled directly away from the bar until the bar was released. Peak force
disturbance was automatically registered in grams-force (gf) by the apparatus (Grip
Strength Meter 2.66, AMETEK’s Test & Calibration Instruments (TCI)). Data were
automatically recorded, and 5 trials per mouse were given in quick succession. The force of
resistance was measured in a single 5-trial session and the strongest measurement was
collected as the score (reviewed by Crabbe et al. 2003). The presented scores (gf) in grip
strength were normalized by mouse weights (g) for statistically comparing control and all
other groups.

Open field test
All groups of transgenic mice, including female Tat-, female Tat+, male Tat- and
male Tat+ mice with/without doxycycline treatment, were housed 2–4 to a cage and were
tested at 6 months of aged. On the test day, mice were moved to the testing room and
allowed to habituate for 60 min before testing. Prior to the evaluation, animals were
habituated to the box for 1 min. Mice were individually placed at the center of a clean open
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field apparatus (30 × 30 × 15 cm, divided into nine squares, Med Associates Inc., St.
Albans, VT, USA). The observed parameter, number of squares crossed (locomotor
activity) was automatically recorded for 10 min (Burger et al. 2005; Ramezani et al. 2011).
The data in open field test (percent of total travel distance in 10min, Fig. 4.2 A, Table 4.1
A) indicate that the scores from 6 month old with 3 month doxycycline treatment were
normalized by the scores from control age-matched groups without doxycycline treatment.

Light-dark Transition Model of Anxiety
All groups of transgenic mice, including female Tat-, female Tat+, male Tat- and
male Tat+ mice with/without doxycycline treatment were, housed 2–4 to a cage and were
tested at 6 months old. On the test day, mice were moved to the testing room and allowed
to habituate for 60 min before testing. The light-dark box was adapted from the originally
described apparatus (Crawley and Goodwin 1980). Two equally sized compartments (30
cm x 30 cm x 15 cm) were separated by a black plastic partition with an opening in the
middle to allow for light-dark transitions (Med Associates Inc., St. Albans, VT, USA). The
box was enclosed in a sound attenuating box equipped with overhead lighting and fan
ventilation. Each mouse was tested by locating it in the center of the white area, facing to
the dark one, and was allowed to explore the novel environment for 10 min. The system
was interfaced with Med Associates software (Med Associates Inc.) enabling automatic
measurement of activity using a set of 16 infrared beam sensors along the X-Y plane. The
observed parameter, number of squares crossed (locomotor activity), was automatically
recorded for 10 min (modified from Malmberg-Aiello et al. 2002). The data in light-dark
box test (Fig. 4.2 B, Table 4.1 B) indicate that the percent of travel distance in dark side
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box from 6 month old with 3 month doxycycline treatment were normalized by the percent
of travel distance in dark side box from control age-matched groups without doxycycline
treatment.

Immunohistochemistry and quantification
For immunohistochemistry (IHC) studies, mice were deeply anesthetized with
isoflurane (Baxter, Deerfield, IL, USA) prior to perfusion with 4% paraformaldehyde (pH
7.4, Sigma-Aldrich Co., St. Louis, MO, USA). After perfusion, brains were removed and
post-fixed in fresh fixative overnight. Brains were hemisected, rinsed several times in 15
mL changes of phosphate-buffered saline (PBS) and left overnight in 15 mL of PBS.
Brains were then cryopreserved through graded sucrose solutions (20 and 30%), embedded
in Tissue Tek OCT compound (Sacura Finetek, Torrance, CA, USA), and stored at –80˚C.
10 µm frozen sections containing the striatum were thaw-mounted on SuperFrost Plus
slides (VWR Scientific, West Chester, PA, USA) and processed for immunostaining. The
brains from female Tat-, female Tat+, male Tat- and male Tat+ mice with doxycycline
treatment were serially cut and numbered and ordered and stored -80˚C until use. For in
vivo studies, to assess proportional numbers of specific cells in the striatum, single or
double immunostaining was performed on 10 µm frozen brain sections including striatum.
Primary antibodies were utilized directed against Iba-1 (1:200, Wako, Osaka, Japan), 3nitrotyrosine (3-NT, 1:100, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), NeuN
(1:200, Millipore, Temecula, CA, USA), Olig2 (1:100, Immuno-Biological Laboratories,
Minneapolis, MN, USA), and Sox2 (1:200, R&D Systems, Inc., Minneapolis, MN USA).
Tissue sections on slides were rehydrated with 1x PBS (pH 7.4, Invitrogen Corp., Carlsbad,
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CA, USA) for 10 min at room temperature. For intracellular markers, tissue sections were
permeabilized with 0.2% Triton X-100 in phosphate-buffered saline containing 1% bovine
serum albumin (Sigma-Aldrich) for 30 min. For double immunostaining, individual
primary antibodies were sequentially applied and incubated overnight at 4ºC in humid
chamber; and host-matched fluorescent-conjugated secondary antibodies were applied for
visualization 1 hour at room temperature (Invitrogen Corp., Carlsbad, CA, USA).
Immunostained tissues were finally incubated with Hoechst 33342 dye (0.5 µg/ml, 8 min,
RT) to identify nuclei (Invitrogen), then mounted in ProLong Gold anti-fade reagent
(Invitrogen) and dried for 8 h in the dark. To assess the proportion of microglia cells, 300–
350 Hoechst+ cells were selected randomly in one side of the striatum to assess the
presence of Iba-1 in striata under oil immersion at 63× using a Zeiss AxioObserver system
with an integrated MRM camera system (Carl Zeiss, Inc., Thornwood, NY, USA, n = 6-7).
To determine the relative activation state of microglia in the striata, an independent group
of 200 Iba-1+ cells were randomly selected per striatum and assessed for the 3-NT
expression. To verify the proportion of neural progenitors and immature oligodendrocytes
in the striata, 300–350 Hoechst+ cells were selected randomly per striatum and assessed for
Sox2 and Olig2 expression, respectively (n = 6-7).

NeuN immunoblots and analysis
In vivo NeuN expression was examined by immunoblotting. Striata were harvested
and homogenized with T-PER Tissue Protein Extract Reagent (Thermo Scientific,
Pittsburgh, PA, USA), including a protease inhibitor cocktail (Roche, Indianapolis, IN,
USA). Homogenized tissue lysates were centrifuged; the supernatants were transferred into
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new tubes and then stored at -80ºC until use. Protein concentration was measured using the
BCA protein assay (Pierce, Rockford, IL). Duplicate samples of 20 µg total protein were
loaded per well onto 10% Tris–HCl Ready Gels (Bio-Rad Laboratories, Hercules, CA)
using Precision Plus Protein Dual Color Standards (Bio-Rad; MW range: 10–250 kDa) to
monitor protein transfer and molecular weight. Proteins were transferred to Hybond-P
PVDF membranes (Amersham Biosciences, Piscataway, NJ, USA), probed with mouse
monoclonal anti-NeuN (1:1000, Millipore) and anti-GAPDH (1:2500, Abcam, Cambridge,
MA, USA). Host-matched IRDye® Infrared Dyes conjugated secondary (LI-COR
Biotechnology, Lincoln, Nebraska) were applied to visualize each protein band. Protein
bands were detected on an Odyssey® Infrared Imaging System and their intensity were
analyzed by Odyssey 2.0 software (LI-COR). The intensities of two NeuN bands in each
sample were combined to analyze. To assess changes in NeuN, the combined band
intensities were normalized with the intensity of the respective GAPDH band.

Nissl staining
In addition to NeuN immunohistochemistry, we analyzed Nissl stainined tissues in
order to estimate the total neuron number in striatum. Nissl staining was performed on 50
µm brain coronal sections were taken serially through the striatum based on stereotaxic
coordinates (3rd ed., Academic Press, Orlando, FL, 2008). Sectioning was performed with
vibrating blade microtome (Leica VT1200S, Leica, Nussloch, Germany). Sections were
prepared in ice-cold PBS (Invitrogen) and each section was stored in 48-well plates by
serial order with cryoprotectant solution (25% of glycerin: 25% of ethylene glycol: 50% of
0.1 M phosphate buffer) until use. The Nissl staining was performed as described by
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Davenport, H.A. (1960) (Davenport 1960). Briefly, free floating brain sections were
mounted on chrom-gelatin coated slides serially and were dehydrated at room temperature
until completely air dried. Brain sections were submerged in water for rehydration for 10
min and then underwent 70, 95, and 100% ethanol submersions for dehydration. The brain
tissues were stained for 6 min with 0.5% cresyl violet (Sigma–Aldrich Co., St. Louis, MO,
USA). After rinsing in water, the sections were submerged in 70% ethanol in 0.34 M acetic
acid for 2-3 sec, and then submerged in 95% followed by 100% ethanol for 5 min each.
Finally, the sections were dehydrated with xilene for 10 min. The sections were mounted
and sealed under coverslips for analysis.

Stereology
For stereology, 50 µm free-floading sections were prepared from fixed brains, as
described in IHC section above. After Nissl staining was performed on these brain sections,
total numbers of Nissl+ neurons in the striata were estimated using the optical fractionator
method (West et al. 1991), with assistance from a computerized stereology system
(Stereologer, Systems Planning and Analysis, Alexandria, VA). Every fifth section was
selected from the total number of sections through striatum in a systematic-random
manner, and 12 sections per sample were generated. The sampling fractions were: (1)
section sampling fraction (ssf), the number of sections sampled divided by the total number
of sections for each striatum; (2) area sampling fraction (asf), the area of the sampling
frame divided by the area of the x-y sampling step; and (3) thickness sampling fraction
(tsf), the height of the disector divided by the section thickness. Each reference space was
outlined at low power (x5), and cells were counted using a high magnification (x100, oil-
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immersion) objective. Nissl+ neurons in striata were counted using the optical fractionator
method in combination with the disector principle and unbiased counting rules (Mouton
2002). Since Nissl staining detects both neurons and glia in striata, Nissl+ neurons were
distinguished from glia and identified by their characteristics for unbiased stereological
counting. Neurons cells were distinguished by relatively a large oval shape nucleus, the
presence of dark, coarsely stained Nissl substance in the cytoplasm, and lightly stained
proximal segments of dendritic processes. In contrast, glial cells contain less endoplasmic
reticulum and have relatively dark, tight and small nucleus (Fitting et al. 2010a; Sherwood
et al. 2006). In counting of neurons, astrocytes and oligodendrocytes, and microglia were
excluded without distinguishing among them. A guard volume of 2.0 mm was used during
cell counting to avoid sectioning artifacts, including lost caps and uneven section surfaces.
Criteria for counting cells required that cells exhibited positive chemical- and immunoreactivity and morphological features consistent with each cell type. Cells were counted on
the left hemispheres. After Hoechst staining was applied on 50 µm free-floading sections,
the Cavalieri principle was applied to measure the volume of the striata. The slides were
viewed by using a Zeiss AxioObserver system with an integrated Sony 3CCD Exwave
HAD camera system (Carl Zeiss, Inc., Thornwood, NY)

Statistical analysis
Linear regression was also performed followed by t-test among groups using
GraphPad Prism 5 (GraphPad Software, Inc., La Jolla, CA). Statistical analyses were done
by one way and main effect analysis of variance (ANOVA) followed by Duncan’s post-hoc
testing using Statistica 6.0 software (Statistica, Tulsa, OK).
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Results

Accelerating rotarod assay
To examine whether the long-term induction of Tat in transgenic mice affects motor
skill in a sex-dependent manner, the accelerating rotarod assay was performed in all groups
of mice, female Tat-, female Tat+, male Tat- and male Tat+. During 3 months of
doxycycline exposure, all mice used in this study performed the rotarod test once a week
during week 1-4 and 9-12. The accelerating rotarod test is a forced performance test based
on a rotating rod with forced motor activity to evaluate basic gait, balance and coordination
and duration on rod and maximum speed can be measured (Jones and Roberts 1968).
Female Tat-, female Tat+, and male Tat- groups showed the obtaining motor skill by the
repeated rotarod tasks and reached their maximum performance at 12 weeks, as measured
by an increase in the duration of time spent on the rotarod (Fig. 4.1 A). Three groups of
mice maintained balance on the rotarod with the maximum latency, around 300-352 sec
(Fig. 4.1 A), and rotation speeds reached the highest rotation speeds of 21-24 rpm before
falling by 12 weeks. Interestingly, female Tat+ mice showed different and slow in obtaining
motor skill compared female Tat- group, even they finally gained the motor skill as much
as female Tat- group at the end of 12 week doxycycline exposure (* P<0.05; linear
regression, t-test, n = 6, Fig. 4.1 A). In contrast, male Tat+ mice significantly had more
difficulty to maintain balance on the rotarod and/or obtaining motor skill after 12 weeks of
doxycycline administration compared to all other groups (Fig. 4.1 A, § p<0.001; linear
regression, t-test, n = 6, Fig. 4.1 A). The maximum time of male Tat+ group only reached
less than 200 sec (Fig. 4.1 A), and their highest rotation speeds in male Tat+ mice groups
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only reached around 14 rpm. In fact, the Tat+ mice did not show any acquisition of the task,
as the slope of their performance measure was not different from 0 (Fig. 4.1 A). The data
showed a clear indication of sex differences in the accelerating rotation tasks. Therefore,
this data might indicate that motor skill/balance and/or the ability to learn a motor task are
more significantly vulnerable to HIV-1 Tat exposure in male than in female.

Forelimb grip strength
Forelimb grip strength test was performed in all 8 groups of mice with/without 3
month doxycycline treatment groups. Reduction or abnormality in grip strength indicates
inappropriate neuromuscular functioning or motor deficits in the brain. Since our
transgenic mice almost exclusively express HIV-1 Tat1-86 in their CNS, the test could be
utilized to assess whether long-term induced Tat might cause motor deficits in their CNS
that can affect strength of forelimbs in sex specific manner. 4 groups of 6 month old mice
without doxycycline exposure showed no significant difference in forelimb grip strength,
based on their sex or genotype difference of Tat transgene, after normalizing by their
weight (Fig. 4.1 B). Doxycycline exposure to 12 weeks induced significant differences
resulted to sex and transgene expression. Importantly, doxycycline by itself did not appear
to influence on forelimb grip strength since female Tat-, female Tat+ and male Tat- mice
had similar strength. Tat expression significantly reduced grip strength only in female Tat+
mice (§* p<0.05, control male Tat- vs. male Tat- with doxycycline treatment, one-way
ANOVA, Duncan’s post-hoc test, n = 6, Fig. 4.1 B). Male Tat+ mice also showed the
weakest grip strength among the groups with doxycycline treatment (**, p<0.01, one-way
ANOVA, Duncan’s post-hoc test, n = 6, Fig. 4.1 B). This result suggests an interactive
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effect of sex and Tat induction, since Tat+ mice with doxycycline showed significant
reduction in forelimb grip strength compared to other groups. Therefore, similar to rotarod
test in gaining motor function, males were more affected by HIV-1 protein Tat than
females in forelimb grip strength.

Open-field test
To examine whether the locomotor activity during exploration of a novel
environment may be affected by long-term induction of Tat in male and/or female mice, an
open-field test was performed in all groups of mice including after 3month Tat induction.
The open field test and light/dark box test can measure a tendency to explore novel
environments. Depressed or anxious animals in this test will show reduced traveling
distances in open field if they lose their will to seek novel environment (Cryan and Holmes
2005; Wallace et al. 2008). The distance traveled in 10 min was significantly reduced in
both male and female Tat+ mice, to the same extent after normalization by age-matched
groups without doxycycline exposure (** p<0.01, *** p<0.001, One way ANOVA,
Duncan’s post-hoc test, n=6-7, Fig. 4.2 A, Table 4.1 A). Interestingly, there was no sex
specific effect. Results suggest that long-term exposure to HIV-1 Tat reduced locomotor
activity and/or exploring behavior independent of sex.

Light/dark box test
A standard light/dark box test was performed to examine whether HIV-1 Tat
expression in mouse CNS induced the anxiety-related behavior in these mice and whether
there were sex dependent factors. In rodent behavior studies, increased time spend or travel
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distance by freely ambulating in dark side box has been taken as an indication of enhanced
anxiety in previous numerous studies with anxiogenic or anxiolytic treatment (Bourin and
Hascoet 2003). The Tat induction by doxycycline treatment did not increase the travel
distance in dark side of female Tat-, femalr Tat+ and male Tat- mice (Fig. 4.2 B, Table 4.1
B). However, age matched male Tat+ mice after Tat induction showed significantly
increased anxiety-like behavior, since Tat+ males showed significantly increased travel
distance in dark side compared to any other groups. (* p<0.05, one-way ANOVA,
Duncan’s post-hoc test, n = 6, Fig. 4.2 B and C, Table 4.1 B). Since the only the group
showed increased travel distance/time on dark side after Tat induction were male Tat+
mice, male mice may be more vulnerable to the anxiogenic effects of HIV-1n Tat exposure.

Effects of long-term Tat induction on the proportion of microglia and their 3-NT
immunoreactivity
Since microglial activation has been detected in CNS from the broad spectrum of
HAND patients (Anderson et al. 2003; Glass et al. 1995; Gray et al. 2001; Patton et al.
1996; Tyor et al. 1995), the effects of long-term doxycycline treatment on sex-specific
microglial activation was determined in the striata of Tat- and Tat+ after 3 month
doxycycline treatment. Firstly, the proportion of microglia was quantified in the striata
from all groups by performing Iba-1 immunohistochemistry as described in the Materials
and Methods. Blinded cell counts revealed that the percent of Iba-1+ cells in total cells in
striata were equivalent in Tat- males and Tat+ females (Fig. 4.3 A). However, long-term Tat
induction caused significant increases in the proportion of Iba-1+ cells in both Tat+ females
and Tat+ males without sex difference. Increases were similar in both male and female Tat+
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mice (** p<0.01, *** p<0.001, one-way ANOVA, Duncan’s post-hoc test, n = 6, Fig. 4.3
A).
We next determined whether microglial activities in male mice have a different
level of those of female mice, the extent of Iba-1 and 3-NT co-localization was examined
by double labeling immunihistochemistry. Since 3-nitrotyrosine is a product of tyrosine
nitration mediated by reactive nitrogen species such as peroxynitrite anion and nitrogen
dioxide. Among CNS cells, activated microglia are considered as a major cell mainly
releasing reactive nitrogen species. 3-NT immunoreactivity has been used to identify
inflammatory cells as a marker of reactive nitrogen species-induced oxidative stress (Ryu
and McLarnon 2006; Shavali et al. 2006; Shishehbor and Hazen 2004; Zhang et al. 2005).
Tissue sections from mouse brains were processed to detect both Iba-1 and 3-NT
immunoreactivity as described in Materials and Methods, and control sections, incubated
with secondary antibodies only, were inspected to verify the specificity of the antibodies
and to determine the pattern of co-localization. Female and male Tat- treated with
doxycycline did not show significant difference in the percentage of Iba-1+ cells that
expressed 3- NT, suggesting that doxycycline by itself had no effect on this parameter (Fig.
4.3 B). However, long-term Tat-induction significantly increased the proportion of 3-NT
immunoreactive microglia in both female Tat+ and male Tat+ groups (* p<0.05, ***
p<0.001 one-way ANOVA, Duncan’s post-hoc test, n = 6, Fig. 4.3 B). Importantly, there
was a significant effect of sex in the proportional reactivity of microglia, since
doxycycline-induced male Tat+ mice had a significantly higher proportion in cells being 3NT staining within microglia compared with female Tat+ mice that also received
doxycycline (** p<0.01 one-way ANOVA, Duncan’s post-hoc test, n = 6, Fig. 4.3 B).
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Effects of long-term Tat induction on the expression of NeuN in striatum
The NeuN antibody is well known to have high specificity to a neuron-specific
nuclear protein and has been widely used to identify the loss or reduced number of
neuronal cells in various studies of HIV neuropathogenesis and other situations including
normal neuronal cell counting (Dou et al. 2003; Everall et al. 2002; Mullen et al. 1992;
Zujovic et al. 2000). It was recently shown that NeuN corresponds to Fox-3 (Feminizing
locus on X-3 or hexaribonucleotide-binding protein 3) containing an RNA recognition
motif and binds specifically to an RNA element for mRNA splicing (Kim et al. 2009). Fox3 is one of a family of mammalian homologues of C. elegans Fox-1, a gene involved in sex
determination. Fox-1 family consists of Fox-1, Fox-2 and Fox-3, and they also known to
have an RNA recognition motif. Even estimated sizes of all these Fox proteins are about
46kDa in size, mouse monoclonal NeuN antibody recognize two bands in 46 and 48kDa
size (Mullen et al. 1992) due to alternative splicing Fox-3 pre-mRNA (Kim et al. 2009). To
assess the effect that long-term Tat induction might have on the number of neurons in the
striatum, the proportional number of NeuN+ cells was counted in striata of age matched
female Tat-, female Tat+, male Tat- and male Tat+ after 3 month doxycycline treatment. In
both female and male Tat- mice, the proportion of total (Hoechst+) cells expressing NeuN
was same (Fig. 4.4 A). Long-term Tat induction significantly decreased the proportion of
NeuN+ cells in both female and male Tat+ mice compared to their respective controls
(***p<0.001, one-way ANOVA, Duncan’s post-hoc test, n = 6, Fig. 4.4 A). Furthermore,
the effect on NeuN was significant in male than in female (**p<0.001, one-way ANOVA,
Duncan’s post-hoc test, n = 6, Fig. 4.4 A). We also confirmed the reduction of NeuN by
performing an immunoblot analysis of all groups. NeuN was detected as two bands at
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approximately 42-kD and 48-kD (Fig. 4.4 D), as mentioned previous studies (Kim et al.
2009; Mullen et al. 1992). The intensity of NeuN bands significantly reduced only in the
tissue lysates from male Tat+ mice compared to other groups (Fig. 4.4 B and C). Although
there was a tendency for reduction in intensities of NeuN bands in the female Tat+ group; it
did not reach statistical significance. Taken together, our results showed that long-term Tat
induction significantly reduces the proportion of total NeuN cells in striatum and overall
NeuN levels are reduced in male Tat+ mice but not in female Tat+ mice.

Stereological analysis of Nissl+ neurons in striatum and striatial volume after longterm Tat induction
Although our results showed a significant reduction in NeuN+ cells in Tat
transgenic mice, there have been reports that decreased NeuN+ cells means the depletion of
NeuN protein level or loss of protein antigenicity by neuronal injury rather than neuronal
cell death or loss (Collombet et al. 2006; Unal-Cevik et al. 2004). We performed unbiased
stereological estimation of total neuron number (Nissl+) and the volume in the striata of
female Tat-, female Tat+, male Tat- and male Tat+ mice after 3 months doxycycline
treatment. Nissl histochemical staining has been commonly utilized to quantify the number
of neurons in all brain regions in numerous stereological studies (Cyr et al. 2005; Fitting et
al. 2010a; Fitting et al. 2008; Nielsen et al. 2009). Since Nissl staining in brain can detect
both neurons and glia, morphological identification was required between Nissl+ neurons
and glia for counting cells. Neurons were recognized by their larger, pale and oval nuclei
surrounded by darkly cytoplasmic stained in their Nissl bodies. In contrast, glia, including
astrocytes, oligodendrocytes and microglia, were identified with relatively smaller size of
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their dark, tight and round nucleus with lack of stained cytoplasm (Fitting et al. 2010a;
Sherwood et al. 2006). All Nissl+ glia were eliminated from counting in unbiased
stereological estimation of total neuron number by morphological identification mentioned
above. The unbiased stereological estimation in total Nissl+ neuron showed that female
mice had higher numbers of neurons than males did (* p<0.05, two-way ANOVA,
Duncan’s post hoc test, N=3, Fig. 4.5 A). There was no significant difference in the
estimated striatal volume from any groups (Fig. 4.5 B). In summary, female mice naturally
had higher numbers of neuron in their striata than did male mice in striata. Striatal volumes
were similar and unchanged by Tat expression, suggesting different cell density. Since
long-term Tat induction did not affect either neuron number or striatal volume, the loss of
NeuN imminoreactivity in striata with Tat induction is likely to be the reduction of NeuN
expression rather than loss or death of striatal neurons in striata.

Effects of long-term Tat induction on the population of neural progenitor cells and
oligodendrocytes in adult striata
Since one of our main interests has been the effect of HIV-1 Tat t on neural
progenitor cells, we also examined the population of Sox2+ cells in adult striata from 4
different groups mentioned above, after 3 month doxycycline treatment. HIV-1 Tat
induction caused significantly decreased the populations of Sox2+ cells in the striata of both
Tat+ females and Tat+ males, but there were no significant differences due to sex (Fig. 4.6
A, * p<0.05; ** p<0.01; one-way ANOVA or two-way ANOVA, Duncan’s post hoc test,
N=6-8). Similarly, Olig2+ oligodendrocytes equally decrease in the striata both Tat+
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females and Tat+ males (Fig. 4.6 B, * p<0.05; ** p<0.01; one-way ANOVA or two-way
ANOVA, Duncan’s post hoc test, N=6-8)

Discussion

cART has dramatically improved survival rates over the past decade, and has
decreased the incidence of HIV-1 associated dementia (HAD), but neurocognitive
impairments still remain in high prevalence and affect up to 60% of HIV-infected people
(Ellis et al. 2007; Wojna et al. 2006) and have shown no decline (Dore et al. 2003;
Lawrence and Major 2002; Sacktor et al. 2001). These phenomenon might be the reflection
of low blood brain barrier (BBB) permeability of many cART medicines, which may
contribute to higher viral loads in the CNS compared to peripheral immune system
(Gonzalez-Scarano and Martin-Garcia 2005; Sacktor et al. 2001). Although the prevalence
of neurocognitive impairments in HIV infected population was rapidly increased along
with acquired immunodeficiency syndrome (AIDS) and HIVE in (Antinori et al. 2007;
Grant et al. 1995; Heaton et al. 1995; Woods et al. 2009), but relatively little is known
about whether sex can influence the prevalence and characteristics of neurocognitive
dysfunction in HIV positive patients.
Whether or not the occurrence of HAND has sex bias in HIV positive patients has
not been conclusively determined. Furthermore, it has been quite a challenge to design and
develop animal models for studying in development of HAND. Several animal models
have been generated for use in understanding the mechanisms in the development of HIV
associated neurocognitive deficits. Transgenic mice expressing HIV-1 gp120 in glial cells
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showed age-related impairments in open field activity and spatial reference memory at 12
month old (D'Hooge et al. 1999), while 3 month old animal didn’t show any changes in
their behaviors. Even simian immunodeficiency virus is different from HIV-1, infection of
this virus in macaque monkeys showed impairments in various cognitive and neuromotor
deficits (Bokhari et al. 2011; Cheney et al. 2008). Intracrebral inoculation of HIV-infected
human monocytes in severe combined immunodeficient mice also resulted in cognitive
impairment and motor deficits (Avgeropoulos et al. 1998).
Inducible HIV-1 Tat1-86 transgenic mice were utilized to determine if sex can
influence to develop symptoms of neurocognitive deficit/impairments by HIV-1 Tat protein
induction in CNS and to begin to uncover the underlying mechanisms. HIV-1 Tat1-86
transgenic mice have been used in numerous studies from our labs for understanding HIV
neuropathogenesis. For instance, doxycycline-induced Tat expression induced the
activation of microglia and astroglia (Bruce-Keller et al. 2008), which resulted in dendritic
abnormality and reductions in spine density of neurons, and structural alterations of OLs in
the striatum (Fitting et al. 2010b; Hauser et al. 2009). HIV-1 Tat induction in these mice
also resulted in circadian rhythm abnormalities and sensory changes (Duncan et al. 2008).
These results in Tat transgenic mice seem to be correlated with neuropathogenesis in HIV
patients showing neurocognitive disorders and impairments. Therefore, they are a
reasonable animal model to study sex differences in development of HAND-like deficits.
For the diagnosis of neurocognitive disorders and impairments in HIV positive
patients, a battery of tests are usually performed to assess cortical and subcortical functions
known to be affected by HIV infection.

The cognitive field tests typically include

executive functions, episodic memory, speed of information processing, motor skills,
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attention/working memory, language, and sensoriperception (McArthur et al. 2010; Woods
et al. 2009). Individual tests would require a comparison in performance to the mean of a
equivalent HIV uninfected group as a control.

In terms of assessing subcortical

dysfunctions, severe motor impairments, such as chorea, myoclonus, dyskinesia, and
dystonia, were not frequently observed in most of HIV positive population (Mirsattari et al.
1998; Woods et al. 2009). Subtle neurocognitive motor abnormalities such as slowed
movement and slowed information processing can be frequently detected in older aged
adult HIV patients along with other motor impairments (Valcour et al. 2008); even when
they were under the cART. Different behavior tests, such as gait velocity (Robertson et al.
2006), handgrip strength (PrayGod et al. 2011; Rabeneck et al. 1998), finger tapping
(Heaton et al. 1995), and manual dexterity with grooved pegboard (Carey et al. 2004;
Wojna et al. 2006) can be used to detect these subtle symptoms of motor deficits in HIV
positive patients. Gait velocity test usually was applied to HIV-1 positive patients in severe
stage of HAND, while most of tests are based on the psychomotor speed tests, which are
limited to motor skill of the upper body and associated with attention and procedural
learning in human subjects, since these tests are often applied to HIV positive patients with
subtle motor deficits. These tests are designed to examine the condition of human subjects,
and cannot be exactly equated with animal behavior tests. However, the present study
shows that some well-characterized animal behavior tests applied to access our HIV-1 Tat
transgenic mouse model to detect a spectrum of motor deficits and disorders. The rotarod
test/grip strength test were performed to assess subcortical motor deficits, while open-field
test and light/dark box test were applied to our animal model to assess the aspect of rodent
behavior that has been linked to mental status of humans.
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The accelerating rotarod test is a forced performance test based on a rotating rod
with forced motor activity to evaluate basic gait, balance and coordination tightly
associated with the function of the basal ganglia (Jones and Roberts 1968). The grip
strength test is also a forced assessment which is widely used in conjunction with the
rotarod test, since a normally coordinated rodent will show a low score with low strength of
forelimbs in the basal ganglia affected by neurodegenerative diseases (Prodoehl et al.
2009). Long-term Tat induction resulted in a significant transgene-sex interaction. Male
Tat+ mice had difficulty in obtaining the rotarod motor skill over the course of 12 weeks
compared to all other groups. Interestingly, female Tat mice also showed some difficulty to
acquire motor skills as shown by the slight, but significant difference in linear regression
analysis compared to female Tat- mice (Fig. 4.1 A). When the results normalized by their
own body weight, male Tat+ mice showed significant reductions in forelimb grip force
strength compared to all other groups with doxycycline and were the only group in which
doxycycline treatment caused reduced grip strength versus controls (Fig. 4.1 B).
Symptoms of HIV related neurocognitive disorders are likely to be accompanied by
abnormal mental health conditions such as anxiety, depression or other mood disorders in
HIV infected individuals. Thus, neuropsychological tests may be performed simultaneous
to cognitive tests. Therefore, we hypothesized that long-term Tat induction might also
induce neuropsychological impairments in transgenic Tat+ mice in a sex specific manner.
The rotarod test and grip strength test are “forced” performance tests, while the open field
test and light/dark box test can be used in rodents as qualitative and quantitative measures
of general locomotor activity and willingness to explore, an indication of mental or
neuropsycological status (Lalonde and Strazielle 2008; Stanford 2007). The open field test

118

and light/dark box test are based upon the rodent's conflict between an innate aversion to
exposed spaces and a tendency to explore novel environments (Cryan and Holmes 2005;
Wallace et al. 2008). In the open field test, depressed or anxious animals will show reduced
traveling distances in an unrestricted environment, reflecting their loss of exploring new
noble environment. In the dark/light box condition, depressed or anxious animals will tend
to spend more time in exploring noble environment in the dark side (Bourin and Hascoet
2003). Both behavior tests were only conducted in short time period (5-10 min), so that the
animals in these tests do not lose their novelty to new environment by habituation.
Interestingly, our results showed that an altered neuropsychological status varied between
sexes varied according to the behavioral test being performed. Long-term Tat induction
significantly attenuated the distance of exploratory activity in an open field in both female
and male mice, with no effect of sex (Fig. 4.2 A) In the light/dark box test, only male Tat+
transgenic mice showed significantly increased time and activities in the dark versus
control (age matched male Tat+ unexposed to doxycycline). All other groups, including
Tat+ females, were not different from their respective control group without doxycycline
administration (Fig. 4.2 B).
All together, our HIV Tat transgenic animal model showed that Tat induction
resulted in significant changes in psycho-behavioral status. Open-field exploratory
behavior was reduced in both sexes; whereas male mice showed preference to stay in dark
conditions, perhaps indicating a sex-specific component of anxiety. Therefore, our results
may mean an underlying sex difference in the vulnerability to certain neurocognitive and
psychological disorders in HIV infected individuals. It has been difficult to study human
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subjects under controlled condition, but our result suggested that sex should be considered
as an important variable.
Based on our behavior test results, multiple evaluations were performed in tissues
from these mice to determine whether CNS cells were affected by long-term Tat induction
in sex specific manner. Such changes might be involved in the development of sex specific
behavioral abnormalities. Microglial activity and their inflammation in vivo became the
first evaluation target in this studies, since previous studies in our laboratory strongly
suggested that Tat can induced changed in microglial numbers and reactivity (Bruce-Keller
et al. 2008; Fitting et al. 2010c; Gupta et al. 2010; Hahn et al. 2010b; Suzuki et al. 2011).
Increased number of microglia and enhanced microglial reactivities significantly increase
the inflammatory stress on neurons as direct effects or secondarily through microglial
activation (Bruce-Keller et al. 2008; Suzuki et al. 2011; Zou et al. 2011). Data from the
present study also showed that the overall proportions of microglia in striata were increased
to a similar extent by long-term Tat induction in both sexes. However, when we assessed
the reactive properties of microglia by assaying for 3-NT expression we noted that it can be
influenced by the sex of animals. Long-term Tat expression appeared to enhance 3-NT
expression in microglia significantly in male mice. Dysregulated macrophages/microglia in
CNS, which over-produce various proinflammatory cytokines/chemokines, are frequently
detected in autopsy studies of the basal ganglia from chronic HIV infection (McArthur et
al. 2010; Pereyra et al. 2009). Therefore, our finding that the striata of male Tat+ mice have
more elevated microglial population with increased 3-NT immunopositivity suggest that
the neurons in male mice striata may be even more vulnerable to the stress from microglial
reactivity than those in female mice. This implies that a similar, sex-related vulnerability
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may occur in the CNS of HIV positive patients. There have been some studies that sex
hormones might play an important role in microglial cytokines/chemokines secretion. For
example, estrogen may modulate immune responses of microglia by leading micriglia in
female mice to release greater anti-inflammatory cytokines than microglia in male mice,
even though the increased proportion of microglia were similar in both sexes after exposure
to Tat and/or opiates (Bruce-Keller et al. 2007). The underlying mechanism and
relationships between microglia activation and sex-specific vulnerability of the CNS are
still correlative and further studies are required to show direct, causal links.
Neurons are considered a major target of the HIV-1 Tat protein. Previous in vivo
studies indicated that certain HIV-1 proteins, including Tat and gp120, are neurotoxic,
since not intended secondary/bystandard effects can induce cell loss, low neuronal integrity
in synapses, caspase-3 activation, mitochondrial hyperpolarization and dendridic spine loss
in parallel with macrophage/microglia activation (Everall et al. 2002; Ratai et al. 2010;
White et al. 2011). Due to neuronal injury or loss, subcortical brain atrophy (Castelo et al.
2007; Cohen et al. 2010) can frequently be detected by resonance imaging in HIV infected
individuals, even these patients are in the cART. We utilized a NeuN antibody to identify
the proportional number of neuronal cells in the striata of transgenic mice, because we
thought the loss of neurons could be basis of behavior changes. In our transgenic mice that
the proportion of NeuN+ neurons in striata was significantly decreased after 3 month of
HIV-1 Tat induction. There was also the effect of sex-Tat interaction to reduction in NeuN+
cell population; male Tat+ mice proportionally lost more striatal NeuN+ cells than females
did under same period of Tat induction. Immunoblotting with NeuN antibody was also
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performed to semi-quantitatively compare the expression levels of NeuN protein in striatal
lysates from those animals.
As the lysates from male Tat+ mice striata showed more reduction in the intensity of
NeuN bands compared to those from female Tat+ mice, the pattern of reduction in NeuN
immunoreactuvity were quite similar to the proportional counting reuslts. Nearby 50% with
the NeuN signal lost in both measurements, this seemed like a tremendous amount of cell
loss, and we hypothesized that long-term induction might cause the depletion of NeuN
expression in neurons, rather than 50% neuron death in the striata. To assess the
hypothesis, unbiased stereological techniques were applied to estimate neuron number in
strata and striatal volume all groups. Comparable to previous reports (Cyr et al. 2005;
Oorschot 1996), we measured neuron number in the striata to be approximately 1.8 million
cells in females and slight, but significantly less in males. Furthermore, prolonged Tat
induction didn’t affect the total neuron number in the striatum or the striatal volumes in any
groups. Thus, in agreement with previous data after 10 days of doxycycline treatment in
these transgenic mice, long-term Tat induction did not result in neuron death (Bruce-Keller
et al. 2008). Based on stereological measurements, we believed now that the striatal neuron
population is not reduced by long-term Tat expression, but that Tat induces neuron damage
and interferes with production if NeuN or its antigenesity by unknown mechanism.
Although NeuN has been utilized as a neuronal specific marker for over a decade; the
NeuN protein was only recently identified as Fox-3, a new member of the Fox-1 gene
family of RNA splicing factors (Kim et al. 2009; Kim et al. 2011). Therefore, the underling
mechanisms of 1) how induction of Tat causes altered expression of NeuN, or 2) how an
altered level of NeuN could affect neurons, 3) how many other environmental cues (i.e.
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inflammatory factors from microglia/astrocytes) would be involved in NeuN associated
pathogenesis are still required further studies.
Since one of our interests was how HIV-1 can affect NPCs in CNS, especially in
striata, we also examined whether long-term induction of HIV-1 Tat alters the population
of NPCs and oligodendrocytes in striata. The population of Sox2+ and Olig2+ cells in
striatum were significantly decreased by 3 month induced Tat expression in all Tat+
transgenic mice groups. There was no sex specific manner in the decline of either cell type.
According to previous reports, HIV-1 proteins such as Tat (Mishra et al. 2010), gp120
(Okamoto et al. 2007) can alter the proliferation of NPCs both in vitro and in the
hippocampus and may result in differentiations more toward astrocytes and less toward
neurogenesis (Krathwohl and Kaiser 2004a; Tran and Miller 2005). The reduction in NPCs
seen here is in line with those results and our results from Chapter 3.in neonatal animal.
There

have

been

some

suggestions

that

cytokine/chemokines

secreted

from

microglia/macrophage induced by HIV-1 or its proteins might increased proliferation of
NPCs (Gong et al. 2006; Peng et al. 2008), however, these studies had limitation that those
experiments were short term condition of exposure and were also in vitro on isolated cells.
Since long-term induction of Tat in CNS in our transgenic mice resulted in significant
increase the activity of microglia, the survival or production of both NPCs and OLs can be
secondarily affected by these activated microglia, which would produce not only proinflammatory cytokine/chemokines but also nitro-oxidtive stress (Das and Basu 2008;
Whitney et al. 2009). The long-period exposure to these multiple factors and HIV-1 Tat
might decrease the population of NPCs by inducing fast turn-over of NPC proliferation or
promoting quiescence of NPCs, since in preliminary studies, still in progress, we couldn’t
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detect any proliferation of NPCs in adult striata by BrdU administration. Our experiment
suggested that long-term Tat induction in CNS significantly decreases populations of NPCs
and OLs as one of evidence of HIV neuropathogenesis. The depletions of NPC and OL
populations correlate with altered motor and psychological behavioral test changes in our
transgenic mice, but we cannot, of cause, conclude that there is a cause of relationship.

In conclusion, the data in this thesis support the hypothesis that HIV-1 Tat protein,
produced by chronic replication of HIV in CNS, could play a significant role in the
development of neurocognitive disorders in HIV patients, perhaps by induction of
pathological microglial activation in the striatum. Data also show in this model that sex
may affect the vulnerability in developing behavioral deficit/impairments with males, being
significantly more affected in several standard rodent tests. Our data also suggested that
sex-related changes in microglial activity may cause the depletion of NeuN immune
reactivity in males, which is more affected than that is in females. In other measures, NPCs
and OLs were reduced similarly in Tat+ males and females. At present, we can only say
that depletion of NeuN+ neurons and enhanced microglial reactivity correlate with sex
related behavioral changes. A cause-and-effect relationship remains to be established in
later studies.
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Figure 4.1
R2=0.94

R2=0.62
R2=0.93
R2=0.02
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Figure 4.1 Long-term Tat expression in transgenic mice revealed a sex difference in Tat
effects on motor activity and grip strength. Four different groups (female Tat+ and Tat-,
male Tat+ and Tat-) were fed chow containing doxycycline continuously for 12 wk to
induce Tat expression in vivo. (A) Rotarod results. There was no difference between these
four groups after 1 wk of doxycycline exposure. However, long-term induction of HIV-1
Tat by 3 month doxycycline administration caused significant difficulty in obtaining motor
skill in the male Tat+ group compared to all other groups. (B) Grip strength results. To
compare and normalize the effects of long-term Tat induction in vivo, a matching set of 4
groups with normal chow feeding were separately prepared. After 12 wk, when all mice
were 6 month old, a grip strength test was performed. There was no difference due to sex
or genotype without doxycycline exposure. However, the long-term exposure to HIV-1 Tat
caused significantly decreased forelimb grip strength in the male Tat+ group compared to
all other groups (§ p<0.05; ** p<0.01, male Tat+ vs. all other groups with DOX, Duncan
post-hoc test, N=6-8). Based on these behaviors, we suggest that long term Tat exposure
affects mice in a sex-specific manner, with effects on male mice that are not observed in
female mice. DOX, doxycycline.
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Figure 4.2
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Figure 4.2 The effect of long-term Tat exposure on locomotor activity and anxiogenic-like
behavior of adult transgenic mice. Open-field tests and light/dark box tests were applied to
two sets of 4 different groups (female Tat+ and Tat-, male Tat+ and Tat-, with/without
doxycycline treatment) were tested at 6 month old. A matching set of 4 groups with feeding
normal chow at 3 month old were separately prepared and tested to normalize the data from
other groups mentioned above. (A) Open field test results. There was a difference in
locomotor activity due to sex, even in groups that did not receive doxycycline treatment.
Long-term Tat induction significantly reduced locomotor activity in both sexes. (B)
Light/dark box results. Long-term Tat exposure selectively induced anxiogenic-like effects
in the male Tat+ group compared to all other groups. (C) Representative diagrams of
light/dark box results. Tat+ males showed significantly increased travel distance in dark
side compared to any other groups. Based on these behaviors, we suggest that long term
Tat exposure affects mice in a sex-specific manner. By most measures, male mice are
adversely affected by Tat induction in comparison to female mice. (* p<0.05; § p<0.05,
female Tat- vs. all other groups, Duncan’s post hoc test, N=6-8.) DOX, doxycycline.
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Figure 4.3
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Figure 4.3 Long-term Tat expression in transgenic mice revealed a sex difference in Tat
effects on microglial populations and their activities in adult striatum. The brains were
harvested from four different groups (female Tat+ and Tat-, male Tat+ and Tat-), with 12 wk
Tat induction by doxycycline in vivo. The effects of long-term Tat exposure on the
microglial population in adult striata were examined by multiple immunohistochemistry.
There was a significantly increased population of Iba-1+ cells in both male and female Tat+
groups compared to their Tat- control (A). Although there was no sex difference in Tat
effect on Iba-1+ cells, long-term exposure to HIV-1 Tat did induce a significant increase in
the activity of microglia in the male Tat+ group compared to all other groups, based on the
expression of 3-nitrotyrosine (3-NT+) (B). Based on these results, we suggest that long
term Tat exposure affects mice in a sex-specific manner, with effects on male mice that are
not observed in female mice. (* p<0.05; ** p<0.01; *** p<0.001; § p<0.05, female Tat- vs.
all other groups, Duncan’s post hoc test, N=6-7.) DOX, doxycycline.
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Figure 4.4
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Figure 4.4 Effects of long-term Tat induction on the population of NeuN+ cells and NeuN
immunoreactivity in adult striatum. NeuN immunohistochemistry were performed on the
brain sections including striata from 4 different groups (female Tat+ and Tat-, male Tat+ and
Tat-) with doxycycline treatment at 6 month old for NeuN+ cell counting. HIV-1 Tat
induction for 12 wk caused significantly decreased the population of NeuN+ cells in the
striata of both female and male Tat+ mice. There was a significant sex effect, as the effect
in Tat+ males was significantly greater than in all other groups (A). Immunoblots were
performed with NeuN antibody to measuring any alteration in the level of NeuN in the
striata after long-term Tat induction. Striata were dissected and harvested from
independently prepared 4 different groups (female Tat+ and Tat-, male Tat+ and Tat- with
DOX treatment at 6 months old) for immunobolting. The intensity of bands was
significantly decreased by Tat exposure only in tissue lysates from male Tat+ mice (B, C).
(* p<0.05; ** p<0.01; *** p<0.001, one-way ANOVA or two-way ANOVA, Duncan’s
post hoc test, N=6-8.) DOX, doxycycline.
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Figure 4.5

Figure 4.5 Effects of long-term Tat induction on total number of Nissl+ neurons in
transgenic mouse striata and the volume of striata. The brain sections including striata from
4 different groups (female Tat+ and Tat-, male Tat+ and Tat-) with doxycycline treatment at
6 month old for stereological estimation of Nissl+ neuron numbers. Unbiased stereological
estimates showed that total neuron number (Nissl+) were higher in female mice than in
male mice; there was no effect of Tat on Nissl+ neurons (A). Furthermore, doxycycline
induced Tat didn’t alter the estimated striatal volume in any group (B). Based on these
results, we suggest that long term Tat exposure might affect expression level of NeuN in
the neurons of male Tat+ mice, without actual loss of neurons or a change in volume of the
striatum. (* p<0.05, two-way ANOVA, Duncan’s post hoc test, N=3.) DOX, doxycycline.
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Figure 4.6

Figure 4.6 Long-term effect of Tat expression in transgenic mice on the population of
neural progenitor cells and oligodendrocyts in adult striata. HIV-1 Tat induction by 12 wk
doxycycline administration caused significantly decreased populations of Sox2+ cells in the
striata of both Tat+ males and Tat+ females, but there were no significant differences due to
sex (A, * p<0.05; ** p<0.01; one-way ANOVA or two-way ANOVA, Duncan’s post hoc
test, N=6-8). Similarly, Olig2+ oligodendrocytes equally decrease in the striata both both
Tat+ females and Tat+ males (B, * p<0.05; ** p<0.01; one-way ANOVA or two-way
ANOVA, Duncan’s post hoc test, N=6-8). DOX, doxycycline.
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Table 4.1 Measurements of activity in open field and light/dark box tests
A.
Travel distance (cm/10min ± SE)
Open field test

6 month old

6 month old

No DOX

3 month DOX

Female Tat-

1904.68±334.36

2184.96±183.83

Female Tat+

2484.53±116.25

1682.55±190.38

Male Tat-

2045.54±165.53

2027.74±128.80

Male Tat+

2152.74±199.09

1689.94± 94.54

B.
% of Travel distance in dark side
(cm/10min ± SE)
Light/Dark test
6 month old

6 month old

No DOX

3 month DOX

Female Tat-

79.77 ± 12.03

80.28 ± 5.63

Female Tat+

77.49 ± 7.57

83.44 ± 6.48

Male Tat-

71.71 ± 8.68

77.82 ± 3.01

Male Tat+

71.39 ± 4.06

81.26 ± 4.69
DOX, doxycycline.
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Chapter 5
Final Conclusions

The introduction of cART has dramatically improved survival rates in the
HIV/AIDS population; however, neurocognitive impairments in these patients still remain
in high prevalence. 60% of HIV-infected people are estimated to be affected by HIV
related neurocognitive disorders (Ellis et al. 2007; Wojna et al. 2006) and the prevalence of
HAND has shown no decline, even with cART treatment (Dore et al. 2003; Lawrence and
Major 2002; Sacktor et al. 2001). Low blood brain barrier (BBB) permeability of many
cART medicines might contribute to these phenomenon, so that higher viral loads still
remained in the CNS compared to peripheral tissues where cART is quite effective in
decreasing viral load (Gonzalez-Scarano and Martin-Garcia 2005; Sacktor et al. 2001).
Approximately, 30% of HIV positive patients were infected through the use of
contaminated needles during injection (UNAIDS 2009). HIV-positive, opiate abusers have
high a risk for faster progression to acquired immune deficiency syndrome (AIDS), as well
as higher incidence of subtle form of neurocognitive disorders compared to non-drug
abusers, especially since misuse of drugs leads them to decrease their adherence to cART
medications (Bell et al. 2006; Bell et al. 2002; Byrd et al. 2011). HIV-associated
neuropathology in the CNS is considered as a combined and complex result generated from
the direct toxicity of multiple viral proteins on neurons as well as by the indirect effects of
pro-inflammatory factors or nitro-oxidative stress propagated by surrounding glial cells
(Brack-Werner 1999; Gendelman et al. 1994; Hauser et al. 2007; Kaul et al. 2001; KramerHammerle et al. 2005b; Persidsky and Gendelman 2003). NPCs exist both in the pediatric
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and adult brain, and the size of their population is relatively small compared to other CNS
cell populations. NPCs are primitive, undifferentiated cells having the capacity of
proliferation and the multi-potential ability to generate various neural lineages of mature
brain cells including neurons, astrocytes, and oligodendrocytes. The size of the NPC
population is substantially reduced with age, as is their distribution and recruitment. The
effect of HIV-1 ± opiates on NPCs has been less well studied compared to other cells,
partially because their small populations and transient characteristics make their study
difficult. We have hypothesized that NPCs may be targets of HIV proteins ± opioid drugs
of abuse and that exposure of HIV ± opiates may alter the balance of cells in the CNS that
derive from NPCs.
In Chapter 2, we have shown that HIV-1 Tat1-86 selectively increases the production
of β-chemokines, CCL3/MIP-1α, CCL4/MIP-1β and CCL5/RANTES from striatal
progenitors using a multi-plex cytokine/chemokine assay. Because of our interests in the
effects of co-morbidity between opiate drugs of abuse and HIV exposure in the CNS, we
chose to examine the striatum, an area which is both rich in opiate receptors and extremely
vulnerable to HIV-induced neuropathology. The chemokines upregulated by Tat also
induced a chemotactic migratory response of both primary microglial cells and the BV-2
mouse cell line. Furthermore, we showed that these effects were mediated by CCR5 by
using

antibody

blockade,

as

expected

with

β-chemokines.

Even

though

immunohistochemistry on NPCs showed that they were immunopositive to MOR and
CCR5/CXCR4, there was not any synergistic effect of opiate interaction or toxicity of
gp120 alone in these experiments. In addition, the survival rate of NPCs was not affected
by any treatments. These findings are significantly relevant to HIV related neuropathology,
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as Tat mRNA and/or protein have been detected in CNS tissue samples from patients
infected with HIV (Hudson et al. 2000; Wiley et al. 1996). Furthermore, some recent
reports suggested that human neural progenitors may be infected by HIV (Lawrence et al.
2004; Rothenaigner et al. 2007; Schwartz and Major 2006), although the extent of NPC
infection in the brain is still controversial. The potential contribution of this infected
population to the chemokine secretions and their effects require further studies.
Importantly, our results show that Tat can affect the function of NPCs in the absence of
infection. In this chapter, we examined two critical components of NPC function, their
communication with other cells through secreted factors and their survival. We suggested
that secretions of β-chemokines by NPCs might be useful in promoting microglial
surveillance of newly formed NPCs and clearing toxic debris. Other potential effects might
to provide trophic support or to regulate microglial proliferation and differentiation,
although we have no evidence for these. Other critical NPC/GPC behaviors including
proliferation and lineage decision are examined in other chapters.
In Chapter 3, to investigate the effect of HIV-1 on proliferation of NPCs in
developing systems, we firstly examined the effect of Tat ± opiates on murine striatal
progenitors in vitro. Individually, Tat and morphine did not affect the proliferation of either
Sox2+ or Olig2+ cells in vitro at 12 h, although the combination of Tat and morphine
interactively reduced the total population of Sox2+, and Sox2+ proliferation index. At the
later time points, Tat alone reduced the proliferation and population of Olig2+ cells,
although interactive effect of Tat + morphine was seen on its proliferating cells. By using
doxycycline-inducible Tat transgenic mice, in vivo experiments were performed in
perinatal model as a next step. Tat and morphine independently both reduced the
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proliferation of Sox2+ and Olig2+ cells. An interactive effect was seen only on Sox2+
proliferation. The Sox2+ population was reduced by both morphine and Tat, while the
Olig2+ population was reduced by only by Tat. We did not observed any interaction
between Tat and morphine on the cell populations we hypothesis that these might be
measured at later time points. Since HIV is a human specific virus, we also examined the
effect of supernatant from HIV-1SF162-infected cells or Tat ± morphine on proliferating
hNPCs. The proliferation of human Sox2+/nestin+ NPCs is similarly reduced by Tat,
morphine, and infective HIV-1SF162 supernatant, and an additive effect between HIV-1SF162
and morphine reduces proliferation further. The additive effect of HIV supernatant and
morphine in reducing hNPC proliferation, which was not seen in Tat + morphine treatment,
may reflect the interaction between multiple factors in HIV supernatant including other
viral proteins such as gp120 (Lee et al. 2011) as well as numerous secreted or reactive
factors present in the medium. Previously, we mentioned that NPCs may be a target of HIV
infection. To examine this, we imaged the HIV-1SF162 supernatant treated NPCs with p24
immunohistochemistry, and our finding supports the possibility of low level hNPC
infection. Taken together, our results show that the effects of HIV-1 Tat or HIV-1SF162
supernatant and morphine significantly reduce the proliferation of NPC/GRPs, and
interactions among them can compromise both murine and human progenitor production
even further. These findings suggest the possibility that HIV infected pediatric patients,
who have developing brains with significant number if NPCs and immature glia, likely will
develop neuropathological complications due to HIV infection alone, and the
complications maybe worse if they are exposed to opiates.
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In Chapter 4, we extend our interest into the effect of long-term Tat exposure on
animal behavior, since chronic low levels of HIV replication in CNS may play a significant
role in the development of neurocognitive disorders in HIV patients. We utilized several
standard rodent tests to examine the effect of long-term Tat induction in animal model.
Interestingly, male Tat+ mice showed overall greater deficits than all other groups.
Doxycycline-induced male Tat+ mice had decreased rotarod performance and forelimb grip
strength, and they also showed increased anxiety-like behavior as compared to
doxycycline-induced female Tat+ mice and control groups. There was no sex related
difference in open field locomotor activity. In parallel to these behavioral tests, we
performed correlative experiments to assess Tat effects on certain cell populations. We
determined that microglial activation was more enhanced in striatum of induced Tat+ males
compared to that of induced Tat+ females, although their microglial number was increased
to the same extent. NeuN levels in striatum were also more reduced in male Tat+ mice by
Tat induction as compared to all other groups. Interestingly, we determined that the
reduction in NeuN immunoreactivity was not consequent to loss or death of neurons in
striatum, suggesting down-regulation of NeuN expression in living neurons. Since we were
also interested in the effect of Tat on NPCs, we also examined the populations of NPCs and
OLs by immunostaining for Sox2 and Olig2. The reduction in their populations was similar
in doxycycline-induced Tat+ males and females. These data suggest that sex related
behavioral changes may be modulated by enhanced microglial reactivity, which may also
cause the depletion of NeuN level in neurons and the reductions in populations of NPCs
and OLs in striata. However, a cause-and-effect relationship remains to be established in
later studies. Overall, our data suggest that HIV patients may be vulnerable to developing
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neurocognitive disorders in a sex dependent manner, making sex an important variable in
human studies.
In conclusion, one of most important findings in our studies is that NPCs are major
targets of HIV-1 viral protein Tat and that certain effects of Tat are interactively affected
by concurrent morphine exposure. Most of our studies are directly related to
neonatal/perinatal systems, which is relevant to the neuropathogenesis in pediatric HIV
population. The role of NPCs is well studied in stem cells, memory formation and repairing
CNS after injury/insults, however, the importance of them has been understudied in HIVinduced pathology in the CNS. Even though neurons in most CNS are formed prenatally,
but production of gliogenesis continues into the postnatal and adolescence period (Chan et
al. 2002; Lee et al. 2000; Skoff 1990; Skoff and Knapp 1991). Because of this reason, the
CNS of younger HIV patients have and require relatively large populations of NPCs
compared to adult HIV patients. Furthermore, these pediatric/adolescent patients have a
great possibility that their CNS could be exposed to opiates. This might appear through the
use of opiates as pain control medication through their lives, for examples, during surgery.
It might also occur during experimentation with drug abuse. Our data strongly suggested
that certain major functions of NPCs are sensitive to both HIV-1 and opiate exposure and
are vulnerable to the interactive effect between HIV-1 and opiates. There are presently few
options for non-opiate, pain-control medications in HIV pediatric patients does not existed
yet, therefore, the development of the new non-opiate, pain-control medications might be
of great clinical benefit to these pediatric patients, for example, toll-like receptor (TLR)
antagonists. Some studies suggested that opiates can induce glial activation mediated by
TLR to lead neuropathic pain, and this glial activation can be alleviate by TLR antagonists
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to reduce the neuropathic pain (Hutchinson et al. 2007). Another important finding in our
studies is that NPC populations existing in the adult CNS can be vulnerable to long-term
HIV exposure. Our data from an in vivo animal model also indicate that behavioral
outcomes might be affected by long-term HIV-1 exposure to CNS in sex-specific manner.
HIV-1 Tat transgenic mouse model, that we have, females show less cognitive and motor
deficits along with less severity in neuropathogenesis compared to males. Interestingly,
changes in Sox2+ NPCs and Olig2+ oligodendrocytes do not correlate to sex-related
behavioral changes, but increased microglia activation and depletion in NeuN level do
show a correlation. Even though a cause-and-effect relationship has not been shown here,
and is required to be established in the future, we cautiously hypothesize that these sex
differences in the phenotype of sub-population of microglia cells may reflect an effect of
sex hormones, such as estrogen, on microglial activation induced by HIV-1 or viral
proteins. Some in vitro studies suggested that pretreatment with estrogen can attenuate
microglial activation, mediated by mitogen activated protein kinase and NF kappa B
pathways, to reduce superoxide/nitrite release, phagocytic activity, and TNF-α secretion
from microglia (Bruce-Keller et al. 2001). Since there have been few studies in adult NPCs
under the long-term condition of HIV infection, further studies are needed to show how
HIV effects on NPCs relate to overall CNS pathology in HIV patients, as well as to the
behavioral deficits/abnormality in HAND, and the influence of sex should also be
considered in future studies.
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